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ABSTRACT
Wiskott-Aldrich Syndrome (WAS) is a X-linked genetic disease caused by 
mutation in the gene encoding for the Wiskott-Aldrich Syndrome protein (WASP). 
WASP is specifically expressed in hematopoietic cells, where it regulates the 
reorganization of actin cytoskeleton in response to extracellular stimuli. WAS is 
characterized by micro-thrombocytopenia, eczema, immunodeficiency and high 
susceptibility to autoimmune disorders and haematological malignancies. Although 
WASP deficiency affects the function of several haematopoietic cells, T cell dysfunction 
plays a predominant role in WAS pathogenesis. Our study focused on the functional and 
molecular analysis of different effector T cell subsets from WAS patients and on a 
possible defect in peripheral tolerance.
We found that WASP lowers the threshold for T cell proliferation, induced by 
TCR/CD28 triggering. Restoration of WASP expression mediated by lentiviral vectors 
gene transfer fully reconstitutes TCR-driven proliferation. Furthermore, we showed that 
WASP regulates the levels of the ganglioside GM1 upon TCR/CD28 triggering. In 
addition, WASP deficiency selectively impairs the production of T hl cytokines, after 
TCR/CD28 triggering in CD4+ and CD8+ T cells from WAS patients, as a consequence 
of reduced Thl cytokine gene transcription. Reduced expression of IL-2 and IFN-y 
mRNA in WAS T cells is associated with reduced nuclear levels of NFAT, and in WAS 
CD4+ T cells also with defective induction of T-bet transcription factor.
The function of natural regulatory T cells (nTreg) from WAS patients was also 
investigated, showing that WASP deficiency impairs the suppressive activity of nTreg 
cells.
10
This study clarifies the role of WASP in T cell activation and effector functions, 
and suggests that dysfunctions in regulatory T cells can be involved in the pathogenesis 
of WAS.
11
1 INTRODUCTION
1.1 Wiskott-Aldrich Syndrome: an overview
Wiskott-Aldrich Syndrome (WAS) is an X-linked genetic disease, characterized 
by micro-thrombocytopenia, eczema, immunodeficiency and increase susceptibility to 
haematological malignancies and autoimmune disorders. The syndrome was described in 
1937 by Wiskott (Wiskott, 1937) and its features of recessive, sex-linked, disorder were 
defined by Aldrich about 20 years later (Aldrich et al., 1954). Initially, the disease was 
linked with altered expression of sialophorin (also called CD43) on the surface of T 
lymphocytes and platelets (Parkman et al., 1981), but this alteration was then showed not 
to be the primary cause of the disease. Indeed, the gene responsible for WAS was cloned 
in 1994 (Derry et al., 1994) and the product of this gene, a 502 amino acid protein, was 
named WASP (Wiskott-Adrich Syndrome Protein). Later on, it was discovered that 
mutations in the WAS gene could lead to a milder form of the disease, called XLT (X- 
linked thrombocytopenia), which is characterized by thrombocytopenia and eczema but 
with an overall preservation of the immune functions. (Notarangelo et al., 2002; Villa et 
al., 1995). Both WAS and XLT are due to mutations which abolish or reduce WASP 
expression and function. Recently, the picture has been made even more complex by the 
discovery of patients, in which mutations leading to a constitutive activation of WASP 
are the cause of a distinct disease, named XLN (X-linked Neutropenia) (Devriendt et al.,
2001). The most relevant clinical manifestation of XLN is a severe neutropenia and 
monocytopenia, which is the cause of major bacterial infections, associated to a block in 
the maturation of myeloid lineage at the premyelocyte/myelocyte stage.
WAS has been, and continues to be, the object of numerous studies aimed to unravel the 
disease pathogenesis and the role of WASP in the immune system. However, much
12
remain to be done to fully clarify the cellular and molecular mechanisms underlying 
WAS.
I.2 Wiskott-Aldrich Syndrome Protein (WASP): structure and function
The gene responsible for WAS was initially found to be located in the X pll.22-
II.23 region (Peacocke and Siminovitch, 1987) and it was subsequently isolated by 
positional cloning (Derry et al., 1994). The WAS gene is constituted by 12 exons and 
encodes for a protein of 502 amino acids. WASP was initially hypothesized to be a 
transcription factor, based on the presence of poly-proline stretches, an highly acidic 
domain at the C-terminus and a putative nuclear localization signal (Dingwall and 
Laskey, 1991)(PADKKRSGKKKISK, residues 222-235). Next studies revealed instead 
that WASP is the prototype of a family of proteins, which controls actin dynamics. These 
proteins are largely conserved throughout evolution and can be divided into two groups, 
according to the structure and mode of activation. The first group comprises WASP 
(Derry et al., 1994), which is expressed in the haematopoietic system, and the more 
widely expressed N-WASP (Miki et al., 1996). The second group comprises three 
Scar/WAVE proteins: WAVE1, WAVE2 and WAVE3 (Bear et al., 1998; Miki et al., 
1998b; Suetsugu et al., 1999). WASP and WAVE proteins share a similar organization in 
the C-terminal portion of the protein, while the structure of the N-terminus is much more 
divergent. A schematic representation of WASP and related proteins is shown in Figure 
I.
13
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Figure I.
Structure of Wiskott-Aldrich Syndrome protein (WASP), neural (N)-WASP and 
Suppressor of cAMP receptor/W A SP fam ily verprolin hom ologous 
(SCAR/WAVE) proteins. WH1: WASP homology domain 1; B: basic region; 
CRIB/GBD: Cdc42 and Rac interactive binding domain/GTPase binding 
domain; PPP: proline-rich region; V: verprolin; C: cofilin; A: acidic. SH/WH: 
SCAR homology/WAVE homology domain.
In the C terminal part of these proteins is located the VCA (verprolin-homology, 
central [or cofillin] and acidic) domain. The V domain binds actin monomers (Miki et 
al., 1998a; Rohatgi et al., 1999), while the CA domain binds a large multi-molecular 
complex, named Arp2/3, which is one of the most important known activator of actin 
polymerization (Welch et al., 1997). Although the VCA domains of WASP and 
Scar/WAVE proteins have similar affinity for Arp2/3 binding, each domain has a distinct 
efficacy in driving actin polymerization. The N-terminal portion (which actually 
comprises >85% of the entire amino acid sequence) of WASP and N-WASP contains a 
WH1 (WASP-homology 1) domain, a basic region (B), a GTP-ase binding domain
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(GBD/CRIB) and a proline-rich region (P). The WH1 domain, which comprises the first 
150 amino acids of WASP was initially thought to mediate the binding to phosphatidyl- 
inositol(4,5)-biphosphate [PI(4,5)P2] (Imai et ah, 1999; Miki et al., 1996), also in view 
of its fold analogy with the pleckstin homology (PH) domain, which binds to 
phosphoinositides (Rebecchi and Scarlata, 1998). Subsequently, the ability to bind PIP2 
was rather attributed to the B domain (Rohatgi et al., 2000). The WH1 domain mediates 
the binding to WIP (WASP interacting protein) (Ramesh et al., 1997) while the 
GBD/CRIB domain binds to GTP-bound Cdc42 (Kolluri et al., 1996; Miki et al., 1998a; 
Symons et al., 1996). Cdc42 is a member of the small Rho GTPase family, which also 
comprises Rho and Rac (Bishop and Hall, 2000). These proteins control a variety of 
cellular processes, including cell migration, cell morphology, endocytosis and adhesion, 
in part through the activity of WASP/WAVE proteins. The respective regulation of 
WASP/N-WASP by Cdc42 and of WAVE proteins by Rac is one of the main differences 
in the specificity of these two groups of related proteins (Bompard and Caron, 2004). 
While WAVE proteins are constitutively active (Miki et al., 1998b), regulation of 
WASP/N-WASP activity is exerted at the level of conformational changes. Indeed, these 
proteins were shown to exist, in resting conditions, as auto-inhibited monomers, in which 
inhibition is achieved through intra-molecular binding of the B/GBD to the VCA domain 
(Kim et al., 2000). The classic model of WASP/N-WASP function implies that 
extracellular stimuli activate WASP/N-WASP by relieving the conformational inhibition 
through the binding of phosphatidylinositol 4,5-biphosphate (PI[4,5]P2) and of activated 
Cdc42 (Higgs and Pollard, 2000; Kim et al., 2000; Prehoda et al., 2000; Rohatgi et al., 
2000). However, recent findings led to further clarify the precise molecular mechanisms 
of WASP/N-WASP activation and underscored the importance of WIP in this process. 
N-WASP activation by Cdc42 was shown to require the binding of Toca-1, a member of 
the PCH protein family, which is highly conserved in eukaryotes (Ho et al., 2004). Given
15
the high homology between WASP and N-WASP, it is likely that a similar mechanisms 
accounts also for WASP activation. In resting lymphocytes more than 95% of WASP is 
bound to WIP (Sasahara et al., 2002). This interaction is important for regulation of both 
localization and activation of WASP. Indeed, many missense mutations causing WASP 
were predicted to disrupt WASP-WIP interaction (Stewart et al., 1999; Volkman et al., 
2002; Zhu et al., 1997). It was therefore proposed that binding of Cdc42 and Toca-1 to 
the (N-)WASP-WIP complex would lead to dissociation from WIP and (N-)WASP 
activation, a process favoured by the binding of PIP2.
Moreover, a variety of SH3-containing proteins, including Src, Fyn, PI3K p85, 
PLCyl, Nek, Itk, profilin, VASP and WISH, were found to bind the poly-proline rich 
region of WASP/N-WASP in either in vivo or in cell-free systems (reviewed in (Imai et 
al., 2003; Takenawa and Miki, 2001)). This region regulates both the subcellular 
localization and the activation of WASP/N-WASP in response to extracellular stimuli. A 
final level of regulation of WASP/N-WASP is exerted by phosphorylation. Indeed, the 
VCA domain of these proteins is serine-phosphorylated by caseine kinase 2 and this 
phosphorylation was shown to increase the actin-nucleating activity (Cory et al., 2003). 
Moreover, both WASP and N-WASP can be tyrosine phosphorylated on a residue, which 
is located into the GBD/CRIB domain. This post-translational modification increases the 
ability of WASP to promote actin polymerization (Cory et al., 2002). An integrated 
model of regulation of WASP activation and localization is shown in Figure II. The 
overall role of WASP/WAVE proteins is to create a branched network of actin filaments. 
Different models of initiation of actin polymerization have been proposed to explain the 
mechanisms of cytoskeleton remodelling. Arp2/3 complex seems to have a non- 
redundant role in this process, by inducing polymerization of new actin filaments on the 
side of pre-existing filaments, thus creating a branching network of actin. The activity of 
Arp2/3 complex was shown to contribute to a variety of cellular functions, including
changing of cell shape, motility, endocytosis and phagocytosis (Welch and Mullins,
2002).
Thus, WASP (in the immune system) as well as N-WASP (in other tissues) are 
positioned, in a well-orchestrated manner, at the cross-road of multiple signalling 
pathways. As a result, WASP family proteins integrate extra-cellular stimuli and 
translate them into remodelling of the actin cytoskeleton, and, possibly, into regulation 
of other downstream targets.
Figure I!
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Figure II. In resting cells (upper panel) WASP exists in a monomeric auto-inhibited 
conformation, mantained by a intra-molecular binding between the CRIB and the VCA 
domain. The majority of WASP is bound to WIP, when inactive. Upon triggering of cell 
surface receptors (low panel), a cascade of signalling events leads to the binding of 
GTP-bound Cdc42 to the CRIB domain. This binding, together with the binding of 
Toca-1 and PIP2, relieves the inhibition and allows the VCA domain to interact with the 
Arp2/3 complex.Tyrosine and serine phosphorylation by Src kinase and CKII, 
respectively, enhances WASP activity.
17
1.3 WASP expression during haematopoietic differentiation
The first evidence of the hematopoietic-restricted pattern of WASP expression 
came from the observation that WASP mRNA was expressed in human T and B cell 
lines, as well as in the spleen and the thymus, but not in other non-haematopoietic tissues 
(Derry et al., 1994). This pattern was consistent with the clinical manifestations of WAS, 
which affects the haematopoietic system. In addition, WASP mRNA was found to be 
expressed already in human CD34+ progenitor cells and its expression was maintained 
throughout the differentiation into all the different lineages (Parolin i et al., 1997). 
Accordingly, WASP was shown to be expressed in CD34+ cells and in various 
haematopoietic cells lineages (Zhu et al., 1997), suggesting that WASP could be 
involved in early differentiation and survival of haematopoietic precursors. This 
possibility was confirmed by the observation that in healthy female carriers of WAS a 
non-random inactivation of the X chromosome was found in all haematopoietic lineages, 
including progenitor CD34+ cells, while in the same subjects a random inactivation of the 
X chromosome was found in non-haematopoietic tissues (Wengler et al., 1995). This 
skewed X inactivation could result from a selection of the cells which have inactivated 
the mutated X chromosome, due to an in vivo selective advantage (Belmont, 1996). 
However, some cases of females subjects with clinical symptoms of WAS were reported. 
In some cases, a random X chromosome inactivation was observed in the haematopoietic 
compartment (Lutskiy et al., 2002). The involvement of WASP in haematopoietic 
progenitor differentiation was further confirmed by the observation that CD34+ cells 
isolated from WAS patients has a reduced ability to give rise to both megakaryocytes, 
granulocyte-macrophages and erythroid colonies in vitro, as well as to a reduced ability 
to form pro-platelets (Kajiwara et al., 1999). Interestingly, normal colony numbers but 
defective pro-platelets formation was observed starting from CD34+ cells isolated from 
XLT patients, (Kajiwara et al., 1999). These data support the possibility that WASP
could confer a selective advantage early during haematopoietic differentiation. Studies 
from one WASP knock-out mouse model showed that transplanted WASP* bone marrow 
(BM)-derived cells had a higher ability to home to BM compared to W ASP cells 
(Lacout et al., 2003). In the same study, skewed X-chromosome inactivation was 
observed in BM cells of heterozygous female mice and was related to an advantage for 
W A SP cells to migrate from fetal liver to BM. Thus, WASP seems to be required both 
for migration and for proliferation/survival of haematopoietic progenitors.
19
1.4 WAS and XLT: pathology
1.4.1 Genotype-phenotype correlation
More than 300 unique WAS gene mutations were identified and collected in a 
WAS database (http://homepage.mac.com/kohsukeimai/wasp/WASPbase.html). These 
mutations are scattered throughout the entire length of the WAS gene, although some 
hotspots have been identified and found to be associated to either WAS or XLT (Jin et 
al., 2004) (Figure III).
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Recent studies, performed on large cohorts of patients, showed a strong 
genotype-phenotype correlation. Indeed, mutations, which abolish WASP expression 
(usually deletion/insertion, nonsense mutations and splice site mutations) are associated 
with a severe clinical phenotype (full blown WAS), a disease score of 3-5 and a life 
expectancy below 20 years of age. On the contrary, missense mutations, which result in 
residual expression of a full-length point-mutated WASP, are associated with a mild
20
clinical phenotype (XLT/WAS), corresponding to a disease score of 0.5-2 and a longer 
life expectancy (Imai et al., 2004; Jin et al., 2004) (Figure IV). All patients harbouring 
mutations in the WAS gene are thrombocytopenic and their platelets are smaller than the 
normal, although in some patients with mutations resulting in a single amino acid 
substitution, the thrombocytopenia is intermittent (Notarangelo et al., 2002). Both WAS 
and XLT patients suffer from haemorrhages, which can be lethal (generally in case of 
intra-cranial haemorrhages). Eczema or atopic dermatitis are another frequent 
complications of WAS and XLT and can be, in some cases, resistant to conventional 
therapies (Imai et al., 2004).
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Figure IV. Clinical manifestations and disease score in individuals with 
mutations in the WAS gene (A). Mutations identified in 124 patients with 
classic WAS and in 116 patients with XLT (B). WAS phenotype is usually 
associated to complex mutations, which abolish WASP expression, while 
XLT is mainly associated to missense mutations.
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1.4.2 Infections
The vast majority of WASP-negative patients have a history of recurrent 
infections, which can be life-threatening (Imai et al., 2004; Sullivan et al., 1994). 
Infections in WAS patients are due to bacteria, virus and fungi. Bacterial infections are 
generally due to encapsulated bacteria and can affect either the airways (causing otitis 
media, pneumonia) the gut (causing enterocolitis), the skin, the urinary tract, the central 
nervous system, or they also can be disseminated. Viral infections are generally due to 
herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein Barr virus (EBV) and 
Molluscum Contagiosum. Among fungal infections, C andida , Aspergillus  and 
Pneumocystis carinii have been reported in WAS patients.
1.4.3 Serum immunoglobulins
Serum immunoglobulin levels are altered in WAS, with IgM levels being 
generally lower then the normal range (although in some patients IgM levels were found 
to be higher than the normal range and this was associated with autoimmune 
manifestations and poor prognosis (Dupuis-Girod et al., 2003)). IgG levels are normal, 
while IgA and in particular IgE levels are often elevated. Although eczema has been 
associated to high IgE levels in the serum, in other immunodeficencies, this seems not to 
be the case in WAS patients (Imai et al., 2004). An inability to produce Abs against 
polysaccharide Ags was classically found in WAS patients (Ayoub et al., 1968) and it 
was proposed to be one of the basis for the susceptibility to infections caused by 
encapsulated bacteria. The reason for this deficiency is still unclear. Although WAS 
patients were shown to produce low levels of Abs (including IgM and IgG) directed 
against polysaccharide Ags of various sources (Streptococcus pyogenes, Haemophilus 
Influentiae capsule, phosphocoline and blood group B), this was not due to an overall 
reduction in the levels of circulating IgG2 (Nahm et al., 1986), which is the subclass 
generally elicited by carbohydrate Ags (Siber et al., 1980).
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1.4.4 Haematological malignancies
In addition to infections, a propensity to the development of lymphoreticular 
malignancies has been reported among full blown WAS patients (Imai et al., 2004; 
Shcherbina et al., 2003; Sullivan et al., 1994). These malignancies were found to occur in 
13-22% of the patients and are mainly constituted by EBV-positive lymphoma and 
myelodysplasia. EBV-positive lymphoma has been frequently observed in patients with 
immunodeficiency, since in these patients the immune-surveillance against EBV, which 
includes production of neutralizing Abs, NK lytic activity, production of EBV-specific 
CTLs, is compromised. In particular, in WAS patients high levels of circulating Abs 
directed against viral capsid antigens (Ag) and low levels of anti-EBV determined 
nuclear antigens (EBNA) were reported (Okano et al., 1984). However, it is likely that 
immunodeficiency is not the only reason of high incidence of lymphoma, as a splice site 
mutation, associated with a mild clinical phenotype, was shown to be associated to a 
high risk of lym phom a (Shcherbina et al., 2003). One case of atypical 
lymphoproliferative disorder was also reported in a WAS patient (Ma et al., 2005), who 
showed reactive lymph node hyperplasia associated to altered nodal architecture, 
hepatosplenomegaly and dysgammaglobulinemia.
1.4.5 Autoimmunity
In addition to malignancies, another severe complication associated to WAS is 
autoimmunity. The reported frequency of WAS patients presenting autoimmunity were 
24%, 40% and 72% in three independent studies (Dupuis-Girod et al., 2003; Imai et al., 
2004; S u ll iv a n  et al., 1994).  Autoimmune manifestations included haemolytic anemia, 
cutaneous vasculitis, inflammatory bowel disease, arthritis and IgA nephropathy. This 
last manifestation has been proposed to be due to alteration of the O-glycosylation 
pattern of IgA (Allen and Feehally, 2000), rather than to the production of specific 
autoreactive Abs (Imai et al., 2004). Interestingly, autoimmunity did not necessarily
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correlate with disease severity, as it was present with a similar incidence in W A SP and 
W ASP patients (Imai et al., 2004). Mechanisms of WAS-associated autoimmunity are 
not clear, although inflammation due to the persistence of pathogen-derived Ag or 
alterations of either central or peripheral tolerance could be responsible for these 
complications.
Because of the high variability of disease severity, in patients with mutations in 
the WAS gene, these studies of genotype-phenotype correlation are of great importance, 
as they showed that WASP expression could be considered a useful prognostic indicator, 
at least for the occurrence of severe infections and haemorrhages. Therefore, analysis of 
WASP expression, when standardized, may help in the management of patients and in 
the evaluation of the best therapeutic option.
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1.5 WAS and XLT: cellular defects
1.5.1 Platelets defects in WAS and XLT
WAS and XLT patients have thrombocytopenia and small platelets and, as a 
result, tendency to hemorrhagic diathesis. Bleeding is still one of the major causes of 
death among WAS and XLT patients (Imai et al., 2004). Platelets count in these patients 
vary from 6000 to 70000/pl (Imai et al., 2004). Clinical manifestations of bleeding were 
reported in 84% of WAS patients (based on a retrospective study) and range from not 
life-threatening, including petechiae, purpura, epixtasis, oral bleeding, to life-threatening, 
including gastrointestinal or intracranial haemorrhages (Sullivan et al., 1994). Although the 
incidence of life-threatening haemorrhages were found to be higher and to have a worse 
outcome in patients harbouring severe WAS gene mutations than in patients with mild 
WAS gene mutations, the presence or absence of WASP expression in lymphocytes did 
not to correlate with the extent of platelets abnormalities (Imai et al., 2004). The precise 
function of WASP in platelets has not been determined yet. Platelet activation was found 
to be defective in WAS/XLT patients. In particular, induction of CD62P (P-selectin) and 
GPIIbllla (receptor for fibrinogen or CD41) in response to thrombin was reduced 
(Semple et al., 1997). Although WASP was shown to be phosphorylated in platelets 
upon collagen binding to the collagen receptor, Glycoprotein VI, possibly by the Tec 
kinase Btk (Oda et al., 1998), contrasting data were collected regarding the ability of 
WASP-deficient platelets to aggregate in response to collagen (Grottum et al., 1969; 
Kuramoto et al., 1970). The nature of the thrombocytopenia in WAS/XLT patients is still 
a matter of debate. Although WAS patients were reported to have normal or even high 
number of megakaryocytes in the BM (Grottum et al., 1969; Imai et al., 2004; Ochs et 
al., 1980), contrasting data have been obtained regarding the ability of BM-derived 
CD34+ cells from WAS/XLT patients to differentiate in vitro into megakaryocytes and to 
form pro-platelets (Haddad et al., 1999; Kajiwara et ak, 1999). Overall, these data
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suggest that ineffective throm bopoiesis is probably not the major cause of 
thrombocytopenia in WAS/XLT patients. Accordingly, normalization of both platelets 
count and size were generally observed in splenectomized patients (Corash et al., 1985), 
suggesting that platelets destruction, occurring in the spleen, has a major role in 
determining thrombocytopenia in WAS/XLT patients. Indeed, extensive co-localization 
of platelets and macrophages was observed in the spleen of WAS patients (Shcherbina et 
al., 1999b). Increased phagocytosis of WAS platelets by macrophages could result either 
from increased phosphatidylserine (PS) exposure on the outer leaflet of platelets plasma 
membrane or to binding of specific Ab to platelets. However, this second mechanism 
seems to be more relevant in the cases of relapse of thrombocytopenia, which may occur 
after splenectomy in WAS patients (Dupuis-Girod et al., 2003). Although WASP acts 
downstream of Cdc42 in mediating Arp2/3 complex activation and actin polymerization, 
normal Arp2/3 activation and localization, as well as normal platelets morphology and 
lamellipodia formation, were reported in platelets from WAS patients (Falet et al., 2002). 
Although some of these events (such as lamellipodia formation) are likely to be regulated 
by WAVE2 in platelets (Oda et al., 2005), these data suggest that WASP deficiency 
could affect the integrity of platelets more than their function. It is conceivable that 
alteration in the structure of platelets determines the physical trapping or destruction of 
normal-sized platelets during the transmigration in the splenic vasculature (Burns et al., 
2004a). Since murine platelets are normally smaller than the human ones, this hypothesis 
could explain why in the mouse models of WAS thrombocytopenia is less severe than in 
WAS patients. A recent study has shown that in the BM of WASP knock-out mice the 
number of megakaryocytes is higher than in wild type mice. The morphology of WAS 
BM megakaryocytes is altered, as they do not have podosomes, which are adhesive 
structures, composed by a central core of actin and actin-associated proteins, surrounded 
by a ring of vinculin and linked to integrins (Tarone et al., 1985). In the same study,
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ectopic formation of proplatelets in the WAS BM has been reported, probably due to the 
lack of a negative feedback transmitted from the BM environment to the megacaryocites 
through the binding of fibrillar collagen I to a2|31 integrin. These results suggest that in 
the absence of WASP premature platelets shedding could occur in the BM and therefore 
this phenomenon could contribute to WAS-associated thrombocytopenia (Sabri et al., 
2006).
Interestingly, mutations which allow residual expression of WASP in 
lymphocytes, resulted in lack of WASP expression in platelets (Shcherbina et al., 
1999a). This could explain why platelets abnormalities are present both in XLT and 
WAS patients and suggest that the stability of a point mutated WASP could be reduced 
with respect of the wild type proteins.
1.5.2 Defects in myeloid cells
The role of WASP in the organization of actin cytoskeleton during a variety of 
cellular functions suggests that a component of WAS-associated immunodeficiency 
could result from defective cell trafficking, pathogen uptake and clearance (Burns et al., 
2004a). Chemotaxis (defined as directed migration along a gradient of a chemoatractant 
molecules) of monocytes isolated from the peripheral blood of WAS patients was 
reduced in response to a variety of stimuli, including MCP-1 (m onocyte 
chemoattractant protein 1) and FMLP (formyl-methionil-leucyl-phenilalanine) (Altman 
et al., 1974; Badolato et al., 1998).
The deficiency of WASP in human macrophages led to the complete absence of 
podosomes (Linder et al., 1999). Podosomes are highly dynamic structures that, during 
chemotaxis, re-localize behind the leading edge of the cell. In W ASP-deficient 
macrophages not only podosomes are missing but also filopodia and lamellipodia, 
whose formation depends on Cdc42 and Rac, respectively, are dispersed around the 
cell, instead of being polarized behind the leading edge (Linder et al., 1999), indicating
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the importance of WASP in regulating cell polarity. Podosomes are also normally 
present in osteoclasts, where are required for bone resorption (Biswas et al., 2004). 
WASP-deficent osteoclasts from WASP knock-out mice displayed a reduction in the 
number of podosomes formed upon adhesion to bone slices, and although they could 
form actin plaques, these structures displayed abnormal organization compared with the 
actin rings formed by normal osteoclasts (Calle et al., 2004). These alterations led to 
impaired formation of sealing zones between cell membrane and bone and, 
consequently, to defective bone resorption. Although no evident bone alterations have 
been reported neither in WAS patients or in WASP knock-out mice, there is one report 
of a Caffey-like disease with the clinical features of infantile cortical hyperostosis 
observed in three WAS patients (Abinun et al., 1988). Similarly to what observed in 
WASP-deficient macrophages and osteoclasts, WASP-deficient immature dendritic 
cells (DC) were also found to lack podosomes, to display an altered morphology and to 
be unable to establish cell polarity and translocate in response to fibronectin (Binks et 
al., 1998; Burns et al., 2001). Moreover, immature DC from WAS patients had a 
reduced ability to migrate in response to M IP-la, a ligand for the receptors CCR1 and 
CCR5 (Allavena et al., 2001), while the migratory capacity of mature DC from WAS 
patients in response to MIP-3p/CCL19 was normal. MIP-3p/CCL19 is one of the 
ligands (together with SLC/CCL21) of the receptor CCR7, whose expression is induced 
in DC upon maturation (Allavena et al., 2000). Similar defects of motility resulted in a 
reduction of net translocation of WASP-deficient murine immature DC on fibronectin, 
as well as of mature DC in response to CCL21 (de Noronha et al., 2004). The relevance 
of these findings was highlighted in the same work by showing defective homing of DC 
from the periphery to local lymph nodes (LN), especially early after skin sensitization, 
and reduced ability to redistribute to T cell areas in the LN upon antigen challenge (de 
Noronha et al., 2004). Since podosomal structures disappear 2-4 hours after DC
maturation (Burns et al., 2004b) suggesting that they are important for the first phases 
of DC migration to secondary lymphoid organs, it is possible that the absence of 
podosomes in WASP-deficient DC contributes to the trafficking defects observed in 
vivo. The contribution of these DC abnormalities to the clinical phenotype of WAS 
remains to be determined, however, it is possible that poor T cell priming by DC occurs 
in the LN during infections. Moreover, the persistence of mature DC in the periphery 
could in part contribute to the initiation or maintenance of inflammatory processes.
In addition to the reported defects in cellular trafficking, an impairment in IgG- 
mediated phagocytosis by WASP-deficient human and murine monocytes/macrophages 
was reported (Leverrier et al., 2001; Lorenzi et al., 2000). Phagocytic process is 
involved in the removal of foreign material (usually derived from extra cellular 
pathogens), and is mediated by the binding of opsonizing immunoglobulins and 
complement components to FcR (Allen and Aderem, 1996). Ligation of FCyR in 
macrophages initiates an intracellular signalling cascade with the recruitment and 
activation of several signalling molecules (Syk, PI3K, PLC) and adaptors (SLP-76, 
Nek). This process leads to the formation of a multi-molecular complex containing 
WASP, Fyb/SLAP, SLP-76, VASP and Nek, which localizes at the level of the 
phagocytic cup (Coppolino et al., 2001) and links FCyR engagement to actin 
cytoskeleton reorganization. Thus, the absence of WASP is likely to impair the 
reorganization of actin and of the plasma membrane during phagocytosis. In addition, 
the phagocytosis and clearance of apoptotic cells by W ASP-deficient murine 
macrophages was also shown to be defective (Leverrier et al., 2001). Clearance of 
apoptotic cells can be either mediated by direct recognition of PS exposed on apoptotic 
cells (Fadok et al., 2000) or by the binding of the complement component C lq , on the 
surface of apoptotic cells (Korb and Ahearn, 1997) and results in the production of anti­
inflammatory cytokines, such as TGF-p. It is therefore possible that in WAS patients
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impaired clearance of apoptotic cells contributes to disrupt immunological tolerance.
In accordance with data obtained in macrophages, it has been shown that 
W ASP-deficient murine immature DC were impaired in the ability to process 
particulated Ag, probably as a results of impaired cytoskeletal function, while they were 
able to process and present protein Ags (Westerberg et al., 2003).
WASP was shown to play a role also in the signalling downstream the FceRI 
(IgE receptor) in mast cells from WASP knock-out mice (Pivniouk et al., 2003). In 
these cells, both degranulation and production of IL-6 and TNF-a in response to FceRI 
triggering were reduced. These functional defects seemed to be the consequences of 
reduced Ca2+ flux and JNKs phosphorylation, respectively.
Therefore, the absence of WASP affects a variety of cellular functions in the 
myeloid compartment. Overall, the processes of Ag presentation and of myeloid cell 
migration are likely to be impaired by WASP deficiency.
1.5.3 Defects in lymphoid cells
1.5.3.1 T cells
T cell dysfunction is generally considered the major cause of immunodeficiency 
in WAS patients (Burns et al., 2004a). My PhD project has focused on the study of 
different subsets of T cells, using either untransformed, IL-2-dependent, T cell lines or, 
in some cases, freshly isolated T cells. This introduction presents the knowledge in the 
field at the beginning of this project and the advancements, which have been made in 
these years, which, together with our contribution, helped to clarify the cellular and 
molecular basis of WAS pathology.
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1.5.3.2 T cell activation
Early studies performed on T cell lines from WAS patients showed defective 
proliferation in response to anti-CD3 mAb, but normal proliferation in response to 
allogenic cells or IL-2 (Molina et al., 1992; Molina et al., 1993). Defective proliferation 
was found to be associated to the inability to secrete IL-2 in response to anti-CD3 mAb 
stimulation, although the addition of exogenous IL-2 was not able to rescue completely 
the proliferation. In that setting, co-stimulation through CD28 engagement was not able 
to elicit any increase of proliferation in WAS patients’ T cells (Molina et al., 1993). In 
accordance with those data, which suggest that the absence of WASP impairs T cell 
activation induced by the T cell receptor (TCR), and possibly by CD28, the Ab response 
against a T cell-dependent protein Ag was found to be reduced in WAS patients (Ochs 
et al., 1980). Alterations of T cell homeostasis was reported in WAS, since reduced 
numbers of T cells in the blood were found in young patients, early after birth (Park et 
al., 2004). Interestingly, this reduction affected more profoundly naive T cells than 
memory T cells and more profoundly CD8+ than CD4+ T cells. Possible explanations for 
these findings could be reduced thymic output or reduced survival/homeostatic 
proliferation in the periphery.
Two WASP knock-out mouse models were generated on different genetic 
backgrounds. In one model the cell maturation in lymphoid organs was not affected 
(Snapper et al., 1998) while in the other WASP deficiency caused a partial block of 
transition from double negative (DN) to double positive (DP) T cells in the thymus 
(Zhang et al., 1999). However, in both cases the numbers of circulating lymphocytes 
were lower in WASP-knock-out than in wild type (wt) animals (Dupre et al., 2006; 
Snapper et al., 1998). These data support a role of WASP in the survival of mature T 
and B cells. TCR-mediated T cell activation was found to be defective in WASP knock­
out mice, both in terms of proliferation and IL-2 production. These defects were not
corrected by the addition of anti-CD28 mAb, suggesting that WASP is required for 
signalling through the TCR and, possibly, through CD28. Interestingly, the phenotype 
of WIP knock-out mice resembles WASP knock-out mice, showing impairment of T 
cell functions, including proliferation and IL-2 secretion (Anton et al., 2002), 
confirming the importance of WASP-WIP interaction for the regulation of WASP 
activity.
1.5.3.3 Cytokine production
At the beginning of this project, IL-2 production was basically the only defect in 
cytokine production attributed to WASP-deficient T cells. A more in-depth analysis of 
cytokine production has been performed during the development of this project, and 
will be presented and discussed hereafter. In addition, during these years a number of 
studies have been done in T cells from the mouse models of WASP, which have also 
highlighted a more complex picture of cytokine deficiency. Analysis of the basis of 
defective IL-2 production was performed in T cells from WASP knock-out mice, 
stimulated through TCR/CD28, showing that WASP absence determined a block in IL- 
2 gene transcription (Cianferoni et al., 2005; Morales-Tirado et al., 2004). This was the 
case both when freshly isolated total T cells or in vitro primed CD4+ T cells were 
analyzed, suggesting that WASP could be required for IL-2 gene transcription both in 
naive and in memory T cells. IFN-y secretion was also reduced in murine WASP knock­
out T cells cultured in Thl polarizing conditions and restimulated through TCR/CD28, 
although this reduction was shown to be due to defective cytokine granules sorting and 
secretion rather than to cytokine synthesis. Indeed, TCR/CD28-driven expression of 
IFN-y mRNA and protein was normal in T hl cells from WASP knock-out mice 
(Morales-Tirado et al., 2004). In the same work IL-4 production by WASP-deficient 
CD4+ T cells was also reduced.
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1.5.3.4 CD8+ T cell activation and effector functions
At the beginning of this project, no data were available about the function of 
WASP-deficient CD8+ T cells. Recently, the contribution of CD8+ T cells to the 
immunological defects in the context of WASP deficiency was highlighted by the 
findings of a reduced secondary immune response against Influenza virus in WASP 
knock-out mice, which was due to a reduction in the frequency of Ag-specific CD8+ T 
cells, associated to defective synthesis of the effector cytokines IFN-y and TNF-a by 
these cells (Strom et al., 2003a). The nature of this defect was next clarified, since it 
was shown that although WASP knock-out mice cleared normally Influenza virus 
during the primary inoculation, the frequency of memory Influenza-specific CD8+ T 
cells in the blood of infected WASP knock-out mice was lower than in wt mice 
(Andreansky et al., 2005). This suggests that WASP deficiency causes either reduced 
differentiation or survival of memory T cells. In addition, WASP knock-out mice 
showed increased susceptibility to lethal pneumonia induced by S. Pneumoniae, which 
was probably due to reduced production of natural Abs. Furthermore, these mice 
showed reduced clearance of Mycobacterium bovis. The clearance of this intracellular 
pathogen required coordinate action of macrophages and T hl cells (Murray, 1999). 
However, macrophages from WASP knock-out mice secreted normal levels of both 
TNF-a, IL-12 and IL-10 upon M. Bovis exposure, suggesting that Thl cell dysfunction 
rather than macrophages dysfunction is likely to be the cause of defective response to 
this pathogen. These data recapitulate some features of the immunological defects of 
WAS patient and suggest that WAS is characterized by defective cellular-mediated 
immunity.
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1.5.3.5 Role of WASP in immunological synapse (IS) assembly
An important part of this PhD project has been to elucidate the molecular 
mechanisms by which WASP controls T cell activation. In the recent years a number of 
evidences underscored the importance of a structure, named the immunological synapse 
(IS), as a central regulator of T cell signalling and activation, and, more in general of 
information transfer between T cells and antigen presenting cells (APC). IS 
organization accompanies receptor clustering, together with recruitment of second 
messengers and adaptor molecules. Upon TCR engagement, these molecules re­
organize according to a precise spatial distribution, with the TCR and associated src- 
kinases in the center, surrounded by a ring of integrins and cytoskeleton-associated 
molecules. This highly-ordered organization of signalling molecules has been called 
supra-molecular activation cluster (SMAC) and can be divided into a central SMAC (c- 
SMAC) and e peripheral SMAC (p-SMAC) according to the topology and molecule 
segregation (Monks et al., 1998). This structure has been named immunological 
synapse, for its analogies with the synapses formed by neuronal cells, and was shown to 
be required for sustained signalling and productive T cell activation. Indeed, at least 2 
hours of IS contact are required to drive cellular division in a naive CD4+ T cell (Lee et 
al., 2002). However, the role of the IS is clearly more complex than what initially 
proposed. The IS was shown to be dispensable for early tyrosine kinases signalling, 
upon TCR engagement, but required for TCR internalization and dampening of the 
signal (Lee et al., 2003; Lee et al., 2002). TCR desensitization and internalization is 
crucial to allow serial engagement of multiple TCR molecules by few peptide-MHC 
complexes (Valitutti et al., 1995b). Thus, the IS is probably involved in the modulation 
of the quantity and the quality of signals delivered through the TCR, so to determine the 
final outcome of T cell activation.
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The formation of conjugates between T cell and APC implies changes in cell 
shape with massive re-orientation and re-organization of the cytoskeleton, requiring 
Ca2+ mobilization and actin polymerization (Donnadieu et al., 1994; Lowin-Kropf et al.,
1998). Accordingly, the transport of the engaged TCRs from all over the cell membrane 
to the interface requires cytoskeletal transport via the activity of myosin/actin (Wiilfing 
and Davis, 1998) and the integrity of actin cytoskeleton was shown to be essential for 
productive T cell activation (Valitutti et al., 1995a). A key transducer of signals from 
the TCR to the actin cytoskeleton is Vav-1, a guanosine exchange factor (GEF) for Rho 
GTPases including Racl and, likely, Cdc42, specifically expressed in T cells. Evidence 
of the importance of Vav-1 in the regulation of actin cytoskeleton, downstream of TCR 
triggering, came from the study of Vav-1 deficient murine T cells, which showed 
defective capping of actin and of TCR molecules (Holsinger et al., 1998). Similarly, 
TCR capping and endocytosis, two processes known to require actin polymerization, 
were impaired in T cells from WASP knock-out mice (Snapper et al., 1998; Zhang et 
al., 1999). The similarities between Vav-1- and WASP-deficient T cells support the 
possibility that Vav-1 acts as a GEF for Cdc42, downstream TCR/CD28, and that this 
pathway links the TCR to actin polymerization, through the action of WASP. In the 
recent years, many important pieces of information have been collected regarding a 
possible involvement of WASP in IS organization. WASP was initially shown to be 
recruited at the site of contact between T cell and APC (Cannon et al., 2001). This 
recruitment is achieved by the formation of a multi-molecular complex, constituted by 
the Src homology 2 domain-containing leukocytes protein of 76 kDa (SLP-76), Vav-1, 
the SH3-containing adaptor protein Nek and Cdc42 (Zeng et al., 2003). While Cdc42 
stimulates WASP activity, as previously said, Nek binding was shown to be required for 
the re-localization of WASP to the IS (Zeng et al., 2003). WASP sub-cellular 
localization is also regulated by WIP. Indeed, in resting T cells the vast majority of
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WASP is bound to WIP. Activation of T cell through the TCR induces phosphorylation 
of WIP, probably exerted by the non-classical protein kinase C 0 (PKC0), and its 
dissociation from WASP, which is then activated (Sasahara et al., 2002). PKC0, which 
is predominantly expressed in haematopoietic cells (Baier et al., 1993) has been 
identified in the last years as a central regulator of T cell activation. This kinase was 
shown to be involved in IL-2 gene transcription, by regulating the activation of different 
transcription factors, including AP-1, NFkB and NFAT (see section 1.5.3.7) (Baier- 
Bitterlich et al., 1996; Coudronniere et al., 2000) and to be recruited at the IS upon 
TCR/CD28 triggering (Bi et al., 2001; Monks et al., 1998). The importance of WASP in 
IS formation was highlighted by studies performed in both human and murine WASP- 
deficient T cells clearly showing that WASP absence impaired both the polarization of 
T cells toward beads coated with anti-CD3/anti-CD28 mAbs (Dupre et al., 2002) and 
the formation of the IS, particularly in conditions of suboptimal TCR triggering (Badour 
et al., 2003; Cannon and Burkhardt, 2004).
1.5.3.6 Role of lipid rafts in T cell activation
A crucial aspect of IS organization is the spatial segregation of surface receptors. 
This segregation was proposed to be achieved through compartmentalization of plasma 
membrane domains (Dustin, 2002). The lipid bilayer of plasma membrane is not 
homogenous but contains different lipid species, which are asymmetrically distributed 
in the cytoplasmic and exoplasmic leaftlet and also precisely organized in the lateral 
dimension (Kusumi and Sako, 1996). Membrane domains enriched in sphingolipids and 
cholesterol, in the outer leaflet of the plasma membrane, were originally identified in 
epithelial polarized cells, in which an apical and a basolateral membrane was physically 
and molecularly distinguishable (Brown and Rose, 1992). These micro-domains (which 
are less than 70 nm in diameter) were proposed to act in living cells as platform (rafts) 
where proteins are “attached”, thus participating to a variety of cellular processes,
including protein sorting and signal transduction (Simons and Ikonen, 1997). Thanks to 
their particular lipid composition, rafts have been proposed to constitute a “liquid- 
ordered” phase of the plasma membrane. Since lipid rafts are relatively insoluble into 
non-ionic detergents (such as Triton X-100), it has been proposed that they can be 
isolated from native membranes as detergent-resistant membranes (DRM) (London and 
Brown, 2000). The importance of rafts in T cell activation came from the evidences that 
CD3£ is recruited to DRM after its engagement by anti-CD3 mAb (Montixi et al., 1998; 
Xavier et al., 1998). This re-localization was shown to put the TCR into contact with 
CD4-Lck, which are also present in DRM, where major tyrosine phosphorylation 
occurs. Indeed, both LAT (linker for activation of T cells) and the Src kinase Lck 
constitutively localize to lipid rafts thanks to lipid modification (Resh, 1996; Zhang et 
al., 1998). In addition, recruitment of several key signalling molecules into DRM upon 
TCR/CD28 triggering was shown to be crucial both for their activation and activity (for 
review see (Miceli et al., 2001)). Interestingly, the dynamic partition of the highly 
glycosylated phosphatase CD45 into DRM or non-DRM fractions was shown to 
regulate its inhibitory versus activatory role in T cell activation (Edmonds and 
Ostergaard, 2002; Zhang et al., 2005). Stimulation of T cells by beads coated with anti- 
CD3/CD28 mAbs, as well as by real Ag-loaded APC, was shown to induce clustering of 
the ganglioside GM1 (a glycosphigolipid containing sialic acid), which is enriched in a 
subset of membrane rafts (Bi et al., 2001; Round et al., 2005; Viola et al., 1999) further 
supporting a model of T cell activation in which re-organization of signalling machinery 
is mediated by transient partition in, or exclusion from, lipid rafts. Actin cytoskeleton 
was proposed to play a role in regulating lipid rafts dynamics and in particular in the 
clustering of lipid rafts at the IS (Sanui et al., 2003; Valensin et al., 2002; Yoon et al., 
2003).
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A further confirmation of the importance of the lipid composition of the plasma 
membrane in TCR/CD28 signalling came from the observation that T cell stimulation 
induces an upregulation of GM1 on the surface of T cells, as well as an increase of total 
GM1 levels (Viola et al., 1999). GM1 relocalization to plasma membrane was shown to 
occur in parallel with translocation of Lck from intracellular compartments, leading to 
the hypothesis that higher levels of plasma membrane GM1 correlates with a more 
efficient signalling machinery (Tuosto et al., 2001). Therefore, the higher GM1 levels 
observed in activated versus resting T cells, as well as in memory versus naive T cells, 
would reflect higher responsiveness upon TCR triggering. In accordance with this 
hypothesis, hyper-reactivity of T cells from patients affected by lupus erythematosus 
were linked to higher levels of the ganglioside GM1 in activated T cells (Krishnan et 
al., 2004), suggesting that alteration in lipid rafts composition/dynamics could be 
involved in alteration immune function and regulation in humans.
Given the relevance of these micro-domains in T cell activation we investigated 
i) whether TCR/CD28-mediated stimulation could influence the partition of WASP into 
DRM or non-DRM fractions and ii) if and to what extent WASP deficiency influences 
the levels of GM1 in resting and activated cells.
Recently, a number of studies challenged or lead to a re-evaluation of the 
possible role of lipid rafts in T cell signalling, or even of the methods used to study rafts 
and raft-association of proteins. Therefore, our results will be discussed in view of these 
recent data.
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1.5.3.7 TCR signalling: an overview
The detection of antigens by T cells is achieved through recognition by the TCR 
of antigenic peptides presented in association to MHC molecules. The final outcome of 
this recognition can be either full activation and acquisition of effector functions or 
establishment of anergy. The current model of T cell activation proposes that at least 
two signals must be provided to a naive T cell to be fully activated and to avoid anergy 
(Linsley and Ledbetter, 1993; Schwartz, 2003). The first signal is necessarily delivered 
through the TCR, while the second signal, generally referred to as costimulation, is 
provided by receptors expressed by APCs or by soluble factors. The main molecule 
involved in the delivering of “signal two” is CD28, whose natural ligand (B7.1/2) is 
highly expressed by activated/mature APC (Acuto and Michel, 2003). Engagement of 
the TCR elicits a cascade of signalling events, which leads to transcriptional activation 
of multiple genes involved in T cell proliferation and differentiation, and to cytoskeletal 
rearrangements (van Leeuwen and Samelson, 1999). The main molecular events 
downstream of TCR and CD28 triggering will be presented here, in order to 
contextualise the “position” of WASP in these pathways, and to underline what is 
known about the role of WASP in TCR/CD28-mediated signalling and what is still 
unclear.
а. TCR signalling: proximal events
The first event upon TCR triggering is the phosphorylation of different tyrosine 
residues in the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3-y,
б, e and £ invariant chains of the TCR. This phosphorylation is exerted by Src kinases 
(mainly Lck) and regulated by the phosphatase CD45 (Palacios and Weiss, 2004; 
Zamoyska et al., 2003). Phosphorylated ITAMs mediate the recruitment and activation 
of the Syk kinase ZAP-70 (Neumeister et al., 1995). Full phosphorylation of the CD3- 
£ is  essential for productive T cell activation (Sloan-Lancaster et al., 1994) and is
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achieved with the help of CD4/CD8 co-receptors, which are constitutively associated to 
Lck. ZAP-70 is a central kinase as it phosphorylates a number of molecules including 
the adaptor molecules LAT (linker of activated T cells), which is constitutively rafts- 
associated (Zhang et al., 1998) and SLP-76. LAT-SLP-76 complex is a fundamental 
organizer of TCR signalling (Figure VA) (Myung et al., 2000).
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One crucial function of LAT is coupling the TCR to the Ras pathway. Indeed, 
phosphorylated LAT recruits the adaptor protein Grb2, which associates with the Ras 
guanine nucleotide exchange (GEF) protein, Sos. Sos/Grb2 can activate the small G 
protein Ras, although an alternative pathway of Ras activation has also been described, 
involving the guanyl nucleotide releasing protein GRP, which can be recruited by DAG 
(see after) (Cantrell, 2003a). Activation of Ras is a crucial event, as it initiates the 
activation of the Raf-l/M EK/ERKl/2 signalling pathway. ERK1/2 (also called p44/42 
MAPKs) controls T cell cycle progression and the transcription of the Fos gene 
(FigureVB) (Hunter and Karin, 1992). Fos gene transcription is essential for the
activation of the AP-1 complex, which is required for IL-2 gene transcription (see 
section g).
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c. Inositol lipid metabolism (I): from PLCy to activation of NFAT
In addition, LAT, together with SLP-76 and the adaptor Gads, mediates the 
recruitment of PLCy, a key molecule of the inositol lipid metabolism. PLCy activation 
requires the activity of Lck, Zap-70 and of the Tec kinases (see section e). The products 
of PLCy enzymatic activity are inositol 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG). IP3 is responsible for release of Ca2+ from the endoplasmic reticulum (ER), 
which then mediate the opening of Ca2+ channels (Ca2+ release activated channels: 
CRAC) on the plasma membrane (Lewis, 2001). Ca2+ increase induces the activation of 
several calm odulin-dependent enzymes, including calcineurin and CAMKII. 
Calcineurin has a crucial role as it dephosphorylates multiple phosphoserine residues on 
the transcription factors NFAT. Phosphorylated NFAT is retained in the cytoplasm in 
resting cells, and upon dephosphorylation it translocates to the nucleus, where it
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mediates the activation of many cytokine genes, including IL-2, IL-4, IFN-y, IL-3, GM- 
CSF, IL-10 (Hogan et al., 2003). Five NFAT family members have been identified, 
which are named NFAT-1-2-3-4 (also called NFATc2-1-4-3) and NFAT-5 (also called 
TonEBP), which is regulated in a different way. The different members of NFAT 
family have a quite redundant role in T cell activation, as shown by the analysis of mice 
lacking individual NFAT proteins (Crabtree and Olson, 2002). However, NFAT2 alone 
is sufficient and necessary for Th2 differentiation (Yoshida et al., 1998).
d. Inositol lipid metabolism (II): from  PLCy to activation of PKC 
Production of DAG is critical for the activation of the serine/threonine kinases
of the PKC family and also to link lipid metabolism to the Ras pathway (Ebinu et al.,
2000). PKCs can be divided into two groups according to their dependence on Ca2+ 
(Mellor and Parker, 1998). In T cells the more relevant form of PKC is the Ca2+- 
independent PKC0. The importance of PKC0 in T cell activation has been highlighted 
in the last years. This kinase is specifically expressed in T cells (and in skeletal muscle). 
Upon TCR triggering, PKC0 translocates to the IS at the levels of lipid rafts (Bi et al.,
2001) and it positively regulates IL-2 gene transcription, likely by modulating the 
activity of the transcription factors AP-1 and NFkB (Bi et al., 2001; Lin et al., 2000; 
Werlen et al., 1998).
e. Inositol lipid metabolism (III): PI3K signalling
A second pathway of inositol lipid metabolism activated by TCR and CD28 
involves the activation of PI3K (Cantrell, 2001). PI3K can be divided into three classes. 
Class I PI3Ks are generally coupled to extracellular stimuli. In T cells, PI3K, which can 
be also activated through CD28, independently on TCR triggering (Ward et al., 1993), 
generates PI(3,4,5)P3, starting from PI(4,5)P2. PI(3,4,5)P3 is then metabolized to 
produce PI(3,4)P2. Generation of PIP3 and PI(3,4)P2 is crucial as these lipids mediates 
the recruitment of several proteins containing pleckstrin homology (PH) domains,
including the Tec kinases (Finkelstein and Schwartzberg, 2004), the phosphoinositide 
dependent protein kinase (PDK) 1, the protein kinase B (PKB/AKT) (Cantrell, 2001) 
and, possibly, Vav-1, which is the guanine nucleotide exchange proteins (GEFs) for 
Rho, Rac and Cdc42 . PDK1 targets different kinases, including p70SKl, GSK3 and 
PKB itself, thus regulating a variety of processes including T cell size, growth, survival, 
glucose metabolism and NFAT localization (Cantrell, 2003b; Patra et al., 2004).
Tec kinases belong to a large family of non-receptor tyrosine kinases. T cells 
mainly express Itk and Rtk Tec kinases (Schwartzberg et al., 2005). Beside being 
required for full PLCy activation, Tec kinases exert an important role in coupling 
TCR/CD28 triggering to actin cytoskeleton rearrangement, by association and 
functional interaction with Vav-1 and WASP. A schematic representation of inositol 
lipid metabolism is depicted in Figure VI.
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f. Activation of JNK and p38 MAPKs
Activation of Rho GTPases links TCR/CD28 triggering to the activation of the 
MAPKs JNK1/2 and p38 (Figure VII) (Davis, 2000; Dong et al., 2002). Both p38 and 
JNK are involved in the transcriptional activation of IL-2 gene, the first by 
phosphorylation of ATF2 transcription factor, the second by phosphorylation of the c- 
Jun transcription factor, which, together with Fos, forms the AP-1 complex (Figure VII) 
(Macian et al., 2001). In addition, JNK has been shown to stabilize IL-2 mRNA (Chen 
et al., 2000).
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g. AP-1 and NFkB
AP-1 complex is formed by Fos family members (c-Fos, FosB, Fra-1 and Fra-2) 
and by Jun family members (c-Jun, JunB and JunD). AP-1 dimer binds DNA either 
alone, or together with NFAT (Karin et al., 1997). During T cell activation, AP-1 binds 
and positively regulates the IL-2 promoter. NFkB comprises a family of factors which 
acts as dimers. NFkB is retained in the cytoplasm of resting T cells through the binding 
to the inhibitors of kB (IkBs). Phosphorylation of IkBs by IkB kinases (IKKs) 
determines their degradation through the ubiquitin-proteasome pathway. PKC0 is 
involved in NFkB activation, possibly by direct phosphorylation of IKKp (Lin et al., 
2000). It has been recently proposed that PKC0 regulates NFkB activation through 
interaction with the CARMA1-Bel-10-MALT1 complex (Thome, 2004). Interestingly, 
this complex is localized at the site of IS formation, at the level of lipid rafts (Wang et 
al., 2004). Therefore, formation of the IS could be required for the productive 
interaction of PKC0 with its downstream targets and eventually NFkB activation. 
Importantly, NFkB activity is also regulated by direct phosphorylation of its 
transactivating subunits p65, c-Rel and relB (Weil and Israel, 2004). NFkB dimers bind 
to IL-2 promoter, contributing to IL-2 gene transcription.
A schematic representation of IL-2 gene transcription is depicted in Figure VIII.
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h. TCR/CD28 and the actin cytoskeleton: a central role for Vav-1 and WASP
Recruitment and activation of Vav-1 is another key event of TCR/CD28- 
mediated re-organization of the actin cytoskeleton. Vav-1 acts as a GEF for Rac and 
possibly for Cdc42, although this issue is more controversial (Tybulewicz, 2005).
In view of the fact that Vav-1 is activated through the TCR/CD28 and it induces 
the activation of Rho GTPases, Vav-1 has been recognized as a crucial transmitter of 
signals from the plasma membrane to the cytoskeleton and a crucial molecule, which 
allows to integrate signals from the TCR and from CD28. Vav-1 is recruited and 
activated through the binding to SLP-76 upon TCR triggering (Tuosto et al., 1996), 
while it possible that a different mechanisms account for Vav-1 recruitment upon CD28 
triggering (Klasen et al., 1998; Michel and Acuto, 2002; Raab et al., 2001). Activated 
Vav-1 is found in a complex containing the adaptor proteins SLP-76 and Nek, and 
WASP (Zeng et al., 2003). Through its GEF activity, Vav-1 has been shown to regulate
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actin cytoskeleton remodelling during IS formation and T cell activation (Wulfing et al., 
2000). Downstream effectors of Vav-1 activity include WASP. WASP is therefore a 
key molecule involved in the transduction of signals from triggered TCR/CD28 to actin 
(Figure IX). Vav-1 has a crucial role not only in cytoskeleton rearrangement, but it was 
also shown to activate the Ras pathway and to regulate PKC0 localization and 
activation (Caloca et al., 2003; Villalba et al., 2000).
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Whether CD28 provide just a quantitative or also a qualitative contribution to 
TCR signalling is still a matter of debate. In accordance with the first model, triggering 
of CD28 alone leads to transient expression of few genes, while TCR triggering is 
required for activation of the main transcriptional programs (Acuto and Michel, 2003). 
Therefore, CD28 would act as an amplifier of TCR signalling, being required to lower 
the TCR signalling threshold. The qualitative model would predict that CD28 can 
provide in trans help to TCR signalling, by activating distinct signalling pathways, 
possibly linked to cytoskeleton rearrangement and microdomains clustering. It is 
however possible that both mechanisms account for the essential contribution of CD28 
to TCR signalling. Indeed, CD28 ligation was shown to both influence the 
phosphorylation status of different molecules, which are downstream of the TCR, and to 
enhance the phosphorylation of Vav-1 and WASP, both in the presence or absence of 
TCR engagement (Kim and White, 2006). Although this last study was performed in 
transformed T cells, it strongly suggests that Vav-1 and WASP are crucial molecules for 
the integration of TCR and CD28 signalling, which could determine the outcome of T 
cell activation.
1.5.3.8 TCR signalling in WASP-deficient T cells
Analysis of signal transduction pathways downstream the TCR in WASP- 
deficient human and murine T cells have unravelled some important aspects of the role 
of WASP in T cell activation. However, the precise mechanism(s) by which WASP 
regulates T cell activation remains to be determined. In particular, the biochemical link 
between structural events (such as IS formation), which directly require cytoskeleton 
remodelling, and physiological events (such as proliferation and cytokine production), 
which rely on transcriptional activation, is unclear.
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Early studies showed that Ca2+ influx and CD3£ phosphorylation were elicited by 
TCR triggering in human WAS and control T cells at comparable levels (Molina et al., 
1993). More in-depth analysis of TCR signalling was then performed in T cells from 
WASP knock-out mice, showing grossly normal activation of the main signalling events, 
including total tyrosine phosphorylation, and in particular phosphorylation of CD3£ and 
of the MAPKs ERK1/2 and SAPK/JNK, both in mature T cells and in thymocytes 
(Zhang et al., 1999). However, in this setting, TCR-driven Ca2+ influx seemed less 
sustained in WASP-deficient T cells than in control T cells, suggesting that despite early 
TCR signalling being conserved, downstream events, such as activation of transcription 
factors, could be disturbed. In accordance, a less sustained Ca2+ influx was observed in 
Vav-1 null Jurkat cells, which was associated with reduced transactivating activity of 
NFAT (Cao et al., 2002). Interestingly, this reduction was observed using both a 
consensus sequence extrapolated from the human IFN-y promoter or from the IL-2 
promoter. In the first case, productive activation required the binding of NFAT alone, 
while in the second case cooperative binding of NFAT and AP-1 was required. 
Moreover, in these cells defective induction of the SAPK/JNK pathway was reported, 
leading to reduced activity of AP-1. This was in accordance with previous data showing 
that activation of JNK/c-JUN/AP-1 pathways occurs downstream of Rac-1 and Cdc42 
(Coso et al., 1995; Minden et al., 1995). Whether WASP is also involved in these 
pathways has been in part addressed in this work and will be discussed hereafter. In 
parallel to our work, studies performed in T cells from WASP knock-out mice support a 
role of WASP in the regulation of transcriptional activation of the IL-2 gene. Indeed, 
WASP was shown to regulate the activation of NFAT in thymocytes from WASP knock­
out mice, stimulated through TCR/CD28 (Badour et al., 2004a). Moreover, nuclear 
levels of NFAT-2 (also called NFAT-c) were lower in CD4+ T cells from WASP knock­
out mice than in wt mice, upon TCR/CD28 stimulation (Cannon and Burkhardt, 2004).
Defective NFAT-1 (also called NFAT-p) activity has also been recently reported in T 
cells from WASP knock-out mice. (Cianferoni et al., 2005). This defect was shown to be 
due to defective NFAT-1 dephosphorylation. Important pieces of information regarding 
the molecular mechanisms by which WASP regulates T cell activation came from the 
finding that, upon TCR triggering, WASP is phosphorylated at the level of tyrosine 291 
by the Src-kinase Fyn, independently of Cdc42 activation (Badour et al., 2004a). This 
phosphorylation occurs early after TCR triggering and is transient. Dephosphorylation is 
exerted by the tyrosine phosphatase PTP-PEST, through the adaptor protein PSTPIP1. In 
WASP knock-out thymocytes, expression, of a WASP mutant in which the tyrosine 
residue 291 was mutated to phenylalanine impaired NFAT activation in response to 
TCR/CD28 triggering. Interestingly, the extent of this reduction was even bigger than the 
one observed in WASP knock-out thymocytes. In addition, actin polymerization and the 
accumulation of PKC0 at the site of IS formation were also impaired by mutation of the 
291 tyrosine residue (Badour et al., 2004a).
WASP was also reported to play a role in TCR endocytosis. Indeed, defective 
TCR down-regulation, after TCR triggering, was reported in T cells from WASP knock­
out mice (Zhang et al., 1999). This could be due either to a requirement of WASP in 
TCR endocytosis, mediated by the binding to the endocytic adaptor protein Intersectin2 
(McGavin et al., 2001) or even to involvement of WASP in endosomes traffic, as it has 
been shown for the yeast WASP homologue, Las 17 [Chang JCB 2005]. TCR 
internalization, which occurs rapidly after its engagement, is crucial to define the 
outcome of T cell activation. Internalized TCR can be either recycled back to the plasma 
membrane, where they can be engaged again (Valitutti et al., 1995b; Viola and 
Lanzavecchia, 1996), or they can be targeted to lysosomal degradation. Therefore, 
altered TCR internalization could also affect TCR signalling in WASP-deficient T cells.
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However, whether all the signalling defects identified in WAS T cells depend on 
the loss of WASP-driven actin polymerization or if WASP could play a role in 
propagating TCR signalling, which is independent of actin polymerization, is a matter of 
debate. Indeed, it was shown that the WH1 domain of WASP, which is responsible for 
WIP binding, is strictly required for the induction of NFAT activity (Silvin et al., 2001). 
In the same work, it was shown that transfection of Jurkat cells with a mutant of WASP 
lacking the C terminal domain led to enhancement of NFAT activity, although TCR 
capping and internalization were not affected. These data led to formulate the hypothesis 
that regulation of IL-2 transcription by WASP could be uncoupled from actin 
polymerization. Recent data obtained in T cells from WASP knock-mice showed that 
although ERK1/2 phosphorylation, upon TCR/CD28 stimulation, was normal, the 
nuclear translocation of ERK1/2 was reduced, in comparison with wt T cells (Cianferoni 
et al., 2005). This defect was associated to reduced induction of c-Fos gene transcription, 
which is dependent on ERK1/2 signalling, and reduced AP-1 DNA binding activity. 
Therefore, it appears that WASP deficiency results in alteration of multiple pathways 
leading to T cell activation. Whether these signalling defects are all consequent to 
alteration of actin dynamics remains to be clarified.
1.5.3.9 NK cells
The high susceptibility of WAS patients to viral infections and lymphoreticular 
malignancies suggests an impairment of immune-surveillance. Although the percentages 
of NK cells in the peripheral blood of WAS patients is normal or even higher than the 
normal range (Gismondi et al., 2004), both the natural and antibody-mediated cellular 
cytotoxicity (ADCC) of NK cells isolated from either WAS or XLT patients was shown 
to be reduced with respect to NK cells of healthy donors (Gismondi et al., 2004; Orange 
et al., 2002). Reduced lytic activity was attributed to alteration of actin dynamics in 
WASP-deficient NK cells. Indeed, it was shown that NK-mediated killing requires the
formation of a highly organized structure, named activatory immunological synapse (IS), 
which is accompanied by re-localization of signalling proteins and lipid rafts (Lou et al., 
2000; Vyas et al., 2001). WASP was shown to be recruited to the IS in NK cells (Orange 
et al., 2002) and its absence resulted in reduced clustering of F-actin and perforin- 
containing granules and in a general alteration of the spatial and temporal organization of 
this structure (Gismondi et al., 2004; Huang et al., 2005; Orange et al., 2002). Moreover, 
the formation of conjugates between NK and target cells itself was also shown to be 
impaired in the absence of WASP (Gismondi et al., 2004). Interestingly, culture in the 
presence of exogenous IL-2 was able to restore normal F-actin clustering and 
cytotoxicity in both WAS and XLT-derived NK cells (Gismondi et al., 2004; Huang et 
al., 2005), indicating that WASP is dispensable for IL-2-mediated signalling in NK cells. 
WASP is likely to regulate actin cytoskeleton reorganization during IS formation in NK 
cells, downstream of Cdc42, which is activated in response to the FcyRIII (CD 16) 
triggering. Further information about the molecular mechanisms by which WASP 
controls NK cell activation and cytotoxicity came from the observation that WASP was 
tyrosine-phosphorylated in response to either CD16 or |32 integrin engagement 
(Gismondi et al., 2004). In accordance to what observed in T cell from WASP knock-out 
mice, in which WASP phosphorylation was shown to be involved in the activation of the 
nuclear factor of activate cells (NFAT), in human NK cells, WASP absence resulted in 
delayed nuclear translocation of NFAT-2 and also of the RelA subunit of NFkB (Huang 
et al., 2005). These alterations in transcription factors activation seemed to be actin- 
independent. This supports a role of WASP in modulating the transcriptional status of 
lymphoid cells, which does not depend on its role of actin nucleation-promoting agent, as 
it was previously shown in a different cellular model (Silvin et al., 2001). The 
importance of WASP not only in NK cell function but also in their survival has been 
pointed out by the finding of a patient with a severe WAS gene mutation in which a
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somatic reverse mutation, likely occurred in a NK cell progenitor, led to the presence of 
a high proportion of WASP* NK cells in the peripheral blood (Lutskiy et al., 2005), 
suggesting that WASP expression confers a selective advantage to NK cell progenitor. 
Moreover, since this high frequency of revertant cells has been found in the CD56d,m 
population, which comprises terminally differentiated NK cells, it is possible that WASP 
is more required for survival and/or function of terminally differentiated “effector” NK 
cells.
Therefore, impaired NK cell function could be one mechanisms underlying the 
high susceptibility to viral infections and to haematological tumours observed in WAS 
patients.
1.5.3.10 B cells
The role of WASP in Ab production and, more in general B cell function is 
still controversial. The first report of immune dysfunction in WAS patients was the 
inability to produce Abs directed against carbohydrate Ag (Ayoub et al., 1968), such as 
Pneumococcus polysaccharides. This family of Ags is defined as thymus-independent 
(T-I) as these Ags are in principle able to trigger B cell activation without the 
requirement for T cell help. Although polysaccharide Ags normally trigger the 
production of IgG2 Abs (Siber et al., 1980), normal serum distribution of IgG 
subclasses were reported in WAS patients, despite reduced levels of Abs directed 
against various polysaccharides Ags (Nahm et al., 1986), suggesting that other 
mechanisms could contribute to this deficiency. Reduced numbers of B cells were 
found in the blood of WAS patients (Park et al., 2005). This deficiency was associated 
to an increase in the frequency of CD21' and CD35' B cells, and, in patients older than 
three years of age, to a reduction in CD27+ post germinal centre B cells. CD21 and 
CD35 are both complement receptors, involved in phagocytosis of opsonized particles 
and in B cell response to T-dependent Ags (Ahearn et al., 1996). CD27, a member of
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the TNFR family, is expressed by circulating memory B cells. In humans, about half of 
circulating memory B cell have undergone somatic hyper-mutation in the germinal 
centres (GC) (Klein et al., 1998), thus CD27 deficiency correlates with the involution of 
germinal centre (GC) observed in the spleen of WAS patients (Vermi et al., 1999). 
Importantly, CD27 is also expressed by marginal zone (MZ) B cells, which, in humans, 
are memory cells expressing high levels of CD21 (Pillai et al., 2005) and are mainly 
involved in the response against encapsulated bacteria, as they can produce anti­
polysaccharides Abs. In WAS patients a depletion of the MZ was observed in the spleen 
(Vermi et al., 1999) could be one reason for the poor immune response to encapsulated 
bacteria. Similar alteration in the B cell areas of the spleen have been recently reported 
in WASP knock-out mice (Westerberg et al., 2005). The development of MZ B cells 
was shown to crucially depend, in the mouse, on signalling through Pyk-2 and NF-kB 1 
(p50) (Cariappa et al., 2000; Guinamard et al., 2000). However, no data about the 
function of these proteins in WASP-deficient B cells are available. Contrasting data 
were obtained regarding transmembrane signalling in WASP-deficient B cells, showing 
either normal or reduced Ca2+ influx upon Ig crosslinking (Henriquez et al., 1994; 
Simon et al., 1992). A possible involvement of WASP in signalling through the B cell 
receptor (BCR), however, was supported by the finding that WASP was tyrosine- 
phosphorylated by the Bruton’s tyrosine kinase Btk, upon BCR triggering (Baba et al.,
1999), suggesting that WASP may be involved either in B cell development or 
activation. As expected, WASP is involved in cytoskeleton remodelling in B cells. 
Indeed, both in human and murine WASP-deficient B cells defective polarization in 
response to IL-4 and CD40 ligation and defective chemotaxis towards a variety of 
chemokines (CXCL13, CCL19, CXCL12) was reported (Westerberg et al., 2001; 
Westerberg et al., 2005). In the same work, reduced homing capacity of murine WASP- 
deficient B cells to both peripheral lymphoid tissues and to BM was found to be
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associated to reduced immune response in WASP knock-out mice. Therefore, it is likely 
that defective trafficking of B cells contributes to WAS associated immune-deficiency.
It is still unclear what is the relative contribution of B versus T lymphocytes in 
WAS-associated immunodeficiency. Studies from WASP and WIP knock-out mice 
showed an overall preserved B cell function, concomitant with reduced T cell function, 
supporting the hypothesis the WAS immunodeficiency is mainly due to T cell rather 
than B cell dysfunction (Anton et al., 2002; Snapper et al., 1998). However, while in the 
WIP knock-out mice the immune response to a T-dependent Ag was compromised 
(Anton et al., 2002) this was not the case in the WASP knock-out mice (Snapper et al., 
1998). It would be of interest to study Ab production by B cells isolated from WAS 
patients and in parallel evaluate the ability of T cells from WAS patients to stimulate 
Ab production by B cells.
1.5.4 Not only one synapse: a general defects in cell-cell cross-talk in WAS?
The term IS was initially used to refer to the interface formed by Ag- 
experienced T cells and Ag-pulsed B cells (Monks et al., 1998). A similar structure, i.e. 
a “mature” synapse, is also formed by naive CD4+ T cells and CD8+ T cells with APC 
(Lee et al., 2002). These structures can be referred to as “stimulatory” synapses, as they 
sustain the activation of the involved T cells. However, synaptic-like structures can be 
formed also for other purposes: a typical example is represented by the conjugate 
formed between a CD8+ cytotoxic T lymphocyte (CTL) and its target cell. The notion 
that lytic granules polarize at the site of CTL-target cell contact was already known 
(Yannelli et al., 1986). However, more detailed studies showed that polarization of 
lytic granules occurs in a defined region, which is juxtaposed to the one where 
signalling molecules accumulates (Stinchcombe et al., 2001) (Figure IVB). In addition 
to polarized secretion, this IS allows also the transfer of membrane proteins from the 
target cell to the activated CTL (Stinchcombe et al., 2001). Acquisition of protein
determinants from target cells has been linked to fratricide killing and dampening of 
the CTLs response (Huang et al., 1999). In addition, as previously said, also NK cells 
form mature synapses in which a cSMAC and a pSMAC can be recognized, upon 
encounter with a susceptible target cell. Interestingly, formation of conjugates with 
non-permissive target cells seems to inhibit the passage from an immature to a mature 
synapse (Vyas et al., 2001).
The role of APC was not really much considered, in the early time of IS 
discovery, however, some studies indicate that APC are not just passive “observers” 
but that they actively polarize their cytoskeleton during contact with T cells (Al-Alwan 
et al., 2001). This finding is of particular interest in the context of WAS, as implies that 
the absence of WASP could in principle alter the ability of different haematopoietic 
cells to correctly interact with other cells of the immune system, or with cells outside 
the immune system. In accordance with this hypothesis, WASP was shown to be 
required for polarization of IL-12-containing granules in mature DC, a process crucial 
for the activation of NK cells (Borg et al., 2004).
In addition, synaptic-like structures were shown to form between T cells upon 
encounter of DC in the absence of the Ag (Revy et al., 2001). These interactions could 
be involved in naive T cell survival. It is then possible that impaired conjugates 
formation between naive T cells and DC contribute to the loss of naive T cells reported 
in the blood of WAS patients (Park et al., 2004). Investigation of T cell-DC contacts in 
a intact lymph node would provide important clues about physiological T cells 
homeostasis in the context of WAS.
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1.6 WAS and XLT: clinical management
1.6.1 Current treatments
Patients with classical WAS have a poor prognosis if untreated. As the risk of 
haemorrhages is one of the most frequent and severe complications of WAS, 
splenectomy is commonly recommended for WAS patients with serious bleeding 
problems and it was found to significantly improve platelets counts and reduce the risk 
of haemorrhages in WAS patients (Mullen et al., 1993b; Sull ivan et al., 1 99 4 ) .  The 
efficacy of splenectomy is due to the fact that the spleen is the major organ where 
platelets destruction takes place. However, one of the major concerns about 
splenectomy is that it increases the risk of fatal sepsis (accounting for 13-15% of 
mortality in splenectomized patients), which however can be reduced by the 
administration of antibiotic prophylaxis. Another limitation of splenectomy is 
represented by episodes of relapse of thrombocytopenia and bleeding episodes 
(idiopathic thrombocytopenic purpura) that was reported in splenectomized WAS 
patients, partially caused by the presence of platelets-associated IgG (Mullen et al., 
1993b). Thus, splenectomy is not an effective treatment, although it increases life 
expectancy and quality in WAS patients (Mullen et al., 1993a). To reduce the risk of 
infections, in many centres WAS patients are treated with intravenous immunoglobulins 
(IVIG) and antibiotic prophylaxis, however it is not clear whether these treatments 
effectively reduce the incidence of life-threatening infections (Conley et al., 2003). The 
treatment of choice for autoimmune manifestations in WAS patients is constituted by 
steroids, which, alone or in association with cyclosporine have been shown to be 
efficacious (Dupuis-Girod et al., 2003). However, the only resolutive treatment for 
WAS is bone marrow transplantation (BMT). BMT is generally the first choice 
therapeutic option for WAS patients for which an HLA-identical sibling donor is 
available. In these cases the percentage of BMT success (in terms of long term survival)
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was 80-100% (Filipovich et al., 2001a; M ullen et al., 1993a; Ozsahin et al., 1996). 
Long-term survival was shorter if BMT was performed from a non-HLA-identical 
related donor (28%, 30% and 52% of the patients receiving this transplant were alive 
after 5 years in the three independent studies cited before). However, it has to be 
considered that this type of transplant has been generally used in patients with severe 
ongoing clinical manifestations, which often required active immunosuppression 
(Ozsahin et al., 1996). Moreover, the requirement for T cell depletion of donor marrow 
(used to lower the incidence of graft-versus-host disease -GVHD-) can increase the risk 
of post-transplant EBV-associated lymphoproliferative disease and severe infectious 
complications (Filipovich et al., 2001a; Ozsahin et al., 1996). However, a high 
percentage of success was also reported in WAS patients transplanted with BM cells 
from matched unrelated donor (MUD) before 5 years of age (mean survival at 5 years 
post transplant: 84% (Filipovich et al., 2001b)).
The overall poor outcome of BMT in WAS patients and the high variability of 
the clinical phenotype associate to this syndrome points out the importance of 
identifying the appropriate treatment for each patient. Recently, the possibility of a gene 
therapy approach has been envisaged basing on promising pre-clinical results obtained 
both in vitro and in vivo (see section 1.6.3.3). A critical evaluation of the safety of this 
approach will determine whether gene therapy can be considered a valid alternative to 
BMT when an HLA-identical sibling donor is not available.
1.6.2 Perspectives for the treatment of WAS: gene therapy
1.6.2.1 Retroviral and Lentiviral vectors for gene therapy
Among the vectors currently available for gene therapy, retroviral vectors (RV) 
are the most widely used. Most of them, as the one used in this work, were derived from 
the retrovirus MMLV (Moloney murine leukemia virus) (reviewed in (Verma and 
Weitzman, 2005)). The genome of MMLV is constituted by a single strand RNA,
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which, after infection of the host cell, is transcribed into a double strand DNA molecule, 
by the viral enzyme reverse-transcriptase (pol). Transport of the viral DNA to the 
nucleus requires nuclear membrane breakdown occurring during mitosis (Roe et al., 
1993). Therefore, MMLV and MMLV-derived retroviral vectors are able to infect only 
dividing cells. The viral genome is constituted by three main genes: gag, pol and env, 
which encodes respectively for structural proteins (gag), reverse transcriptase and 
integrase (pol), and proteins of the viral envelope (env). The peculiarity of retrovirus, 
which make them suitable and safe vectors for gene therapy, is that the only elements 
required for viral replication and packaging in cis are represented by the 5 ’ and 3’ long 
terminal repeats (LTR), which contain promoter, poly-adenylation sequence and the 
packaging site (ip). All the other proteins can be supplied in trans. Therefore, all the 
genes encoding for proteins necessary to produce infectious particles can be removed 
and replaced with a cDNA encoding for the gene of interest. Transcription of this 
cDNA can be driven either by viral LTR or by an internal promoter. Since it is often 
necessary to express two genes within the same retroviral vector (usually one is the 
gene of interest and the other is a selectable marker gene), different strategies have been 
exploited to this purpose. One possibility is to use the viral LTR to drive the expression 
of one gene and an internal exogenous promoter to drive the expression of the second 
gene. However, the presence of two promoters, in the context of the same vector, 
reduces cDNA expression. Therefore, alternative strategies have been developed, such 
as the use of a polycistronic message with the addition of an internal ribosome entry site 
(IRES) (Zitvogel et al., 1994). To produce RV, packaging cell lines have been 
developed. GP+Aml2 (Freas-Lutz et al., 1994) is a third-generation packaging cell 
lines, generated by stably transfecting NIH 3T3 cell line with two different plasmids, 
encoding for gag-pol and env proteins, respectively. Vector production by the 
packaging cell line is achieved by stable or transient transfection with the vector
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plasmid, derived from the vector backbone and containing the ip sequence and the 
gene(s) of interest. Safety of this system is guaranteed by the fact that three independent 
events of recombination would be necessary to produce a replication competent virus. 
GP+Aml2 is an amphotropic packaging cell lines, since it express an envelope, which 
allows the infections of both murine and human cells.
While retroviral vectors can infect only dividing cells, lentiviral vectors (LV) 
derived from HIV-1 are able to infect both dividing and non-dividing cells (Naldini et 
al., 1996). Third generation lentiviral vectors are constructed in a way to address the 
biosafety requirements, which imply the removal of all the proteins involved in AIDS 
pathogenesis, while all the other structural and enzymatic proteins are provided in trans 
in three different plasmids. These vectors were shown to efficiently transduce human 
BM-derived repopulating CD34+ cells after short ex vivo manipulation (Guenechea et 
al., 2000) making them a suitable tool for gene therapy trials in haematological diseases. 
Moreover, the construction of so-called self-inactivating (SIN) vectors, which contain a 
deletion in the viral LTR, (Miyoshi et al., 1998) significantly reduced the risk of 
recombination of the vector in transduced cells (Bukovsky et al., 1999). LV are able to 
transfer complex genetic elements, including regulatory elements and to provide high 
level and stable transgene expression, in different cell types, including human CD34+ 
progenitor cells (May et al., 2000; Miyoshi et al., 1999). Regulatory elements would 
allow regulated and tissue-specific expression of the therapeutic gene, avoiding ectopic 
expression and reducing the potential toxicity of the treatment.
Both RV and LV carry the risk of insertional mutagenesis. This risk has been 
generally evaluated as very low, basing on the probability of insertion in a given site of 
the host cell genome. Recently, the issue of insertional mutagenesis has dramatically 
come to the attention, due to the occurring of adverse events in one ongoing clinical 
trial based on RV (which will be discussed in the next section). Therefore, the safety of
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RV is now being reconsidered. LV are likely to become the vectors of choice for the 
future gene therapy clinical trial, as they accomplish two important safety requirements: 
the usage of transcriptional regulatory elements and low genotoxicity due to the 
possible influence of the vector on the transcription of neighbouring genes (Montini et 
al., 2006).
1.6.2.2 Gene therapy of primary immunodeficiency: the paradigm of X-SCID and
ADA-SCID
Gene therapy approaches have been shown to be efficacious in the treatment of 
two different severe combine immunodeficiencies (SCID). These diseases are different 
from WAS, as the prognosis of affected children is more severe. Indeed, in SCID 
patients, death generally occurs in the first two years of age, due to overwhelming 
infections, if not treated. This is due to the profound deficiencies of lymphocytes, being 
different subsets variably affected depending on the genetic defect (Buckley, 2004). 
BMT in SCID patients has been shown to have an overall rate of success of 77% and 
65% in two different retrospective studies (Antoine et al., 2003; Buckley, 2004). The 
treatment of choice is BMT from HLA-identical sibling donor, with a rate of survival of 
more than 90%, while BMT from HLA-haploidentical related donor is affected by 
higher risk of morbidity and mortality. Crucial issues was also the age at transplant, as 
the rate of success was higher if children were transplanted during the first 3.5 months 
of life (Buckley, 2004). In view of the higher risks for patients who do not have a HLA- 
identical donor available, correction of autologous haematopoietic stem cells by gene 
transfer has been exploited as an alternative therapy. Up to now, gene therapy has been 
successfully used to treat two types of monogenic SCID: X-SCID and ADA-SCID. The 
first originates from the lack of the y subunit of the IL-2 receptor, also called the 
common y chain (Kovanen and Leonard, 2004). The second is due to the lack of 
adenosine deaminase, an ubiquitous enzyme involved in the purine metabolism, whose
absence causes an accumulation of toxic metabolites, which is particularly detrimental 
to lymphoid cells, but also non-lymphoid tissues (Blackburn et al., 1998). Gene therapy 
trials were started, based on the use of retroviral vectors derived from the Moloney 
murine leukaemia virus (MMLV) containing the cDNA of the therapeutic gene. BM- 
derived CD34+ cells from the SCID patients were transduced ex vivo with the retroviral 
vector and re-infused in the patients (Cavazzana-Calvo et al., 2000; Gaspar et al., 2004). 
The French gene therapy trial of X-SCID was successful in the majority of patients, 
which were fully immune-reconstituted and who showed long-term transgene 
expression. However, three patients developed leukaemia, approximately 2.5 years after 
gene therapy. In two of these patients, transformed T cells expressed vector-derived 
y-chain and the oncogene LMO-2 (Hacein-Bey-Abina S et al., 2003) (agence francaise 
de securite sanitaire des produits de sante -AFSSAPS-). This gene is normally 
expressed in haematopoietic progenitors and its locus is involved in chromosomal 
translocation in cases of acute of T cell leukaemia (Rabbitts et al., 1999). Indeed, 
ectopic LMO-2 expression in transduced T cells was due to insertion of the RV in the 5 ’ 
region of the gene, within a chromosomal common fragile site (Bester et al., 2006; 
Hacein-Bey-Abina S et al., 2003). In addition, there is increasing evidence that y-chain 
expression, driven by RV, plays a cooperative role in the process of oncogenesis, 
possibly by influencing T cell differentiation (Dave et al., 2004; Woods et al., 2006) In 
contrast, no adverse events were reported in the ADA-SCID gene therapy clinical trial. 
Eight patients have been enrolled in this trial up to now, of which six have been 
followed up for more than six months. All patients are healthy and show partial to full 
immune reconstitution, with improved systemic detoxification (Aiuti et al., 2002) (and 
A.Aiuti, Personal communication).
However, the occurrence of leukaemia in the French trial raised urgently the 
issue of insertional mutagenesis caused by RV integration. Analysis of the integration
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pattern of RV in both cell lines and non-human primate haematopoietic progenitor cells 
revealed a preferential integration close to transcription start sites of active genes, while 
LV preferentially target the entire transcriptional unit of active gene, without a 
preference for the transcriptional start region (Laufs et al., 2003; Mitchell et al., 2004; 
Schroeder et al., 2002; Wu et al., 2003). Therefore, the main risk associated with RV 
seems to be the activation of a potential oncogene, while the main risk of LV could be 
the disruption of a regulatory gene. However, different parameters will influence the 
transcriptional profile of transduced cells, including the stage of maturity and the ex 
vivo culture conditions. Ongoing studies are being performed in order to assess the 
safety of LV in a setting of HSC transduction and transplant.
1.6.2.3 Gene therapy approaches for WAS
In the last years, considerable efforts have been devoted to the development of a 
gene therapy approach for WAS. The ability of either RV or LV-based WAS gene 
transfer to correct cellular dysfunction has been evaluated in haematopoietic cell lines 
derived from WAS patients and in WASP knock-out mice. As exposed later, part of my 
project has been focused on the comparison of the efficacy of RV versus LV vectors- 
mediated WAS gene transfer to correct WAS T cells defects.
The first studies were performed in immortalized B cell lines from WAS 
patients, showing that expression of WASP, mediated by RV, was able to restore actin 
polymerization and to partially correct the abnormal pattern of glycosylation of 
membrane proteins, which was considered one of the typical hallmarks of WAS- 
associated cellular abnormalities (Candotti et al., 1999; Huang et al., 2000). However, 
given the crucial role of T cells in WAS pathology, the main challenge remained the 
correction of these cells. Restoration of WASP expression in primary T cells from WAS 
patients by a MSC (mouse stem cell virus)-based retroviral vector containing human 
WASP cDNA under the control of the viral LTR lead to correction of proliferative
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response to immobilized anti-CD3 mAb and partial correction of IL-2 production 
(Strom et al., 2003a). However, no data were available regarding the ability of 
transduced T cells from WAS patients to respond to sub-optimal stimulation. Correction 
of this parameter could be of crucial importance, given the role of WASP in T cell 
activation (see discussion). Therefore this point has been addressed in our study. 
Retroviral vectors were also used to transfer murine WASP cDNA, under the control of 
CMV promoter, into HSC of WASP knock-out mice. WASP-transduced HSC were 
found to differentiate in mature T and B cells, when transplanted into RAG2 congenic 
recipients, and correction of the proliferative response of T cells to anti-CD3 mAb was 
achieved (Klein et al., 2003). This system was particularly challenging because WASP 
knock-out mice spontaneously developed colitis within the first 4 months of age 
(Snapper et al., 1998). Although the nature of this colitis was not fully elucidated, 
transfer of WASP knock-out HSC into RAG2/_ mice lead to the development of colitis, 
which was less frequent and severe in RAG27' mice receiving HSC transduced with the 
WASP-encoding RV. In addition, RV-mediated transduction of murine WASP- 
deficient HSC and transplantation into WASP knock-out recipients significantly 
improved the secondary immune response to Influenza virus, which is defective in these 
mice (Strom et al., 2003b), providing evidence that WASP expression can restore 
immune functions in vivo. In the same work selective advantage of WASP-expressing T 
and B cells over WASP-deficient cells (but not of neutrophils and monocytes) was 
reported. The presence of in vivo selective advantage will be crucial in the outcome of a 
gene therapy treatment for WAS in humans.
The limits of the studies described here before are that RV used are not 
clinically applicable as they contain murine WASP cDNA and GFP, as a reporter gene 
and that the transduction efficiency achieved was generally low. In addition, only 
correction of T cells was evaluated. The use of third generation, self-inactivating, HIV-
1-derived LV led to promising results (some of them will be presented and discussed 
later) both in human WAS mature T cells and in WASP knock-out mice HSC. The 
proof of principle of the efficacy of human WASP in correcting cellular and immune 
dysfunctions in WASP knock-out mice was achieved by the use of a SIN HIV-1 derived 
vector (Charrier et al., 2005). LV transduction was able to restore physiological WASP 
expression and to correct T cell proliferative defects and cytoskeletal abnormalities in 
BM-derived DC. Interestingly, correction of this latter phenotype required physiological 
WASP expression, while correction of T cell proliferation to anti-CD3 mAb was 
achieved also with sub-optimal WASP expression.
Another important issue is the regulation of WASP. The use of WASP 
autologous promoter to drive WASP expression in a LV was exploited and resulted in 
tissue-specific expression of WASP in human cell lines (Martin et al., 2005). WASP 
autologous promoter would in principle allow physiological and regulated WASP 
expression. In this setting, it is possible to envisage functional correction of the cells 
achieved with low numbers of integrated vector per cell. This will be an important point 
for future safety studies.
1.7 W AS-associated autoimmunity: a role for naturally occurring T regulatory
(nTreg) cells?
As previously said, WAS patients often suffer from autoimmune manifestations. 
This observation could seem paradoxical as these patients have variable degree of 
immunodeficiency, which generally implies poor reactivity of their T cells, in 
particular, and of the immune system, in general. However, the association between 
immunodeficiency and autoimmunity is not unusual. Patients affected by various 
primary immunodeficiency, including chronic granulomatous disease (CGD), familial 
hemophagocytic lymphohistiocitosis (FHL), hyper-IgM syndrome, complement
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deficiency, autoimmune polyendocrinopathy-candidiasis-ectoderm al dystrophy 
(APECED), immune dysfunction-polyendocrinopathy-enteropathy X-lined (IPEX) and 
common variable immunodeficiency (CVID) (Arkwright et al., 2002) present various 
autoimmune manifestations, which, in some cases, can be lethal. Autoimmunity has 
generally been attributed to the inability to clear pathogens and to a subsequent 
exacerbated and sustained inflammation. This seems indeed to be the case for some of 
the diseases cited here before, and it is also a possible mechanism underlying 
autoimmunity in WAS patients. However, another possible cause of autoimmunity 
could be the loss of tolerance to self Ags.
Immunological tolerance is a crucial feature of the immune system, which 
ensures the discrimination between harmful and non-harmful Ags. This second category 
comprises self Ags, food Ags and environmental Ags. During T cell maturation, cells 
harbouring self-reactive TCR are generated. The vast majority of these cells are deleted 
in the thymus by a process called negative selection, which eliminates cells which binds 
with too high affinity to complexes formed by self-peptides and self MHC (Sha et al., 
1988). Interestingly, there are specific mechanisms allowing the ectopic expression of 
tissue-specific Ags in the thymus, in order to delete the potentially reactive T cells. One 
gene involved in this process is the autoimmune-suppressor gene (AIRE), whose 
mutations are responsible for APECED (Anderson et al., 2005; Nagamine et al., 1997). 
However, negative selection is not able to eliminate all the potentially reactive T cells 
and some of them are found in the periphery as mature T cells, in healthy individuals. In 
the periphery different mechanisms have been shown to control the potential 
detrimental effect of these cells. One mechanism is the induction of anergy. Anergy is 
defined as a state of long-term T cell unresponsiveness, consequent to partial activation 
(Schwartz, 2003). Another mechanism is active suppression of autoreactive effector T 
cells by regulatory T cells (Treg). In the last years, specialized subpopulations of Treg
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cells have been discovered and their mechanism of action has been extensively studied, 
although it is still not completely unravelled. Regulatory T cells type 1 (Trl) (Groux et 
al., 1997) were characterized on the basis of their unique profile of cytokine secretion. 
These cells are anergic to TCR stimulation in vitro, and their suppressive activity is 
mediated by secretion of IL-10 and transforming growth factor [3 (TGF-|3) (Roncarolo et 
al., 2001a). Differentiation of naive CD4+ T cells into T rl cells has been shown to occur 
upon stimulation with immature “tolerogenic” DC (Jonuleit et al., 2000; Roncarolo et 
al., 2001b). It is than conceivable that T rl cells are involved in the maintenance of 
active peripheral tolerance toward foreign non-harmful Ags or self Ags. Since DC 
status is important in the generation of these cell subset, it is possible that in WAS 
patients reduced or delayed migratory capacity of mature DC to the draining 
lymphnodes could alter the generation or homeostasis of Trl cells.
Another subset of Treg cells is constituted by the CD47CD257FoxP3+ cell 
population. These cells are called naturally occurring T regulatory (nTreg) cells, as 
there are a number of evidence indicating that they are produced in the thymus, as a 
mature and functionally distinct population. Indeed, they are present in the thymus both 
in humans and in mice (Darrasse-Jeze et al., 2005; Fontenot et al., 2005a). NTreg cells 
can be isolated from the peripheral blood of healthy subjects, were they constitute 5% 
of CD4+ cells (slightly higher percentages are found in the mouse) (Bacchetta et al., 
2005). The more typical hallmark of nTreg cells has been for a while considered the 
expression of high levels of CD25, which is the a-chain of the IL-2 receptor. As CD25 
is normally upregulated upon T cell activation, it is conceivable that nTreg represents a 
population of pre-activated (or primed) cells. More recently, the importance of the 
forkhead transcription factor FoxP3 as a distinctive marker of nTreg cells came from 
the evidences that mutation in this gene cause a severe autoimmune manifestations both 
in mice (Brunkow et al., 2001) and in humans, where they cause IPEX (Bennett et al.,
2001). The requirement of murine and human nTreg cells for the FoxP3 expression 
seems to be different. Indeed, FoxP3 mutation completely abolish the presence of 
CD47CD25+ nTreg cells in the scurfy mouse, while in patients affected by IPEX nTreg 
cells are present, but their suppressive ability is reduced (Bacchetta et al., 2006). In 
addition, ectopic expression of FoxP3 in murine naive T cells led to the acquisition of 
suppressive functions (Hori et al., 2003), while this was not to be true for human CD4+ 
T cells, where ectopic expression of FoxP3 led to the acquisition of “anergic” features 
but not of suppressive capacity (Allan et al., 2005). Whether nTreg cells really represent 
a separate lineage from effector T cells, arising uniquely from the thymus, or whether 
generation of nTreg is possible also in the periphery is still a matter of investigation.
The presence of nTreg cells in the periphery is required to actively maintain self­
tolerance, indeed transfer of CD25-depleted CD4+ T cells into athymic nude mice is 
sufficient to induce several autoimmune manifestations (Sakaguchi et al., 1995). The 
mechanism of action of nTreg cells has not been completely unravelled, however, a 
number of evidences indicate that they require cell-cell contact for their suppressive 
activity. In some cases TGF-(3 was shown to be involved in nTreg suppressive capacity 
(Levings et al., 2002) or even in their generation (Chen et al., 2003). In addition, a clear, 
non-redundant, role of IL-2 in the generation and function of nTreg was reported 
(Malek and Bayer, 2004).
Another big issue regards the repertoire and specificity of nTreg cells. Different 
studies showed that the nTreg cells have a quite high affinity for self peptides (not as 
much to be negatively selected) (Jordan et al., 2001; Kawahata et al., 2002). Therefore 
it is possible that their specificity imply a predominant role in the maintenance of 
tolerance to self Ags.
Reduced suppressive activity of nTreg cells was reported in different human 
diseases with an autoimmune base, including multiple sclerosis (MS) (Haas et al.,
68
2005), rheumatoid arthritis (Ehrenstein et al., 2004) and, recently, IPEX (Bacchetta et 
al., 2006). It is therefore possible that a dysfunction in the generation or function of 
nTreg cells constitute one of the basis of WAS-associated autoimmune manifestations.
Data obtained in our laboratory, revealed that despite normal proportion and 
phenotype of nTreg cells are present in the thymus and in the spleen of WASP knock­
out mice, their in vitro suppressive activity is defective, if compared to the one nTreg 
cells isolated from wild type mice (Marangoni F., Personal communication). In 
addition, an independent study performed in a different strain of WASP knock-out 
mouse showed that the ability of WAS nTreg cells to control autoimmune colitis, 
induced by the adoptive transfer of effector cells into SCID mice, is defective (Snapper 
S., Personal communication). Therefore, part of this project was dedicated to the 
characterization of the phenotype and the function of nTreg in WAS patients.
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2 SPECIFIC AIMS
Wiskott-Aldrich syndrome is a complex genetic disease, caused by mutation in the 
gene encoding for WASP, with a major involvement of the immune system. WAS 
patients are more susceptible to both infections and autoimmune disorders than healthy 
individuals. WASP is expressed in all the haematopoietic cells, where it acts to regulate 
actin polymerization in response to extracellular stimuli. Although WASP deficiency 
impairs several cellular functions, thereby affecting both innate and adaptive immune 
response, a central role of T cells has been demonstrated in the pathogenesis of WAS.
Despite its well-characterized role as actin cytoskeleton regulator, it was not 
clear how, and to what extent, WASP deficiency could affect T cell activation and 
effector functions. In addition, the complex picture of WAS clinical manifestations, 
which includes immunodeficiency and autoimmunity, suggests that a general 
deregulation of T cell function/homeostasis could occur in these patients. The study 
presented here was integrated in the more general goal of our Institute to establish, in 
the future, an efficacious and safe protocol of gene therapy for WAS.
We therefore investigated i) the cellular and molecular mechanisms of WASP- 
mediated T cell activation in T cell lines from WAS patients, ii) the effector functions 
of CD4+ Th cells and of CD8+ CTLs from WAS patients, iii) the phenotype and the 
function of nTreg cells isolated from WAS patients and iv) the use of RV and LV to 
restore WASP expression in T cell lines from WAS patients, in order to correct their 
functional defects.
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3 MATERIALS AND METHODS
3.1 Patients and T cell lines
3.1.1 Clinical phenotype
Patients W l, W2, W3, X6, W8, W12, W13, which have been studied here, were 
previously described (Dupre et al., 2002; Jin et al., 2004; Notarangelo et al., 2002). 
Patient W l was diagnosed as full blown WAS (clinical score 4, according to Zhu Q. et 
at. (Zhu et al., 1997)), on the basis of clinical phenotype and WAS gene mutation 
(eczema, thrombocytopenia, recurrent HSV infections, candidiasis, pneumonia). He was 
been often treated with antibiotic prophylaxis and IViG infusions and his clinical 
conditions are stable. Patient W2 was diagnosed as full WAS (score 5) based on clinical 
symptoms and molecular analysis of the WAS gene. At the age of six years, he 
underwent bone marrow transplant from matched unrelated donor. He died in the first 
year following BMT due to Cytomegalovirus infection. Patient W3 was diagnosed as 
XLT (score 2). He was thrombocytopenic and during infancy he developed severe 
eczema and haemorrhagic diathesis. Patient W4 was diagnosed as full-blown WAS 
(score 5), he developed mild eczema and autoimmune manifestations, including 
vasculitis, arthritis and IgA nephropaty. Patient X6 was diagnosed as XLT (disease 
score 0.5) and shows thrombocytopenia and transient eczema but he has not a history of 
infections. Patient W8 was diagnosed as full WAS, he had thrombocytopenia and mild 
eczema, with recurrent otitis media (disease score 3). He died of intracranial 
haemorrhage at the age of three years. Patient W ll was diagnosed as full blown WAS 
(score 5). At diagnosis he had bloody diarrhea and was severely thrombocytopenic and 
during the first two years of life he experienced autoimmune haemolytic anemia, which 
was treated with steroids administration, and presented severe eczema, dermatitis and
petecchiae. He underwent BMT from MUD at the age of 1 year. At the time of blood 
sampling he was under steroids treatment. Patient W12 was diagnosed as full WAS 
(score 3), he had eczema, thrombocytopenia, episodes of bloody diarrhea, and airways 
infections. Patient W13 (disease score 2-3) is the older brother of patient W12. He 
presented no clinical symptoms until the age of 5, when he presented with muco­
cutaneous haemorrhages. He developed mild eczema and, at the age of 12 years, 
reactive lymphoadenopathy. Patient W14 (disease score 5) had thrombocytopenia, mild 
eczema, autoimmune colitis and vasculitis. He was under prednisone treatment.
Blood samples from WAS patients and healthy donors were obtained according 
to standard ethical procedure.
3.1.2 T cell lines
Untransformed, polyclonal T cell lines were generated from PBMC of WAS 
patients and healthy donors as previously described (Dupre et al., 2002). Briefly, PBMC 
were purified from peripheral blood on Lymphoprep (Nycomed Pharma AS, Oslo, 
Norway) gradient and seeded at a concentration of 5x l05 cells/ml. Cells were stimulated 
in the presence of a feeder mixture composed of lx l0 6/ml allogenic PBMC (irradiated 
with 6000 rad by an X-ray source) and lx l0 5/ml EBV-transformed B cell line JY 
(irradiated with 10000 rad by an X-ray source), 1 pg/ml PHA and 100 IU/ml rhIL-2 
(Chiron Corp., Emeryville, USA). Cells were cultured in IMDM (Cambrex Bio Science, 
Verviers, Belgium) supplemented with 10% YSSEL medium (Dyaclone, Besan9on, 
France), 5% FBS (Cambrex Bio Science) and penicillin/streptomycin (Bristol-Myers 
Squibb, Sermoneta, Italy). T cells were re-stimulated as described every two weeks. 
CD4+ and CD8+ T cells subsets were purified by positive selection from established T 
cell lines, using anti-CD4 or anti-CD8 microbeads, respectively, (Miltenyi Biotech, 
Bergische Gladbach, Germany) according to the manufacturer’s instructions (purity was 
> 95%).
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To generate JY-specific T cell lines, which were used in the cytotoxic assay, PBMC 
from WAS1 and two normal donors were purified from peripheral blood on 
Lymphoprep (Nycomed Pharma) gradient and seeded at a concentration of 5 x l0 5 
cells/ml. Cells were stimulated in the presence of lx l0 5/ml EBV-transformed B cell line 
JY (irradiated with 10000 rad by an X-ray source) with 40 IU/ml IL-2. CD8+ T cells 
subsets were purified by positive selection from established T cell lines, using anti-CD8 
microbeads (Miltenyi Biotech) according to the m anufacturer’s instructions. 
Alternatively, allo-specific T cell lines were generated by stimulating PBMC from 
patient W l and from healthy donors with a mixture of irradiated JY cells and PBMC 
obtained from a single allogenic donor. The culture conditions were the same as 
described here before.
EBV-transformed B cell line JY and chronic myelogenous leukaemia cell line K562 
were maintained in IMDM supplemented with 10 % FBS and penicillin/streptomycin.
3.2 Beads preparation
Coating of anti-CD3 mAb and anti-CD28 mAb on the surface of polystyrene 
latex beads (Interfacial Dynamic Corp., Portland, USA) was performed by incubating 
the beads at a concentration of 12xl06 beads/ml in PBS in the presence of the indicated 
concentration of anti-CD3 mAb alone, or anti-CD3 plus anti-CD28 mAb. Incubation 
was performed under constant gentle agitation, at 4°C, overnight. Then, 2% FBS was 
added to the beads suspension and two wash steps were performed. Non-specific 
binding sites on the beads were blocked by a 1-hr incubation in complete medium. 
Coated beads were used immediately or stored at 4°C in complete medium for a 
maximum of 5 days.
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3.3 T cell activation
When indicated, resting T cell lines (9-14 days after feeder) were starved over 
night without IL-2. Latex beads were coated with the indicated amount of anti-CD3 and 
anti-CD28 mAbs (BD Biosciences Pharmingen), as previously described. The beads 
were eventually re-suspended in the required medium and added to the cells, at ratio of 
2 bead per cell. Alternatively, T cells were stimulated with plastic-bound anti-CD3 plus 
soluble anti-CD28 mAbs. In this case, plates were coated overnight with anti-CD3 
mAbs in 0.1M Tris pH 9.5, then washed in PBS. T cells were plated in the presence of 
10 pg/ml soluble anti-CD28 mAbs.
3.4 T cell proliferation
Resting WAS and control T cell lines were seeded at 1x10s cells/well in a 96- 
well plate round-bottom with 2x l05 beads coated with the indicated amount of anti-CD3 
and anti-CD28 mAbs, in a final volume of 200 pi. T cell proliferation was analyzed 
after 72 hr of stimulation, by a 16- hours pulse with 1 pCi/w ell 3H-thymidine 
(Amersham Pharmacia Biotech) followed by harvesting using the 96-well plate 
harvester (Tomtec, Hamden, USA) and counting by liquid scintillation. All experiments 
were performed in duplicate or triplicate wells.
3.5 TCR down-regulation
Resting T cells were stimulated with plate-bound anti-CD3 mAb (OKT3) for 4 
hs at 37°C, 5% C 0 2. Then cells were harvested and TCR surface expression was 
evaluated by staining with anti-TCRa/p mAb (BD Biosciences). The staining was 
performed in PBS 0.3% BSA. Analysis of TCR expression was performed by FACS. In
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order to minimize TCR internalization and recycling after the 4-hs stimulation, all the 
procedure was performed on ice.
3.6 Analysis of cytokine production
3.6.1 ELISA
The secretion of cytokines was measured in the supernatants of resting and 
activated WAS and control T cell lines, which were plated at the initial density of lxlO 5 
cells/well. Supernatants were collected at different time points (18 hr for IL-2 and 48 hr 
for the other cytokines) and the presence of cytokines was detected by standard capture 
ELISA, which was performed according to the manufacturer’s instructions (BD 
Biosciences Pharmingen). Concentration of cytokines was calculated by parallel 
measurement of a standard curve, generated using recombinant human cytokines (R&D 
System).
3.6.2 Cytometric bead array (CBA)
Alternatively, cytokine levels in the supernatants of stimulated cells were 
assessed using the cytometric beads array (CBA: Beckton Dickinson), according to the 
manufacturer’ s instructions. 50 pi of supernatants were used in this assay. Analysis was 
performed by FACScalibur.
3.6.3 Intracellular cytokine staining
Resting T cells ( lx l0 6/ml) were stimulated either with beads coated with anti- 
CD3 mAbs plus anti-CD28 mAbs or with 10 ng/ml TPA plus 500 ng/ml ionomycin in 
complete medium, at 37 °C, in a 5% C 0 2 atmosphere. Upon initiation of the 
experiment, plates were centrifuged for 2 min at 800 rpm. After 3 hr, 10 pg /m l 
Brefeldin A (Calbiochem) was added to the wells. After additional 3 hr, T cells were 
collected and fixed in 2% formaldehyde. After fixation, T cells were permeabilized by 
10 min incubation in blocking buffer (PBS 0.3% BSA, 0.1% NaN3) supplemented with
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0.5% Saponin (Sigma Aldrich). Permeabilized T cells were incubated in blocking buffer 
with 0.5% Saponin in the presence of PE-labelled anti-hIL-4, PE-labelled anti-hIL-2 
and FITC-labelled anti-hlFN-y (BD Biosciences Pharmingen). After washing, cells 
were analyzed by FACS and data were analyzed by CellQuest software.
3.7 Western Blotting
3.7.1 WASP expression
Cell extracts were prepared from lxlO 6 resting T cells. Briefly, T cells were 
washed in PBS and resuspended in lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2 
mM EDTA, 1% NP-40), supplemented with protease inhibitor cocktail (Sigma Aldrich, 
St-Louis, USA). After 30 min on ice, lysates were cleared by centrifugation and an 
aliquot of supernatants was used for determining protein concentration with the BCA 
protein assay (Pierce, Rockford, USA). Laemmli buffer was added to supernatants and, 
after boiling, equal amounts of proteins were subjected to SDS-PAGE. Proteins were 
transferred to nitrocellulose membrane and WASP was detected by the anti-WASP 
polyclonal Ab H-250 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by 
secondary HRP-conjugated anti-mouse Abs (Dako Cytomation). Control of protein 
loading was performed by hybridizing the same membranes with an anti-G3PDH mAb 
(Chemicon, Temecula, CA, USA). Detection was performed using ECL detection 
system (Amersham Pharmacia Biotech, Little Chalfont, UK).
3.7.2 Analysis of ERK1/2 phosphorylation
CD4+ and CD8+ T cell lines from WAS patients and from healthy donors were 
starved for 12 hours in IMDM containing low fetal bovine serum (1%), then stimulated 
with beads coated with 1 pg/ml anti-CD3 plus 10 p,g/ml anti-CD28 for the indicated 
times. Reactions were stopped by wash in cold PBS and immediate lysis in whole-cell 
lysis buffer. After 30 min on ice, lysates were cleared by centrifugation and an aliquot
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of supernatants was used to determine protein concentration with the Bradford protein 
assay (Biorad). Laemmli buffer was added to supernatants and, after boiling, samples 
with equal amount of proteins were subjected to SDS-PAGE. Proteins were transferred 
to nitrocellulose membrane and phosphorylated ERKs were detected by anti- 
phosphoERKl/2 mAb (Cell Signalling Technologies, Danver, MA). To detect levels of 
total ERK1/2, membranes were stripped by a 15-min incubation, at room temperature, 
in Restore Buffer (Pierce Biotechnology, Rockford, USA) and re-probed with anti- 
ERK1/2 pAb (Cell Signalling Technologies). Incubation with primary Abs was 
followed by incubation with goat anti-mouse or anti-rabbit HRP Ab, according to the 
specificity of the primaru Abs (Dako Cytomation). Detection was perfomed by ECL 
detection system (Amersham Pharmacia Biotech).
3.7.3 Analysis of JNK1/2 and of IkBa phosphorylation
CD4+ and CD8+ T cells from WAS patients and healthy donors were starved for 
12 hours in low serum (1%), then stimulated with beads coated with 1 pg/ml anti-CD3 
plus 10 pg/ml anti-CD28 for the indicated times. Cytosolic and nuclear fractions were 
extracted using NE-PER extraction system (Pierce) in the presence of inhibitors of 
proteases and phosphatases (Sigma) according to the manufacturers’ instructions. For 
Western Blotting, 20 pg of cytosolic extracts were boiled in Laemmli buffer and loaded 
on SDS-PAGE. Upon blotting onto nitrocellulose membrane, levels of phosphorylated 
JNK2/2 were detected by anti-phosphoJNKl/2 pAb (Cell Signalling Technologies). To 
detect levels of total JNK1/2, membranes were stripped as indicated here before, and re­
probed with anti-JNKl/2 (Cell Signalling Technologies). Phosphorylation levels of 
IkBa were detected by anti-phosphoIkBcx (Cell Signalling Technologies). Control of 
protein loading was performed by hybridizing the same membranes with anti-G3PDH 
Ab.
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3.7.4 NFAT and Fos nuclear levels
To detect nuclear levels of NFAT-1, NFAT-2 and Fos, 5 x l0 6 CD4+ and CD8+ T 
cells from WAS patients and healthy donors were starved for 12 hours in low serum 
(1%), then stimulated with beads coated with 1 p,g/ml anti-CD3 plus 10 p,g/ml anti- 
CD28 for the indicated times. Cytosolic and nuclear fractions were extracted using NE­
PER extraction system (Pierce) in the presence of inhibitors of proteases and 
phosphatases (Sigma) according to the manufacturers’ instructions. For Western 
Blotting, 12 |ig of proteins were boiled in Laemmli buffer and loaded on SDS-PAGE. 
Upon blotting onto nitrocellulose membrane, NFAT-1 was detected by anti-NFAT-1 
T2B1 Ab (a kind gift of A. Rao and S.Feske) and NFAT-2 and Fos were detected by 
anti-NFAT-2 mAb clone 7A6 and anti-Fos k-25 pAb, which recognizes c-Fos, Fos-B, 
Fra-1/2 (Santa Cruz Biotechnology). Protein normalization and quality of cell 
fractionation were assessed by re-probing the same nitrocellulose membranes with an 
anti-Spl pAb (Santa Cruz Biotechnology) for nuclear extracts, and with an anti-G3PDH 
mAb (Chemicon) for cytosolic extracts. Densitometric analysis was performed by 
ImageQuant software. Values corresponding to unstimulated cells were subtracted.
3.8 Transduction of T cell lines and PBMC
3.8.1 Production of retroviral vectors
The retroviral vector, used in this study (LDSW), was generated by I.J. Molina 
starting from the LDNSN vector (Mavilio et al., 1994). Briefly, the WASP cDNA 
sequence was cloned by PCR using the PCR™3 plasmid (Invitrogen) containing WASP 
cDNA (kindly provided by O. Parolini) as a template. To generate the LDSW vector 
(LTR-dNGFR-SV40-WASP), the LDNSW vector was digested with Hindlll plus Nael 
restriction enzymes, to excide the Neomycin resistance (NeoR) gene. The digested 
vector was purified from agarose gel and its termini were filled using the Klenow
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fragment of E.Coli DNA polymerase I to generate blunt ends. WASP cDNA was then 
ligated into the vector downstream of the SV40 promoter. A stable amphotropic Am l2- 
based producer cell line (Markowitz et al., 1988) was generated as follows: LDSW 
plasmid was transfected into GP+E86 ecotropic packaging cell line by Ca2P 0 4 
precipitation. Supernatant from transfected GP+E86 cells was used to infect A m l2 cell 
lines, in the presence of 8 pg/ml polybrene. Transduced Am 12 cells (AM12-LW) were 
analyzed by FACS for dNGFR expression using an anti-dNGFR biotin-conjugated mAb 
(ATCC, Rockville, MD), followed by streptavidin-PE. Cells expressing dNGFR were 
immunoselected after staining with anti-dNGFR mAb, using rat anti-mouse conjugated 
magnetic beads (Dynabeads M-450; Dynal, Oslo, Norway). To collect viral 
supernatants, AM12-LW  were trypsinized and plated in fresh medium at a 
concentration of 5 x l0 4/cm2. After 48 hs, medium was replaced and the volume was 
scaled-down to 6 ml in a T75 flask. Supernatants was collected in three rounds (every 
12 hours), starting from 24 hs after the last change of medium. Supernatants were 
filtered with a 0.45 pm filter and immediately frozen at -80°C . As control, the 
SFCMM3 vector (clone#16) (LTR-tk/SV40-dNGFR) was used (Verzeletti et al., 1998).
3.8.2 Transduction of T cell lines with retroviral vectors
T cells from WAS patients or healthy donors were stimulated for 48 hs with 1 
pg/ml plate-bound anti-CD3 mAb, plus 1 pg/ml soluble anti-CD28 mAb, in the 
presence of 100 IU/ml IL-2 (Chiron Corporation) and 10 ng/ml IL-7 (R&D Systems). 
After pre-stimulation, cells were collected and plated (106cells/well in a 24-well plate) 
on retronectin-coated plates. Two rounds of transduction were performed, the first of 24 
hs and the second of 6 hs, as previously described (Pollok et al., 1998). Three days after 
transduction, DNGFR expression was analyzed by FACSscan. T cells expressing 
dNGFR were immunoselected as described in the previous section.
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3.8.3 Production of lentiviral vectors
To construct third generation self-inactivating (SIN) lentiviral vectors, WASP 
cDNA was extracted from the LXSDN plasmid by digestion with Bbsl and BamHI. 
WASP fragment was blunted and inserted into the pBluescriptll (KS) plasmid digested 
with EcoRV. The PGK-WASP construct was generated by inserting the WASP cDNA 
fragment (obtained by digestion with the enzymes BamHI and Sail) into the 
pRRLsin.cPPT.PGK.E-GFP.Wpre plasmid (PGK-GFP) (Follenzi et al., 2000), in place 
of the E-GFP cDNA fragment. The construct containing WASP autologous promoter 
(wasp-WASP) was obtained by removal of the PGK promoter, followed by insertion of 
the 5’ promoter region of the WAS gene (-1580/+33), kindly provided by Dr. Morrone 
(Petrella et al., 1998). Production of lentiviral vectors was performed as previously 
described (Follenzi et al., 2000). Briefly, WASP-encoding transfer plasmids were 
transfected together with the three packaging plasmids (encoding gag-pol, VSV-G env 
and rev, respectively) into 293T cells by CaC12 precipitation. After 14 hs, culture 
medium was replaced by fresh medium. A single harvest of viral supernatants was 
performed after 24 hs, and virus particles were concentrated by ultracentrifugation. 
Virus concentration was evaluated by measurement of p24 by ELISA.
3.8.4 Transduction of T cell lines and of PBMC with lentiviral vectors
T cells from WAS patients or healthy donors were stimulated as described in 
section 3.8.2. After 48 hs of pre-stimulation, cells were collected and plated at a density 
of 106cells/ml. Alternatively, PBMC were stimulated according to a method previously 
published (Cavalieri et al., 2003), with the following modifications: PBMC were 
stimulated for 96 hs with 60 IU/ml IL-2 plus 5 ng/ml IL-7, before transduction. 
Transduction was performed in the presence of 8 pg/ml polybrene (Sigma) at the 
indicated concentration of TU/ml for the PGK-GFP vector or at a concentration of 100
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ng p24/105 cells in a volume of 0.5 ml for PGK-WASP and wasp-WASP vectors. A 
single round of 24 hs of transduction was performed.
3.9 T cell adhesion
To analyze adhesion to anti-CD3 mAb or fibronectin, resting T cell lines from 
patients W1 and W2 and from three healthy donors were loaded with 5 mM Calcein- 
AM (Molecular Probes, Inc., Eugene, OR). Briefly, cells were resuspended in PBS with 
Calcein-AM and incubated at 37°C, for 30 min. Then, an equal volume of PBS, 10% 
FBS was added to the cells. After 10 min, cells were washed and resuspended in 
adhesion medium (RPMI without phenol red, 0.5% human serum albumin, glutamine). 
Anti-CD3 mAb (escalating doses) or fibronectin (5 ^ig/ml) (Sigma) were coated in 96- 
well plates by a 12-hs incubation in PBS, followed by washing in PBS and by a 2-hs 
blocking in PBS, 1% BSA. Cells were left to adhere for 30 minutes, at 37°C, 5% C 0 2, 
then the fluorescence was analyzed by Typhoon (“pre”). Subsequently, non-attached 
cells were removed by a 5 min centrifugation, up side down, at 150g. Then, 100 ml of 
adhesion medium were added to the cells and Calcein fluorescence was analyzed by 
Typhoon (“post”). All the experiments were performed in triplicates. Fraction of 
adherent cells was calculated as follows: l-((pre value -  post value)/ pre value).
3.10 GM1 and GM3 expression
To evaluate the levels of surface GM1 and GM3, resting T cell lines from WAS 
patients and healthy donors were stimulated as indicated, with beads coated with anti- 
CD3 mAb alone, or plus anti-CD28 mAb, or, alternatively, with plate-bound anti-CD3 
mAb alone, or plus soluble anti-CD28 mAb. After 72 hs of stimulation, cells were 
collected and GM1 and GM3 surface expression was evaluated after staining with 
Cholera Toxin B subunit FITC (Sigma) or with anti-GM3 mAb, clone GM36
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(Seikagaku Corporation, Tokyo, Japan), followed by goat anti-mouse IgM PE 
conjugated, respectively. Cells were then analyzed by FACScan.
In order to evaluate the levels of total cellular GM1, after stimulation, cells were 
fixed overnight in 2% formaldehyde in PBS, at 4°C. After washing in PBS, 0.3% BSA, 
cells were permeabilized with PBS BSA plus 0.5% Saponin, for 10 min at room 
temperatures. Staining was performed with Cholera Toxin B Subunit FITC, in the 
presence of 0.5% Saponin, for 30 minutes at room temperature. Analysis was performed 
using a FACScan.
3.11 Analysis of Ca2+ flux
Ca2+ flux upon TCR triggering was analyzed in resting T cell lines from patients 
W1 and W2 and from two healthy donors. Cells were resuspended in KRH solution 
(125 mM NaCl, 5 mM KC1, 1.2 mM KH2P04, 25 mM HEPES pH 7.4, 2 mM CaC12, 6 
mM Glucose) and a 1:1 mixture of 4 jxM Fluo3-AM (Molecular Probes) and Pluronic 
Acid was added to the cells. Loading of Fluo3 was achieved by a 30-min incubation at 
room temperature, under gentle agitation. Cells were then washed with KRH in the 
presence of the anion transporter inhibitor Sulfynpirazone (Sigma), at 200 fxM. 
Stimulation was performed in KRH. Anti-CD3 mAb (1 p-g/ml) was added to the cells on 
ice. After 15 min, cells were analyzed by FACS. Fluorescence was recorded for 20 sec 
ca., then cell-bound anti-CD3 mAb was crosslinked by the addition of 5 p,g/ml of goat 
anti-mouse Ab. Fluorescence was recorded for 6 minutes, then 1 mM ionomycin was 
added to the cells. Analysis was performed using CellQuest Software, calculating the 
mean fluorescence intensity (MFI) of the cells population, in adjacent gates of 10 sec 
ca. each.
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3.12 RNAse protection assay (RPA)
Resting T cells were stimulated by 1 pg/ml of immobilized anti-CD3 mAbs plus 
10 pg/ml soluble anti-CD28 mAbs or by 10 ng/ml TPA plus 500 ng/ml ionomycin. 
After 4 hr of incubation at 37 °C, in a 5% C 0 2 atmosphere, cells were collected and 
RNA was extracted as previously described (Guidotti et al., 1999). Total RNA extracted 
from either CD4+ or CD8+ T cells was analyzed for the content of the messages for IFN- 
Y, IL-2, IL-4 and IL-10 by using the highly sensitive multi-probe RNase protection 
assay (RPA). Briefly, probe synthesis was driven by T7 bacteriophage RNA polymerase 
with a -[32P]UTP as the labelling nucleotide. The subsequent steps of probe purification, 
RNA-probe hybridization, Rnase treatment, purification of protected RNA duplexes, 
and resolution of protected probes by denaturing PAGE was performed as described 
(Hobbs et al., 1993). Probe bands were visualized by autoradiography and quantified by 
phosphor imaging analysis, using the ImageQuant analysis software (Amersham 
Biosciences). For the latter, rectangular fields (with local background subtraction) were 
used for volume quantification. The relative abundance of mRNA species was obtained 
dividing the value of each field by the relative L32 value of that sample in order to 
obtain a relative expression value for each individual mRNA species. Values 
corresponding to unstimulated cells were subtracted.
3.13 T-bet and GATA-3 mRNA expression
To measure T-bet and GATA-3 mRNA levels, CD4+ T cell lines from WAS 
patients and healthy donors were stimulated with immobilized anti-CD3 mAbs plus 10 
pg/ml soluble anti-CD28 mAbs for four hours. Total RNA was extracted from lx lO 6 
cells using Eurozol (Euroclone S.p.A., Milan, Italy) and RNA was reverse transcribed 
by using the High Capacity cDNA Archive Kit (Applied BioSystems, Foster City, CA,
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USA) according to the manufacturer’s instructions. T-bet and GATA-3 mRNA species 
were quantified using the Assay on Demand kit (Applied Biosystems) and Taqman 
Master Mix (Applied Biosystems). Each sample was analysed in duplicate and the 
relative expression of T-bet and GATA-3 was defined by calculating the ACt, with 
respect to the housekeeping gene HPRT, run in the same tube.
3.14 Cytotoxic assay
Cytotoxic activity of CD8+ T cells was assessed by a standard 51Chromium (51Cr) 
release assay as previously described (Fleischhauer et al., 1996). Briefly, after a 2-min 
slow-speed centrifugation, 500 51Cr-labeled target cells (JY cell line) and effector CD8+ 
T cells, at the indicated effector:target ratio, were incubated for 4 h at 37 °C, in 5% C 0 2. 
Exhaustion of NK-like activity was obtained by 45-min incubation of effector cells with 
not-radiolabeled (cold) K562 cells, before adding radiolabeled JY cells. Alternatively, T 
cell blasts obtained by a 5 days culture in the presence of 100 IU/ml IL-2 and 1 pg/ml 
PHA were used as target cells. Radioactivity released in the supernatants by lysed target 
cells was measured with a y-counter. Percentage of specific lysis was calculated 
according to the following formula: 100 x (cpm experimental release- cpm spontaneous 
release) / (cpm maximum release- cpm spontaneous release).
3.15 Differentiation of Thl cells
Naive (CD45RO ) CD4+ T cells were purified from PBMC of W1 and two age- 
matched healthy donors by negative selection, using the CD4+ T cells isolation kit 
according to the manufacturer’s instructions (Miltenyi Biotech). Naive CD4+ T cells 
were obtained by depleting CD45RO+ cells with anti-CD45RO Myltenyi beads 
(Miltenyi Biotech), according to the manufacturer’s instructions (purity ranged from 85 
to 95%). Naive CD4+ T cells were activated by co-culture with murine L cells, stably
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transfected with hCD32 (FCyRII), hCD58 (LFA-3), and hCD80 (de Waal Malefyt et al., 
1993). L cells were trypsinized and X-ray irradiated (7000 rad). Following washing, 
cells were seeded at 4 x l0 5 cells/well in a 24-well plate in IMDM supplemented with 
10% FBS, penicillin/streptomycin and 100 ng/ml anti-CD3 mAbs (Orthoclone OKT3, 
Janssen-Cilag, Milan, Italy). After adhesion of L cells, 4 x l0 5 naive CD4+ T cells were 
plated in either non-polarizing (ThO) conditions, or in the presence 10 ng/ml rhIL-12 
(R&D systems, Minneapolis, USA), and 200 ng/ml anti-hIL-4 mAbs (BD Biosciences 
Pharmingen, San Diego, USA) for Thl polarization. At day three, 40 IU/ml IL-2 was 
added to all culture conditions. After one week, cells were restimulated with either 10 
pg/ml plate-bound anti-CD3 mAbs plus 1 p,g/ml soluble anti-CD28 mAbs, or with 10 
ng/ml TPA (Calbiochem Biochemicals, La Jolla, USA) plus 500 ng/ml ionomycin 
(Calbiochem Biochemicals) and analyzed for the profile of cytokine production.
3.16 Inhibition of glycosphingolipids synthesis
To inhibit glycosphingolipids biosynthesis, T cell lines established from healthy 
donors were stimulated with either beads coated with anti-CD3 plus or minus anti- 
CD28 mAbs, or with immobilized anti-CD3 plus or minus soluble anti-CD28 mAbs, in 
the presence of the ceramide analogue, L,D-threo-l-phenyl-2-decanoylam ino-3- 
morpholino-1-propanol (PDMP, Sigma Aldrich), used at a concentration of 10 p,M. To 
test the effect of PDMP, after 72 hours of stimulation, T cell lines harvested and the 
level of the glycosphingolipid/ganglioside GM1 on the cell surface was assed by 
staining with CholeraToxin B subunit-FITC. In some cases the level of another 
ganglioside, GM3, was measured by surface staining with anti-GM3 mAb as previously 
described. Cells were then analyzed by FACScan. To test the effect of PDMP on T cell 
proliferation and IL-2 secretion, T cell lines were loaded with CFSE. Briefly, cells were 
resuspended in PBS at a concentration of 107/ml in the presence of 2.5 pM CFSE
(Molecular Probes) and kept under gentle agitation for 8 min in the dark. Extracellular 
fluorescence was quenched by the addition of PBS containing 5% FBS. CFSE-loaded 
cells were washed twice and resuspended at a concentration of 106/ml in complete 
medium. Stimulation was performed with anti-CD3 plus or minus anti-CD28 mAbs, in 
the presence, or absence, of 10 pM PDMP. IL-2 level was measured in the supernatants 
of stimulated cells after 18 hours, by capture ELISA, Cell proliferation was assed by 
analyzing CFSE dilution after 72 hours of stimulation. Dead cells were excluded from 
the analysis by a short pre-incubation of Propidium Iodide.
3.17 Isolation of detergent-resistant membranes (DRM) by flotation in a sucrose
gradient
In order to analyze the partition of WASP into DRM (non-soluble) or non-DRM 
(soluble) fractions, resting T cell lines from healthy donors were stimulated for the 
indicated times with 1 pg/ml anti-CD3 plus 10 pg/ml anti-CD28 mAbs, followed by 
crosslinking with 30 pg/ml goat anti-mouse Abs (Dako Cytomation) at 37 °C. 
Stimulation was stopped by washing in cold PBS and lysis in Buffer A (2 mM Tris pH 
7.5, 150 mM NaCl, 5 mM EDTA) containing 1% non-ionic detergent (Brij58), followed 
by Dounce homogenization and a 45-min incubation on ice. The cell lysate was mixed 
at a 1:1 ratio with 85% Sucrose in Buffer A and a discontinuous gradient (30-5%) of 
Sucrose was stratified over the cell lysate, followed by a 16-hours ultracentrifugation at 
4 °C in a swing-out SW41 rotor (Beckman Instruments, Inc.). After centrifugation, low 
density floating fractions (DRM) and high density fractions (non-DRM) were collected. 
Proteins were precipitated from the entire fractions by addition of tricloroacetic acid and 
the protein pellet was washed with acetone 73%. After precipitation, protein pellets 
were directly re-suspended in Laemmli buffer and pH was adjusted by exposure to NH3 
vapours. Proteins were then resolved by SDS-PAGE. Proteins were transferred to
nitrocellulose and WASP, LAT and CD3-£ were detected by anti-WASP pAb (Upstate 
Biotechnology), anti-LAT Ab (Santa Cruz Biotechnology) and anti-CD3-£ Ab (Santa 
Cruz Biotechnology), respectively. After incubation with the secondary- HRP- 
conjugates Abs, proteins were detected by chemiluminescence using either SuperSignal 
West Dura (Pierce) or ECL (Amersham).
3.18 Isolation and characterization of nTreg cells from WAS patients
3.18.1 CD25 and FoxP3 expression
Human PBMCS were purified on Ficoll gradient (Nycomed Pharma A/S, Oslo, 
Norway) from blood samples of WAS patients and age-matched healthy donors. The 
following antibodies were used for immunophenotyping of nTregs: anti-CD4 (SK3), 
anti-CD25 (2A3), all from BD Pharmingen. Foxp3 expression was evaluated by 
intracytoplasmic staining using the hFoxp3 (PHC101) Staining Set from eBioscience, 
accordingly to manufacturer’s instructions. Analysis of the CD4, CD25 and FoxP3 
expression was performed using a FACScalibur flow cytometer.
3.18.2 In vitro suppression assay
CD4+CD25+ nTregs and CD4+CD25' effector T cells were isolated from PBMCS 
by FACS sorting. Cells from healthy donors were used as control: CD4+ T cells were 
purified either by FACS sorting or, alternatively, by negative selection with the CD4+ T 
cell isolation kit (Miltenyi Biotec). Subsequently, cells were separated into CD25+ and 
CD25' fractions by positive selection (Miltenyi Biotec). In both cases, purity of nTreg 
cells ranged from 80 to 95% and purity of CD4+CD25' effector T cells was > 95%. 
Suppression assays with purified human nTregs were performed as follows: 5 x l0 4 
CD4+CD25' effector T cells were plated in 96-well round bottom plates together with 
nTregs and stimulated by CD3-depleted APCs (irradiated at 6000 rad) and soluble anti- 
CD3 mAbs (OKT3, 1 ng/ml) in a final volume of 200 pi. Alternatively, when very low
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numbers of nTregs were recovered, lxlO4 effector T cells were cocultured with nTregs 
and stimulated with beads coated with anti-CD3 and anti-CD28 mAbs (Dynal Biotech), 
at a responder:bead ratio of 1:0.6. Suppressive activity of nTregs was assessed by co­
culture of effector cells with nTregs at a ratio of 2:1 or 4:1. After 72 hours of culture, 
cell proliferation was evaluated by liquid scintillation counting, and IFN-y secretion was 
evaluated on supernatants using the human Thl/Th2 cytokine cytometric bead array 
(CBA) system (BD Biosciences). Samples were analysed on a BD FACSCalibur flow 
cytometer, according to manufacturer’s instructions. Values of IFN-y in the supernatants 
were normalized to a number of 2xl05cells per 200 pi.
4 RESULTS
4.1 WASP lowers the threshold for TCR/CD28-driven T cell activation
4.1.1 Bulk T cell lines established from WAS patients PBMC show defective
proliferation in response to anti-CD3 mAb
WASP-deficient T cells from WAS patients and WASP knock-out mice showed 
defective proliferative response to anti-CD3 mAb (Molina et al., 1993; Snapper et al., 
1998; Zhang et al., 1999). To further characterize the extent of this proliferative defect 
and to clarify the role of WASP in TCR/CD28 responsiveness, untransformed T cell 
lines were established from three WAS patients, with different clinical phenotype 
(Table 1). Western Blot analysis showed that in resting T cells from WAS patients 
WASP expression was undetectable (Figure 1A). However, upon stimulation with anti- 
CD3 mAb low levels of full-length WASP were detected in T cells established from 
patient W3, (Figure IB), who has a missense mutation which can be compatible with 
the expression of residual, point-mutated, WASP protein. WAS T cells proliferated 
poorly to immobilized anti-CD3 mAb (Figure 2A). In particular, stimulation with low 
dose of anti-CD3 mAb (0.1 fxg/ml) was able to induce maximal proliferation of control 
cells, while it failed to elicit proliferation in WAS T cells. However, WAS T cells could 
proliferate to relatively high levels when high concentration of anti-CD3 mAbs was 
used (Figure 2A). Despite defective proliferation, WAS T cells retained normal ability 
to down-regulate surface expression of the TCR upon stimulation with immobilized 
anti-CD3 mAb (Figure 2B).
Since WASP is required for actin polymerization and it is recruited to the site of 
contact between T cell and APC (Cannon et al., 2001), it is possible that WASP plays a 
role in the establishment of cell-cell conjugates. Therefore, we tested the proliferative 
response using beads coated with anti-CD3 mAb or antiCD3 plus anti-CD28 mAb.
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Such a stimulation was used to mimic T cell-APC contact and was shown to induce 
both polarization of lipid rafts and T cell proliferation (Krause et al., 2000; Viola et al., 
1999). WAS and control T cell lines were stimulated with beads coated with escalating 
doses of anti-CD3 mAb alone (Figure 2C), or in the presence of 10 p,g/ml anti-CD28 
mAb (Figure 2D). Proliferation of WAS T cells was reduced with respect to control 
cells upon stimulation with anti-CD3 mAb (Figure 2C). The addition of anti-CD28 to 
anti-CD3 mAbs greatly enhanced the proliferative response of normal T cells (Figure 
2D), while proliferation of WAS T cells was significantly lower (p<0.05 at all doses of 
anti-CD3 tested for patients WAS1 and WAS2, p<0.05 for patients WAS3 at the doses 
of 0.01 and 0.1 pg/ml anti-CD3 mAbs). These data indicate that TCR- or TCR/CD28- 
mediated proliferation of WAS T cells is defective, especially in conditions of 
suboptimal TCR-mediated stimulation. This defect is not due to impairment in the 
ability to internalize the triggered TCRs.
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T a b le  1
Patient Disease(score3)
Ageb
(years)
Mutation
W1
WAS
(4) 24
Deletion (+2-*+5 tgag) 
Intron 9, donor splice site
W2
W3
W4
X6
WAS
(5)
XLT
(2)
WAS
(5)
XLT
(0.5)
23
10
Deletion (484 ag)
Exon 4, STOP at codon 167
Missense (t348-»c), 
Exon 3, K 105-*P
Deletion (150 t)
Exon 6, STP at codon 260
Missense (c207-*g) 
Exon 2, P58-^R
W8
W11
WAS
(3)
WAS
(5)
Insertion (+31), 
Intron 8, donor splice site
Missense (c435-*t) 
Exon 4, A134^V
W12 WAS(3) 11
Missense (t150-»c), 
Exon 1, L39-*P
W13 WAS(2-3) 14
Missense (t150-^c), 
Exon 1, L39-*P
W14 WAS(5)
Missense (g397^a), 
Exon 4, E 121-»K
a Disease score is given according to the classification by Zhu Q. et al., 1997 
and Jin Y. et al., 2004 
b Age refers to the time of blood sampling
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Figure 1. Defective WASP expression in T cell lines from WAS patients. T cell 
lines from healthy donors (HD) and WAS patients in resting state (A) or after 24 
hours of stimulation with 10 pg/ml immobilized anti-CD3 mAb (B) were analysed 
for WASP expression by Western Blot.
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Figure 2. Defective proliferation of WAS T cell lines after TCR and TCR/CD28 
triggering. T cell lines from healthy donors (HD: filled symbols) and WAS patients 
(W: empty symbols) were stimulated with increasing doses of immobilized anti- 
CD3mAb (A). The rate of TCR downregulation was analyzed in WAS and control 
cells after 4  hours of stimulation with immobilized anti-CD3 mAb (B). 
Alternatively, cells were stimulated with bead coated with the indicated doses of 
anti-CD3 mAb only (C) or anti-CD3 plus anti-CD28 mAb (D). Proliferation was 
evaluated by 3H-thymidine incorporation after 72 hours of stimulation. Values 
represent triplicate cultures. Error bars represent standard deviation. One 
representative experiments out of five is shown.
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4.1.2 CD4+ and CD8+ T cell lines from WAS patients show defective proliferation
in response to TCR/CD28-mediated stimulation
Our T cell cultures contain a mixed population of CD4+ and CD8+ T cells, with a 
preferential selection in favour of CD4+ T cells in cultures from WAS patients (not 
shown). These two cell subsets can have intrinsic differences in their response to anti- 
CD3 mAb stimulation, which could derive from different threshold required for 
activation, response to co-stimulation or even susceptibility to activation induced cell 
death (AIDC). In addition, it is possible that in a mixed culture the response of one cell 
subset is influenced by the other one, by expression of membrane molecules or by 
release of soluble factors. Therefore, we decided to perform experiments using purified 
CD4+ and CD8+ T cell lines, in order to clarify the relative contribution of CD4+ and 
CD8+ T cells to the proliferative defect observed in WASP-deficient T cell lines.
CD4+ and CD8+ T cell lines were established from 4 WAS patients (W l, W2, 
W8, W12) and 1 XLT patient (X6) (see Table 1) and from healthy controls. Analysis of 
WASP expression in resting T cells showed that the levels of WASP in CD4+ T cells 
from WAS patients were almost undetectable (Figure 3A and 3B), while a very faint 
band corresponding to full-length WASP was present in WAS CD8+ T cells (Figure 
3B). The results are different from what we previously observed in bulk T cells from 
patients W l and W2, where WASP was undetectable by Western Blot (Figure 1). It 
should be noted that a different anti-WASP Ab was used to evaluate WASP expression 
in bulk T cells. Expression of residual full-length WASP could be expected in CD8+ T 
cells from patient W12, who has a missense mutation, but not in T cells from patient 
W2, who has a deletion leading to a premature STOP codon. A possible explanation 
could be cross-reactivity of the Ab with the WASP homologue N-WASP, whose size is 
similar to the one of WASP. T cells from the XLT patient showed residual WASP 
expression that was clearly detectable in both CD4+ and CD8+ T cells (Fig. 3A and 3B).
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FACS analysis showed that CD4+ and CD8+ T cells from the XLT patient were 
uniformly WASP"1'"1 (not shown), indicating that the mutated WASP is expressed at 
comparable levels in all cells. Upon stimulation with beads coated with a fixed dose of 
anti-CD28 mAb and escalating doses of anti-CD3 mAb, both CD4+ and CD8+ T cells 
from WAS patients showed defective proliferation at all doses of anti-CD3 mAb tested, 
however, proliferation of WAS T cells was more affected at low anti-CD3 mAb doses 
(Figure 3C and 3D). Interestingly, T cells from the XLT patient displayed an 
intermediate level of proliferation (Fig. 3C and 3D). A more severe proliferative defect 
in CD8+ T cells, compared to CD4+ T cells, was reproducibly observed in patients X6, 
W l and W2 while CD4+ and CD8+ T cells from patients W8 and W12 showed a 
comparable defect in proliferation.
These results indicate that both CD4+ and CD8+ T cells require WASP for 
TCR/CD28 induced proliferation and suggest that WASP expression levels correlates 
with the ability of CD4+ and CD8+ T cells to respond to TCR/CD28-mediated 
stimulation. In addition, data presented here suggest that WASP plays a crucial role in 
lowering the threshold for TCR/CD28-driven proliferation.
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Figure 3. WASP expression and proliferation of CD4+and CD8+ T cell lines 
from WAS/XLT patients and healthy donors. Western Blot analysis of WASP 
expression in resting CD4+ (A) and CD8+ (B) T cells from WAS and XLT 
patients (W l, W2, X6, W8 and W12) and from healthy donors (HD1 and HD2). 
Proliferation of CD4+ (C) and CD8+ (D) T cells from healthy donors (n=4) and 
WAS/XLT patients was measured by 3H-thymidine incorporation, after 72 hours 
of stimulation with beads coated with the indicated doses of anti-CD3 plus 10 
pg/ml anti-CD28 mAb. Values represent mean of duplicate cultures and are 
representative of one out of three independent experiments including all patients 
and out of six experiments involving patients W l and W2. Error bars in the HD 
line represent standard deviation of n=4 healthy donors’ proliferation values.
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4.1.3 LV-mediated WASP gene transfer restores physiological WASP expression
and rescues proliferation to anti-CD3 mAb in WAS T cell lines
In order to verify whether WASP deficiency is directly responsible for reduced 
proliferation to anti-CD3/CD28 mAb of WAS T cells, RV were used to transfer WAS 
cDNA into T cell lines from WAS patients. LDNSW vector, derived from the LNSN 
vector (Mavilio et al., 1994), contains WAS cDNA under the control of the SV40 
promoter and the reporter gene dNGFR under the control of the viral LTR (Figure 4A). 
Efficiency of transduction of activated WAS T cells, evaluated by dNGFR expression, 
was very low (around 3%: not shown). Therefore, in order to enrich for the proportion 
of transduced cells, immunoselection was performed, achieving more than 85% of 
dNGFR+ cells (not shown). WASP expression was then evaluated in resting WAS T 
cells transduced with LDNSW vector (Figure 4B), showing that expression of full- 
length WASP was present, although at lower levels than in control cells. At the time 
these experiments were performed, it was not possible to evaluate the percentages of 
WASP4 cells, however, the results obtained here indicate that the RV used was not able 
to induce physiological levels of WASP expression, despite the fact that the vast 
majority of the cells were transduced.
Analysis of proliferative response to beads coated with anti-CD3 plus anti-CD28 
mAb showed that WASP expression significantly enhanced the proliferation of WAS T 
cells with respect to their untransduced counterparts (p<0.01 t test for the anti-CD3 
mAb doses of 0.1 and 1 pg/ml), while transduction with control RV (containing only 
dNGFR cDNA) did not significantly affect the proliferation of W l cells (Figure 4C). 
However, the proliferation of WASP-transduced W2 T cells remained below the normal 
levels at all anti-CD3 mAb doses tested, indicating that in these cells proliferation was 
only partially corrected. Indeed, WASP-transduced T cells from both W l and W2 
patients failed to proliferate in response to the lowest anti-CD3 mAb dose (0.01 p,g/ml).
Interestingly, WASP-transduced T cells from patient W3 showed complete correction 
of the proliferation (Figure 4C). It should be noted, however, that W3 T cells, when 
activated through the TCR, were able to induce expression of endogenous WASP, 
although at low levels (Figure IB).
These results indicate that RV vectors are able to restore WASP expression in T 
cell lines from WAS patients. However, only low levels of WASP expression were 
detected in WASP-transduced T cells from WAS patients, which is probably the cause 
of the only partial rescue of the proliferation.
An alternative approach based on the use of LV was tested to transfer WAS gene 
into WAS T cell lines. LV were chosen in order to improve the efficiency of 
transduction. Although no data are available regarding fine-tune regulation of WASP 
expression related to the state of maturation or of cell activation, it is possible that 
constitutive WASP expression results in a toxic effect to the cells. For these reason, the 
possibility of driving WAS cDNA expression by using WASP gene endogenous 5 ’ 
regulatory elements was evaluated in this study.
Two different third-generation, SIN HIV-derived LV vector were constructed, 
in which WAS cDNA was put under the control either of the ubiquitous PGK promoter 
(PGK-WASP) or of the endogenous WASP promoter (Wasp-WASP) (Figure 5A). As 
control, a vector containing the green fluorescent protein (GFP) under the control of 
PGK promoter (p-G) was used (Follenzi et al., 2000) (Figure 5A). TCR/CD28-activated 
W l T cell line was transduced with WASP-encoding LV vectors and WASP expression 
was analyzed by FACS, showing a close-to-normal expression and high percentages of 
transduction (Figure 5B). WASP expression driven by LV was able to restore normal 
proliferation in W l T cell lines stimulated via the TCR, at all doses of anti-CD3 mAb 
tested (Figure 5C).
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Figure 4. Transduction of T cell lines from WAS patients with MMLV-derived 
retroviral vectors. MMLV-derived RV (LDNSW) is shown in figure 4A. WASP 
expression was driven by SV40 promoter, dNGFR was used as reporter gene and put 
under the control of the viral LTR. Western Blot analysis of WASP expression in 
whole cell lysate of WAS T cell lines after transduction with LDNSW RV and 
immunoselection (B ). As control, WASP expression level in one T cell line from 
healthy donor is shown. Proliferation in response to stimulation with beads coated 
with anti-CD3 plus anti-CD28 mAb was evaluated in RV-transduced T cells from 
WAS patients (W-tr). As control, proliferation of untransduced WAS T cells (UT: 
empty simbols) and of W l T cells transduced with a control vector (mock) was 
shown (C ). Values correspond to triplicate cultures. Error bars represent standard 
deviation. One representative experiment out of five is shown.
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Figure 5. Transduction of T cell lines from WAS patients with HIV-derived 
lentiviral vectors. Three different types of HIV-derived retroviral vectors are shown 
in figure 6A. WASP expression was driven by either PGK promoter (Pgk-WASP/p- 
W) or by the autologus WASP promoter (Wasp-WASP/w-W). As control, a 
lentiviral vector encoding for GFP was used (pgk-GFP/p-GFP). WASP expression 
in W1 T cell lines was analyzed by FACS six weeks after transduction with the 
indicated LV vectors. As control, WASP expression level in untransduced T cell 
lines from W1 and one healthy control is shown (B). Cell proliferation was 
measured by 3H-thymidine incorporation in T cell lines from patient W1 either 
untransduced, transduced with p-GFP or with the two WASP-encoding LV. As 
control, the mean proliferation of two healthy donors’ T cell lines (HD) is shown 
(C). One representative experiment out of three is shown. Values correspond to 
triplicate cultures.
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These results indicate that LV allow high efficiency of tranduction and close-to-normal 
restoration of WASP expression in WAS T cells. Importantly, endogenous WAS 
promoter was as efficient in driving WASP expression and in correcting the 
proliferation, as the constitutive PGK promoter. Therefore, the use of LV containing 
autologous WASP promoter seems to be the best approach to transduce mature WAS T 
cells, which could represent a possible target of gene therapy in some WAS patients. 
Based on the results obtained in human T cell lines, these LV were also evaluated in 
their ability to mediate WAS gene transfer into repopulating murine WASP-deficient 
HSC. Results obtained from experiments performed in WAS murine model will not be 
presented here but will be discussed hereafter, as they constitute a proof of principle of 
the efficacy of LV-mediated gene therapy in the correction of WAS T cells defects 
(Dupre et al., 2006).
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4.1.4 LV efficiently transduce WAS PBMC without TCR triggering
Since LV are in principle able to transduce non-diving cells, transduction of 
PBMC from patients W l, stimulated by anti-CD3/CD28 mAb or by cytokines was 
performed in parallel. WAS PBMC were transduced with PGK-GFP (P-G) vector upon 
short-term culture with IL-2 and IL-7, a pre-stimulation method which allowed efficient 
in vitro transduction of PBMC (Cavalieri et al., 2003). In parallel, PBMC were 
stimulated through TCR/CD28, in the presence of IL-2 and IL-7 (Figure 6, top). 
Although the overall transduction efficiency was lower when cytokines alone were used 
to pre-stimulate WAS PBMC, this kind of stimulation allowed the maintenance of a 
naive phenotype, as shown by the expression of CD45RA. As expected, TCR/CD28- 
driven stimulation allowed high efficiency of transduction (Figure 6, top), but the vast 
majority of the cells lost the naive phenotype. We also compared the efficiency of the 
constitutive PGK promoter and of autologous WAS promoter to transduce WAS PBMC 
after cytokine mediated stimulation (Figure 6, bottom). A LV in which GFP expression 
was driven by the WASP promoter was used, in parallel with P-G LV. Results indicate 
that although levels of transduction were lower when the autologous WASP promoter 
was used with respect to the PGK promoter, the WASP promoter was able to drive GFP 
expression in a significant proportion of naive cells (Figure 6, bottom).
Together, these data indicate that LV are able to transduce efficiently WAS 
PBMC, while preserving the naive phenotype. If a gene therapy approach targeting 
peripheral T cells was envisaged, it would be possible to efficiently transduce T cells 
without TCR engagement, thus maintaining the natural T cell repertoire and with 
minimal influence on the homeostasis of transduced cells, which should be re-infused in 
the patient.
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Figure 6. Transduction of PBMC from W1 patient with HIV-derived lentiviral 
vectors without TCR triggering. PBMC of patients W1 were transduced with p-G 
LV, after a 48-prestimulation with anti-CD3 plus anti-CD28 mAb (TCR) or a 96-h 
prestimulation with IL-2 and IL-7 (cyto). Percentage of transduction (GFP+) and of 
naive (CD45+) cells was analyzed by FACS 10 days after transduction. Two 
different experiments are shown. Top of the figure shows the comparison between 
transduction with p-G vector with TCR stimulation (TCR) versus cytokine 
stimulation (cyto). Bottom of the figure shows comparison of transduction with the 
constitutive PGK promoter (P-G) and the autologous WASP promoter (W-G) after 
cytokine stimulation.
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4.1.5 Exogenous IL-2 restores proliferative response to anti-CD3 mAb in WAS
CD8+ T cell lines
It was been previously shown, both in human T cell lines and in freshly isolated 
T cells from WASP knock-out mice, that WASP deficiency leads to defective IL-2 
secretion (Dupre et ah, 2006; Molina et al., 1993; Zhang et ah, 1999). Therefore, we 
investigated whether defective proliferation of WAS CD4+ and CD8+ T cell lines was 
due to suboptimal IL-2 production. First, the ability of CD4+ (Figure 7A) and CD8+ 
(Figure 7B) T cells from W1 and W2 patients to proliferate in response to different 
doses of exogenous IL-2 was investigated, showing that WAS T cells respond normally 
to exogenous IL-2. These data indicate that defective proliferation of WAS T cells in 
response to anti-CD3 mAb is probably due to lack of sufficient IL-2 secretion. In order 
to assess whether the addition of exogenous IL-2 was able to rescue the proliferation of 
WAS T cells in response to TCR triggering, CD4+ (Figure 1C) and CD8+ (Figure 7D) T 
cells were stimulated with anti-CD3 mAb-coated beads in the presence of escalating 
doses of IL-2. Since W1 and W2 CD4+ T cells proliferated more than W1 and W2 CD8+ 
T cells in response to TCR triggering, WAS CD4+ T cells were stimulated with a lower 
dose of anti-CD3 mAb (0.5 p-g/ml) than CD8+ T cells (1 p,g/ml), in order to better 
evaluate the contribution of IL-2 to the proliferation. Addition of IL-2 did not increase 
the proliferation of control T cells (Figure 7C and 7D), since, at the dose of anti-CD3 
mAb used in the experiment, they had already reached the plateau of proliferation. In 
contrast, addition of IL-2 to anti-CD3 mAb enhanced the proliferation of both WAS 
CD4+ and CD8+ T cells. While in WAS CD4+ T cells the combination of IL-2 anti-CD3 
mAb induced a proliferative response similar to the one induced by IL-2 alone, in WAS 
CD8+ T cells low doses of IL-2 (12.5-25 IU/ml), combined to anti-CD3 mAb, elicited 
higher proliferation than IL-2 or anti-CD3 mAb alone. Therefore IL-2 and anti-CD3 
mAb had a synergistic effect on the proliferation of WAS CD8+ T cells.
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Together, these data indicate that WAS T cells respond normally to IL-2 and 
that their defective proliferation in response to anti-CD3 mAb is mainly due to defective 
IL-2 secretion.
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Figure 7. P roliferation of WAS T cell lines in response to exogenous IL-2. 
Proliferation was evaluated by 3H-thymidine incorporation in CD4+ (A) and CD8+ 
(B) T cell lines from patients W1 and W2 and from two healthy donors, in response 
to escalating doses of IL-2. Alternatively, CD4+ (C) and CD8+ (D) T cell lines were 
stimulated with IL-2 in the presence of a fixed dose of anti-CD3 mAb. Values 
represent triplicate cultures. One representative experiments out of four is shown.
105
4.2 WASP is required for effector functions of CD4+ and CD8+ T cells
4.2.1 Defective production of Thl cytokines by WAS CD4+ T cell lines upon
TCR/CD28 triggering
To further analyze the cytokine profile of WAS T cell lines, secretion of 
different cytokines was analysed upon stimulation of the cells with anti-CD3 plus anti- 
CD28 mAb-coated beads. As expected, IL-2 secretion was lower than the normal range, 
but not abolished, in WAS CD4+ T cells (Figure 8 p<0.05). Interestingly, patient W2, 
who had a more severe clinical phenotype than patient W l, showed a more severe 
impairment in IL-2 secretion than patient W l. IFN-y and TNF-a secretion was absent or 
severely compromised in both patients (Figure 8 p<0.01). On the contrary, secretion of 
IL-4, IL-5 and IL-10 did not differ significantly between patient W l and control CD4+ T 
cells. In CD4+ T cells from patient W2, the secretion of IL-5 was slightly defective 
(Figure 8 p<0.05), while secretion of both IL-4 and IL-10 was normal (Figure 8). Upon 
stimulation with TPA/ionomycin, the secretion of all the cytokines tested was 
comparable among WAS and control CD4+ T cells (not shown).
To further confirm the differential Thl versus Th2 cytokine profile, production 
of IL-2, IFN-y and IL-4 was investigated by intracellular staining in CD4+ T cells from 
four WAS and one XLT patients. As shown in Figure 9, in all WAS patients the 
percentages of CD4+ T cells producing IL-2 and/or IFN-y were strongly reduced, with 
respect to healthy donor cells stimulated through TCR/CD28 [range of IL-2+ cells for 
healthy donors (n=5) was: 28-44%; range of IFN-y+ cells was: 17-30%]. In particular, in 
WAS patients the population of cells producing both IL-2 and IFN-y was the one 
displaying the strongest reduction. Interestingly, CD4+ T cells from the XLT patient 
produced normal levels of IL-2, while IFN-y production remained below the normal 
range. Conversely, stimulation with TPA and ionomycin induced robust production of 
IL-2 and IFN-y both in patients and in control cells. Intracellular IL-4 production by
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WAS patients CD4+ T cells was considerably higher than IL-2 and IFN-y production 
(Figure 9). When cells producing IL-4 only were considered, percentages among WAS 
patients were just below the normal range [range of IL-4+ cells for healthy donors (n=5) 
was:22-38%]. However, the percentage of cells producing both IL-4 and IFN-y was 
strongly reduced in WAS CD4+ T cells compared to control cells.
Together, these data demonstrate that in CD4+ T cells from WAS patients, the 
secretion of Thl cytokines is defective, while the secretion of Th2 cytokines is normal, 
or minimally reduced.
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Figure 8. Pattern of cytokines secretion by WASP-deficient CD4+ T cell lines.
Secretion of IL-2, IFN-y, TNF-a, IL-4, IL-5, and IL-10 was evaluated by capture 
ELISA performed on the supernatants of CD4+ T cell lines from patients W l and W2 
and two healthy donors stimulated with beads coated anti-CD3 (1 p-g/ml) and anti- 
CD28 (10 p,g/ml). Values represent the mean of triplicate cultures. Three to four 
independent experiments are shown in each graph. Values from two healthy donors 
were shown for each experiment. Backgound levels were subtracted. Statistical 
analysis was performed using the Wilcoxon Signed Rank Test for IL-2 and the 
Wilcoxon Rank Sum Test for the other cytokines. Significance is represented as 
follows: * p<0,5; ** p<0,01.
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Figure 9 . Pattern  of cytokines production by WASP-deficient CD4+ T cell lines.
CD4+ T cell lines from WAS patients and healthy donors were stimulated with beads 
coated with 1 pg/ml anti CD3 plus 10 pg/ml anti-CD28 mAb, or with TPA plus 
ionomycin. Production of IFN-y versus either IL-2 or IL-4 was analyzed by 
intracytoplasmic staining. Only percentages >1 are indicated. Experiment shown is 
representative of three independent experiments including all the patients and of six 
experiments including patients W l and W2. One representative healthy donor out of 
five is shown. Ranges of cytokine production by T cells from the five healthy donors is 
indicated in the text.
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4.2.2 Defective TCR/CD28-mediated IL-2 and IFN-y production by WAS T cells 
cultured in Thl-polarizing conditions
To determine whether the failure to produce Thl cytokines was due to the 
inability of WAS naive CD4+ T cells to differentiate into Thl cells, CD45RO'/CD4+ T 
cells from patient W l were cultured in Thl-polarizing conditions and tested for 
cytokine production after one round of stimulation. To overcome differences in IL-2 
levels secreted by WAS and control cell cultures, differentiation was carried out in the 
presence of exogenous IL-2. Upon stimulation with anti-CD3 plus anti-CD28 mAb, the 
percentage of IFN-y-producing cells was higher both in W l and control cells grown in 
Thl-polarizing conditions, with respect to the same cells cultured in ThO conditions 
(Figure 10). Furthermore, IL-4 production was down-regulated (not shown), indicating 
effective Thl differentiation. However, upon TCR/CD28-mediated stimulation, W l 
cells showed a strong reduction in the proportion of cells producing IFN-y, with respect 
to control cells. The defect was mostly evident in the subset of IL-27IFN-y+ CD4+ T 
cells. On the contrary, stimulation with TPA/ionomycin induced similar levels of 
cytokine production in W l and control T h l cells, indicating that these cells are 
intrinsically able to produce IL-2 and IFN-y.
These data show that, although WASP-deficient CD4+ T cells can undergo Thl 
differentiation in culture conditions in which IL-12 is supplied, they retain a defect in 
the production of IFN-y and IL-2 in response to TCR/CD28-mediated signals.
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Figure 10. T h l polarization in WAS CD4+ T cells. Intracytoplasmic staining of 
cytokine production by ThO and Thl cells generated from naive CD4+ T cells of 
WAS1 and one normal donor (out of two) is shown. Cells cultured for one week 
in either ThO or Thl-polarizing conditions were stimulated for 6 hr with either 10 
p,g/ml immobilized anti-CD3 plus 1 pg/ml soluble anti-CD28 mAbs or TPA plus 
ionomycin, in the presence of brefeldin A. Only percentages >1 are indicated. 
One representative polarization experiment out of two is shown. Values of 
cytokine production were confirmed in three independent stainings.
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4.2.3 Defective cytokine production by WAS CD8+ T cell lines
In order to investigate the consequences of WASP deficiency in CD8+ T cells, 
cytokine secretion and production by WAS and XLT CD8+ T cell lines, generated in 
parallel to the CD4+ T cell lines described above, was investigated. CD8+ T cells from 
patients W l and W2 showed a complete block in the secretion of IL-2, IFN-y and TNF- 
cx (Figure 11) (p< 0,01 for the three cytokines tested). IL-5 secretion by WAS CD8+ T 
cells was also reduced compared to control CD8+ T cells (range observed in three 
independent experiments was: 0.2-0.7 ng/ml IL-5 in WAS CD8+ T cells; 3.2-22.6 ng/ml 
IL-5 in control CD8+ T cells) (not shown). IL-4 and IL-10 were low or undetectable (0- 
400 pg/ml) in the supernatants of both WAS and control CD8+ T cells (not shown).
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Figure 11. P atte rn  of cytokines secretion by W ASP-deficient CD8+ T cell 
lines. Secretion of IL-2, IFN-y, TN F-a was evaluated by capture ELISA 
performed on the supernatants of CD8+ T cell lines from patients W l and W2 
and two healthy donors stimulated with beads coated with 1 pg/ml anti-CD3 
plus 10 pg/ml anti-CD28. Values represent the mean of triplicate cultures. 
Three to four independent experiments are shown in each graph. Values from 
two healthy donors were shown for each experiment. Backgound levels were 
subtracted. Statistical analysis was performed using the Wilcoxon Rank Sum 
Test. Significance is represented as follows: * p<0,5; ** p<0,01.
I l l
According with the results of cytokine secretion, a strong reduction in the 
proportion of cells producing IL-2 and IFN-y in response to TCR and CD28 triggering 
was observed by intracellular staining in all WAS patients (Figure 12) [range of IL-2+ 
cells in healthy donors (n=5) was: 29-47%; range of IFN-y+ cells was: 26-65%]. 
Similarly to what shown for CD4+ T cells, CD8+T cells from the XLT patient displayed 
normal production of IL-2 and sub-optimal IFN-y production. In different experiments, 
levels of IL-2 and IFN-y production by CD8+T cells from this patient were either within 
or slightly below normal range, and consistently higher than those found in WAS CD8+ 
T cells. Although stimulation with TPA/ionomycin induced robust production of IL-2 
and IFN-y by CD8+ T cells from all patients (Figure 12), in patients W2, W8 and W12, a 
reduction in cells producing both IL-2 and IFN-y was still present [range of IL-27 IFN- 
y+ cells in healthy donors (n=5) was: 75-89%].
Together, these results show an inability of CD8+ T cells from WAS patients to 
produce and consequently secrete IL-2, IFN-y and TNF-a in response to TCR/CD28 
triggering.
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Figure 12. P a tte rn  of cytokines production by WASP-deficient CD8+ T cell 
lines. CD8+ T cell lines from WAS patients and healthy donors were stimulated 
with beads coated with 1 pg/ml anti-CD3 plus 10 pg/ml anti-CD28 with or with 
TPA plus ionomycin. Production of IFN-y versus IL-2 was analyzed by 
intracytoplasmic staining. Only percentages >1 are indicated. Experiment shown is 
representative of three independent experiments including all the patients and of 
six experiments including patients W l and W2. One representative healthy donor 
out of five is shown. Ranges of cytokine production by T cells from the five 
healthy donors is indicated in the text.
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4.2.4 Defective cytokine production by PBMC from WAS patients
It is important to determine the in vivo relevance of our findings regarding the 
profile of cytokine production by WAS T cell lines. In particular, it would be important 
to verify whether a different ability to produce Thl versus Th2 cytokines by Th cells is 
present also in freshly isolated T cells. To this aim, cytokine secretion by total PBMCs 
isolated from two WAS patients (W ll and W13) was analyzed upon stimulation with 
anti-CD3/CD28 mAb or with TPA/ionomycin. The pattern of cytokine secretion is 
depicted in Figure 13. In accordance to what observed in WAS T cell lines, the 
secretion of IL-2, IFN-y and TNF-a was reduced in PBMC from both WAS patients, 
compared to control cells, after stimulation with anti-CD3 plus anti-CD28 mAb. 
Stimulation with TPA plus ionomycin induced normal production of IL-2, IFN-y and 
TNF-a in PBMC from patients W l 1, while production of both IL-2 and TN F-a by W13 
PBMC was reduced with respect to control cells, also upon TPA/ionomycin stimulation. 
These data show that IL-2 and IFN-y are not secreted by WAS PBMC upon TCR 
mediated activation and therefore confirm our data obtained in T cell lines.
We noted that levels of IL-4 and IL-5 secreted by primary T cells from normal 
donors after TCR/CD28 triggering are much lower than those secreted by CD4+ T cell 
lines. IL-4 secretion by WAS PBMC was defective both upon TCR/CD28 triggering 
and TPA/ionomycin stimulation. IL-5 secretion was defective in W13 PBMC and in the 
low range of normal values in W ll PBMC, upon TCR/CD28 triggering. Stimulation 
with TPA plus ionomycin induced similar levels of IL-5 secretion in WAS and control 
PBMC.
It should be noted that patient W l 1 was under steroids treatment, at the time of 
blood sampling, which could have negatively influenced the secretion of cytokines by 
his cells. Analysis of cytokine production profile is being currently extended to other
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WAS patients, with different clinical phenotypes. However, this analysis depends on 
several variables, first of all the effective proportion of CD4+ and CD8+ T cells among 
total PBMC. Extension of this analysis to PBMC of other WAS patients will be 
essential to confirm that a dichotomy of Thl versus Th2 cytokine production is already 
present in freshly isolated cells.
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Figure 13. Pattern of cytokines production by freshly isolated PBMC from two 
WAS patients. Freshly isolated PBMC from patients W ll and W13 and from four 
healthy donors (HD) were stimulated with immobilized anti-CD3 plus soluble anti- 
CD28 mAb or with TPA plus ionomycin. Secretion of cytokines was evaluated after 
18 hours (IL-2) or 48 hours (all the other cytokines). Error bars represent standard 
deviation.
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4.2.5 Normal lytic activity of WAS CD8+ T cells against allogeneic cells
Previous studies showed that NK cells isolated from WAS patients displayed 
reduced lytic activity (Gismondi et al., 2004), which could be restored by the addition 
of IL-2. No data were available regarding the effect of WASP deficiency on the lytic 
activity of CTL. Therefore, CD8+ T cell lines specific for an allogenic B-EBV cell line 
(JY) were generated starting from PBMC of patient W l and of two healthy donors and 
analyzed for their ability to lyse JY cells. As shown in Figure 14A, the percentage of 
lysis of target cells was comparable in W l and control CD8+ T cells at the different 
effector:target ratio tested. Exhaustion of the NK-like lytic activity, which could 
partially account for the lysis of JY cells, by pre-incubation with the MHC class I- 
negative K562 cell line, resulted in a reduction of the JY-specific lytic activity 
especially by W l CD8+ T cells, which nevertheless remained within the normal range 
(Figure 14B). EBV-transformed B cells are known to be very strong stimulators, as they 
express high levels of costimulatory molecules. In order to investigate whether WAS 
CTLs could lyse efficiently also non-transformed allogenic cells, three different allo- 
specific CD8+ T cell lines were established from PBMC of patient W l and of three 
healthy donors. Lytic activity was then tested using PHA-blasts, according to the cell 
line specificity. WAS CTL were able to lyse target cells as efficiently as control cells 
also in this system (Figure 14C).
These data suggest that WASP-deficiency does not affect the ability of CTL to 
lyse allogenic cells. Therefore, WASP seems to be dispensable for lytic function, 
although it is required for T cell activation and the production of effector cytokines. 
However, in order to generalize this concept, the Ag-specific activity of WAS CTL 
needs to be investigated and the analysis needs to be extended to other patients.
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Figure 14. Lytic activity of CD8+ T cell lines from  patient W l. Cytotoxic activity 
of JY-specific CD8+ T cells from patients W l and two healthy donors directed 
against allogeneic EBV-transformed B cells (JY), in the absence (A) or in the 
presence (B) of non-radiolabeled K562 cells (cold inhibition of NK-like lytic 
activity) is shown. Each point of the indicated effectoritarget ratio is the mean of 
duplicate values. One representative experiment out of three is shown.
Cytotoxic activity of JY/allogenic donor-specific CD8+ T cells from patients W l 
and from healthy donors against allogenic PHA-blasts (C ). Results represent the 
average of the specific lysis by three different cell lines from patient W l and three 
different cell lines, with the same specificity, derived from three different healthy 
donors. Error bars represent standard deviation.
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4.3 WASP is required for T cell activation and effector functions: cellular and 
molecular mechanisms
4.3.1 WASP is recruited to detergent-resistant membranes (DRM) upon T cell
activation
Previous findings indicated that WASP is recruited at the site of contact between 
T cells and APC and is required for IS formation (Badour et al., 2003; Cannon and 
Burkhardt, 2004; Cannon et al., 2001; Krause et al., 2000). Since IS has been shown to 
be accompanied by the re-organization and clustering of lipid rafts and re-orientation of 
actin cytoskeleton, we decided to study the sub-cellular localization of WASP during T 
cell activation, investigating in particular whether WASP could ever be recovered into 
DRM fractions. Therefore, resting T cell lines from healthy donors were stimulated with 
anti-CD3 plus anti-CD28 mAbs and detergent-resistant membranes (DRM), which have 
been proposed to represent the counterpart of lipid rafts in intact cells (Melkonian et al., 
1999),were isolated by flotation in a sucrose gradient, after cell lysis in non-ionic 
detergent (Simons and Ikonen, 1997). Resting T cell lines from healthy donors were 
stimulated for the indicated times with anti-CD3 plus anti-CD28 mAb and high-density 
(non-DRM) and low-density (DRM) fractions were isolated (Figure 15). The 
localization of LAT, which is constitutively rafts-associated, was then investigated. As 
shown in Figure 15, the adaptor molecule LAT was always recovered in low-density 
fractions (DRM), indicating that DRM are enriched for proteins which have a high 
affinity for rafts in living cells. WASP was found in non-DRM fractions in resting T 
cell lines (Figure 15). However, already 10 seconds after TCR/CD28 triggering, and at 
all the other time points of stimulation evaluated, a fraction of WASP was recovered in 
DRM fractions (Figure 15). CD3-£ was recovered only in soluble, non-DRM fractions
in resting T cells, while it was recovered into DRM fractions upon T cell stimulation 
through TCR/CD28, as previously shown (Figure 15) (Montixi et al., 1998; Xavier et 
al., 1998), with a kinetic that resembled the one of WASP recruitment. These findings 
also indicate that our fractionation procedure was able to separate membrane proteins 
according to their affinity with portions of the membrane with different physical 
characteristics.
Together, these data show that TCR/CD28 triggering in T cells induces the 
partition of a fraction of WASP to DRM fractions, indicating a change in the physical 
properties of this protein, which is likely to depend on its re-localization from the 
cytosol to specific portion of the membrane. Since WASP has been shown to localize at 
the level of the IS (Cannon et al., 2001) and, in our assay, DRM are highly enriched for 
a raft-resident protein (LAT), it is possible that WASP re-localization occurs at specific 
site of plasma membrane corresponding to a subset of lipid rafts.
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Figure 15. Partition of LAT, WASP and CD3-£ into DRM and non-DRM  
(soluble) fractions. Resting T cell line from healthy donor was stimulated 
through TCR and CD28 for the indicated times. Following lysis with non-ionic 
detergent and flotation in a sucrose gradient, the different fractions were 
resolved by SDS-PAGE. The presence of LAT, WASP and CD3-^ in the 
different fractions was revealed by hybridization with specific Abs.
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4.3.2 Defective GM1 upregulation upon TCR/CD28 triggering in WAS T cell
lines
T cell activation has been associated both to clustering of lipid rafts and to 
elevation of the levels of GM1, a ganglioside enriched in a subset of membrane rafts, on 
T cell plasma membrane (Lanzavecchia and Sallusto, 2000; Viola et al., 1999). We 
therefore investigated the levels of GM1 in WAS and control T cell lines, after a three 
days-stimulation with beads coated with anti-CD3 alone, or plus anti-CD28 mAb 
(Figure 16A and 16B). In resting T cells from patients W l and W2 the levels of GM1 
were slightly lower than in control T cell lines (Figure 16A and 16B) (p<0.001 t test, in 
five experiments), while GM1 levels in resting W3 T cells were in the normal range 
(Figure 16A and 16B). Upon stimulation with beads coated with high dose of anti-CD3 
mAbs (10 |^g/ml) both WAS and control T cell lines up-regulated GM1 on the cell 
surface, although the final GM1 levels were lower in WAS than in control T cell lines 
(Figure 16A). Addition of anti-CD28 to anti-CD3 mAb increased the upregulation of 
GM1 in control T cells at low anti-CD3 mAb doses (Figure 16B), indicating that 
upregulation of GM1 strongly depends on costimulation in conditions of suboptimal 
TCR triggering. In T cells from WAS patients the levels of surface GM1 after 
TCR/CD28 triggering were lower than in control cells (Figure 16B p<0.001 t test, in 
five experiments at the maximal anti-CD3 mAb dose).
These data suggest that low levels of GM1 on the plasma membrane of WAS T 
cell lines could be partially responsible for WAS T cell unresponsiveness to TCR/CD28 
stimulation. To further investigate whether reduced levels of GM1 on the plasma 
membrane of WAS T cells were due to a reduction in the total amount of cellular GM1 
(intracellular and surface one) or to defective transport of pre-existing GM1 to the 
plasma membrane, the levels of surface versus total GM1 were evaluated in the same 
stimulation conditions (Figure 16C and 16D). Upon stimulation with either anti-CD3
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mAb alone, or anti-CD3 plus anti-CD28 mAb the levels of total GM1 in WAS T cells 
were lower than in control T cells (Figure 16C and 16D). It should be noted that since 
the basal GM1 levels were also lower in WAS than in control T cells, the fold increase 
was not so much different between the two cell populations (WAS: 2.2, HD: 2.5 fold 
with anti-CD3 mAb; WAS 2.1, HD: 3.1 fold with anti-CD3/CD28 mAb). However, 
after stimulation, the mean fluorescence intensity (MFI) of surface GM1 was 
comparable to that of total GM1 in control cells (Figure 16C and 16D), suggesting that 
the vast majority of the cellular GM1 was on the plasma membrane. On the contrary, in 
stimulated WAS T cells there were no changes in the MFI of surface versus total GM1, 
when compared to resting WAS T cells, thus suggesting a possible impairment in the 
transport of GM1 to the plasma membrane.
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Figure 16. Analysis of GM1 levels on the surface of WAS T cell lines upon 
TCR/CD28 triggering. T cell lines from patients W l, W2, W3 and from three 
healthy donors were stimulated for 72 hours with beads coated with the indicated 
amounts of anti-CD3 alone (A) or anti-CD3 plus 10 p,g/ml anti-CD28 mAbs (B). 
GM1 levels were analyzed by surface staining of the cells with CtxB-FITC. One 
representative experiments out of three is shown. Parallel analysis of total (black 
bars) cellular versus surface (white bars) GM1 was performed in WAS and control 
T cell lines stimulated with anti-CD3 mAb only (C ) or with anti-CD3 plus anti- 
CD28 mAb (D).
123
In order to evaluate the contribution of CD4+ versus CD8+ T cells to the defects in GM1 
upregulation observed in WAS T cells, the analysis of surface GM1 levels was 
performed in purified T cell subsets from patients W l and W2 and from two healthy 
donors (Figure 17). Stimulation of control T cells with beads coated with escalating 
doses of anti-CD3 mAb induced the upregulation of GM1 on the cell surface, at higher 
levels than in WAS T cells (Figure 17). The impairment of GM1 upregulation was more 
profound in CD8+ than in CD4+ T cells from these WAS patients.
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Figure 17. Analysis of GM1 levels on the surface of WAS T cell lines upon TCR 
triggering. CD4+ (A) and CD8 + (B) T cell lines from patients W l, W2 and from 
two healthy donors were stimulated for 72 hours with beads coated with the 
indicated amounts of anti-CD3 alone. GM1 levels were analyzed by surface staining 
of the cells with CtxB-FITC. One representative experiments out of three is shown.
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We then asked whether defective GM1 levels in WAS T cells reflect a disruption of 
general lipid rafts structure. Therefore, total cell lysates from WAS and control T cells 
were fractionated by flotation in a sucrose gradient and the localization of p56 Lck and 
LAT, two signalling molecules which are constitutively rafts-associated via lipid 
modification, was analyzed (Figure 18). These proteins were recovered mainly in low- 
density DRM fractions both in control and in WAS T cells. This finding suggests that 
low levels of glycosphingolipids in WAS T cells do not alter the basic organization of 
lipid rafts. However, it should be noted that this kind of analysis doesn’t give 
information regarding the original cellular localization of the DRM recovered.
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Figure 18. Isolation of DRMs from T WAS T cells. Resting T cell lines from 
healthy donor and one WAS patient were lysed by non-ionic detergent. DRM and 
non-DRM (soluble) fractions were separated by flotation in a sucrose gradient. 
Proteins contained in the different fractions were resolved by SDS-PAGE. The 
presence of LAT and of p56(lck) was revealed by hybridization with specific Ab.
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Together, these data indicate that defective activation of WAS T cells correlates 
with defective GM1 upregulation, which reflects a reduction in both the total amount of 
cellular GM1 and in the relative levels of GM1 on the plasma membrane. Although 
basic organization of rafts in WAS T cells seems not to be substantially altered in 
steady-state, a more detailed analysis of rafts composition both in terms of lipids and 
associated proteins will clarify if and to what extent lipid rafts organization could be 
affected by WASP deficiency.
4.3.1 Inhibition of glycosphingolipids synthesis in T cell lines does not affect
either proliferation or IL-2 secretion
To investigate the functional consequences of reduced levels of GM1 on T cell 
activation, the synthesis of glycosphingolipids was inhibited in normal T cell lines, 
during stimulation through TCR/CD28, to reproduce the situation observed in WAS T 
cell lines. To this aim, T cells from healthy donors were stimulated with plastic-bound 
anti-CD3 plus or minus anti-CD28 mAb, in the presence of the ceramide analogue 
PDMP, which inhibits the synthesis of glucosyl-ceramide, and consequently of 
glycosphingolipids. Analysis of GM1 levels on plasma membrane of resting and 
activated T cells showed that a non-toxic dose of PDMP (10 pM) blocked GM1 
upregulation, but not the increase of cell size, in T cells stimulated with immobilized 
anti-CD3 plus anti-CD28 mAbs (Figure 19A). Quantification of G M lbrlght cell 
population in T cells, after 72 hours of stimulation with anti-CD3 mAb alone or anti- 
CD3 plus anti-CD28 mAb showed that PDMP prevented the upregulation of GM1 
(Figure 19B p< 0.05 for GM1 fold increase in untreated, activated cells, versus PDMP- 
treated cells). Addition of PDMP did not have significant effect on unstimulated T cells
(not shown), which was probably due to the relatively slow turnover of 
glycosphingolipids in resting cells. However, the rate of cell division, as assessed by 
CFSE dilution after 72 hours of stimulation, was not significantly affected by PDMP 
treatment (Figure 19C). IL-2 secretion was also analyzed, showing that PDMP 
treatment induced a reduction in IL-2 secreted by T cells stimulated with anti-CD3 mAb 
alone (Figure 19D p<0.05). However, the overall levels of IL-2 secreted by T cells 
stimulated through TCR alone were very low. Addition of anti-CD28 to anti-CD3 mAb 
induced the secretion of higher levels of IL-2, which was not significantly affected by 
PDMP treatment (Figure 19D).
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Figure 19. Effect of inhibition of glycosphingolipids synthesis on T cell 
activation. T cell lines from healthy donors were loaded with CFSE and 
stimulated with imm.aCD3 plus soluble anti-CD28 mAb, in the presence, or 
absence, of the glycosphingolipid synthesis inhibitor PDMP. After 72 hours, levels 
of surface GM1 were evaluated by CtxB-FITC staining (A). Quantification of 
GM1 fold increase was evaluated considering the percentages of GM1 positive 
cells in T cells from healthy donors (n=6) (B). Proliferation was evaluated by 
analysis of CFSE dilution at day three (C) and IL-2 secretion was measured in the 
supernatants collected after 18 hours of stimulation (D).
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These experiments were performed by stimulating the cells with immobilized 
anti-CD3 mAb. It is possible that the overall independence of T cell activation on 
glycosphingolipids levels could be due to the fact that formation of IS-like structure is 
not required for optimal T cell activation, in this system. Therefore, the effect of PDMP 
treatment during stimulation with beads coated with anti-CD3 alone or anti-CD3 plus 
anti-CD28 mAb was also evaluated. Similarly to what shown here before, GM1 
upregulation was completely prevented by the addition of PDMP (Figure 20A and 
20B), although the overall upregulation of GM1 induced by Ab-coated beads was lower 
than the one induced by immobilized anti-CD3 plus soluble anti-CD28 mAb. In 
addition, we found that TCR/CD28-mediated stimulation induced also the upregulation 
of another ganglioside, GM3 (Figure 20A). GM3 was expressed at higher levels than 
GM1, indeed all resting T cells were GM3+. GM3 upregulation was also prevented by 
PDMP (Figure 20A). Proliferation of T cells in response to anti-CD3 or anti-CD3/CD28 
mAb-coated beads was not significantly affected by PDMP treatment (Figure 20C). 
Accordingly, IL-2 secretion elicited by TCR/CD28 triggering was comparable in 
untreated and PDMP-treated cells (Figure 20D). Stimulation with beads coated with 
anti-CD3 mAb alone induced very low levels of IL-2 (Figure 20D).
Altogether, these results indicate that prevention of glycosphingolipids 
upregulation on the plasma membrane during T cell activation does not block 
proliferation or IL-2 secretion. Therefore, reduced glycosphingolipids levels on 
stimulated WAS T cells are likely to be the consequence and not the reason for WAS T 
cells unresponsiveness to TCR/CD28-driven signals. In WAS T cells, defective 
TCR/CD28 responsiveness could be due to impaired formation of the IS, which affects 
several “late” events of T cell activation, including upregulation of plasma membrane 
glycosphingolipids.
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Figure 20. Effect of inhibition of glycosphingolipids synthesis on T cell 
activation. T cell lines from healthy donors were loaded with CFSE and 
stimulated with beads coated with anti-CD3 plus anti-CD28 mAb, in the 
presence, or absence, of the glycosphingolipid synthesis inhibitor PDMP. After 
72 hours, levels of surface GM1 was evaluated by CtxB-FITC staining (A). 
Quantif cation of GM1 fold increase was evaluated considering the percentages 
of GM1 positive cells in T cells from healthy donors (n=4) (B). Proliferation was 
evaluated by analysis of CFSE dilution at day three (C) and IL-2 secretion was 
measured in the supernatants collected after 18 hours of stimulation (D).
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4.3.4 WAS T cells display normal ability to adhere to immobilized anti-CD3 mAb
or fibronectin
Reduced proliferation in response to anti-CD3 mAb stimulation could be also 
due to an inability of WAS T cells to adhere to a surface coated with anti-CD3 mAb. 
Therefore, we investigated the adhesion of T cell lines from patients W1 and W2 and 
from three different healthy donors to plastic-bound anti-CD3 mAb coated at different 
doses. Stimulation with the lowest anti-CD3 mAb dose (0.1 pg/ml) elicited in some 
cases an increase of the adhesion of control T cells, but never of WAS T cells (Figure 
21A). However, this difference was not significant. At the other doses of anti-CD3 mAb 
tested, WAS and control cells showed comparable adhesion (Figure 21A). Formation of 
conjugates between T cells and APC involves initially the interaction of adhesive 
molecules, such as integrins. If the TCR is productively engaged, the avidity of 
integrins binding to their ligands is positively modulated by a mechanism called inside- 
outside signalling (Kinashi, 2005). We therefore analyzed the ability of WAS and 
control T cells to adhere to fibronectin (a natural ligand of integrins), in the presence of 
the same doses of anti-CD3 mAb tested before. Figure 21B shows that adhesion of 
WAS and control T cells to fibronectin alone was low, while addition of anti-CD3 mAb 
induced an increase in the adhesive capacity of both WAS and control cells. Similarly 
to what was shown for the binding to anti-CD3 mAb only, a reduction in the adhesion 
capacity, although not statistically significant, was observed in WAS T cells plated on 
fibronectin, in the presence of the lowest dose of anti-CD3 mAb (0.1 pg/ml).
Altogether, these data indicate that WASP deficiency does not significantly 
impairs neither the ability of T cells to adhere to anti-CD3 mAb nor to fibronectin.
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Figure 21. Adhesion of WAS T cell lines to immobilized anti-CD3 o r anti- 
CD3 mAb plus fibronectin. Resting T cell lines from patients W1 and W2 
(W) and from three healthy donors (HD) were left to adhere to immobilized 
anti-CD3 at the indicated doses in the absence (A) or presence (B) of 
fibronectin, for 30 min. After removal of non-adherent cells, the fraction of 
adherent cells was calculated. Results correspond to four independent 
experiments using cells from two WAS patients and from the same healthy 
donors.
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4.3.5 WASP is required for IL-2 and IFN-y gene transcription by CD4+ T cell
lines
Defective IL-2 secretion in T cells from WASP knock-out mice were shown to 
be due to a block in IL-2 mRNA expression (Cianferoni et al., 2005; Morales-Tirado et 
al., 2004). However, no data were available on the expression of IL-2 mRNA and of 
mRNA for other cytokines in human WASP-deficient cells. To address this point, and 
to further analyze the mechanisms responsible for the dichotomy of Thl versus Th2 
cytokine production observed in WAS CD4+ T cells, cytokine mRNA levels were 
analyzed by RNAse protection assay (RPA) in CD4+ T cell lines from patients W1 and 
W2 and from two healthy donors (Figure 22A). Quantification in one representative 
experiment (Figure 22B) shows that upon TCR/CD28-mediated stimulation, levels of 
both IL-2 and IFN-y mRNA were lower in WAS CD4+ T cells, as compared to control 
CD4+ T cells. This reduction was observed in three independent experiments (W l: IL-2 
mRNA=10-52% of the normal values; W2: IL-2 mRNA=22-63% of the normal values). 
In contrast, IL-4 mRNA was expressed by WAS CD4+ T cells at higher levels than 
those observed in control T cells, while production of IL-10 mRNA was in the normal 
range (Figure 22B). Independently from the absolute values, CD4+ T cells from WAS 
patients stimulated through TCR/CD28 reproducibly showed higher IL-4 versus IFN-y 
mRNA ratio than control CD4+ T cells, indicating a difference in the balance between 
these two cytokines. In accordance to what observed with the secreted cytokines, 
stimulation with TPA plus ionomycin induced comparable expression of the different 
mRNA transcripts in WAS and control CD4+ T cells (Figure 22B).
Therefore, defective IL-2 and IFN-y production, after TCR/CD28 triggering, in 
WAS CD4+ T cells is determined at the transcriptional level.
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Figure 22 . Analysis of cytokine mRNA expression in WAS CD4+ T cell lines.
RNAse protection assay of the indicated mRNA species extracted from WAS and 
normal CD4+ T cell lines, stimulated with 1 pg/ml imm. anti-CD3 plus 10 pg/ml 
soluble anti-CD28 mAbs or TPA plus ionomycin (A). Results obtained from 
densitometric analysis were expressed as a ratio of each cytokine value versus the 
corresponding L32 value. mRNA levels of IL-2, IFN-y, IL-4 and IL-10 (B) are 
shown. Background values were subtracted. One representative experiment out of 
three is shown. Mean value of the two healthy donors is shown for each mRNA 
species analyzed.(A.U.: arbitrary units).
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4.3.6 WASP is required for IL-2 and IFN-y gene transcription by CD8+ T cell 
lines
To investigate whether a similar mechanism accounted for defective production 
of IL-2 and IFN-y in WAS CD8+ T cells, RPA was performed on CD8+ T cell lines from 
the same patients (W1 and W2) and healthy controls (Figure 23A). Similarly to what 
observed for WAS CD4+ T cells, following anti-CD3/CD28 mAb stimulation, WAS 
CD8+ T cells expressed lower levels of IL-2 and IFN-y mRNA, as compared to control 
CD8+ T cells (Figure 23B). The defect was not present when cells were stimulated with 
TPA plus ionomycin (Figure 23B).
These findings indicate that defective IL-2 and IFN-y production in WAS CD8+ 
T cells is also dependent on TCR/CD28-mediated stimulation, and is determined at the 
transcriptional level.
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Figure 23. Analysis of cytokine mRNA expression in WAS CD8+ T 
cell lines. RNAse protection assay of the indicated mRNA species 
extracted from WAS and normal CD8+ T cell lines, stimulated with 1 
pg/ml imm. anti-CD3 plus 10 [xg/ml soluble anti-CD28 mAbs or TPA 
plus ionomycin (A). Results obtained from densitometric analysis were 
expressed as a ratio of each cytokine value versus the corresponding L32 
value. mRNA levels of IL-2, IFN-y (B) are shown. Background values 
were subtracted. One representative experiment out of three is shown. 
Mean value of the two healthy donors is shown for each mRNA species 
analyzed.(A.U.: arbitrary units).
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4.3.7 Normal ERK1/2 phosphorylation in CD4+ and CD8+ T cell lines from
WAS patients
To further investigate the consequences of impaired IS formation in WAS T 
cells at the molecular levels, phosphorylation of the MAPKs ERK1/2 was analyzed in 
WAS and control CD4+ and CD8+ T cell lines, upon stimulation with beads coated with 
anti-CD3 alone (10 p-g/ml) or with anti-CD3 (1 fig/ml) plus anti-CD28 mAb (Figure 
24). Stimulation of control CD4+ T cells with high doses anti-CD3 mAb or anti-CD3 
plus anti-CD28 mAb induced ERK1/2 phosphorylation (Figure 24). In WAS T cells, 
similar levels of phosphorylated ERK1/2 were detected (Figure 24). In WAS and 
control CD8+ T cells, stimulation with high anti-CD3 mAb doses induced comparable 
levels of phosphorylation (Figure 24). Stimulation of CD8+ T cells with a lower anti- 
CD3 mAb dose plus anti-CD28 mAb induced lower levels of ERK1/2 phosphorylation, 
which were however comparable between WAS and control T cells. Overall, these 
results indicate the activation of the ERK1/2 pathway is conserved in WAS T cells.
Since sustained ERK1/2 activation has been shown to be required for IFN-y 
production, but not for IL-4 production (Badou et al., 2001), ERK1/2 phosphorylation 
was analyzed also at late time points of activation in WAS CD4+ T cells, in order to 
verify whether differential IL-4 versus IFN-y production in these cells could be related 
to inability to sustain ERK activation. As shown in Figure 25, stimulation with anti- 
CD3 plus anti-CD28 mAb-coated beads induced phosphorylation of ERK 1/2 in both 
control and WAS CD4+ T cells, which was maintained, at comparable levels, up to four 
hours.
These data show that overall activation of ERK 1/2 is preserved in WAS CD4+ 
and CD8+ T cells, indicating that the signalling leading to the activation of these 
molecules, downstream of TCR/CD28, is functional in WAS T cells.
137
Figure 24
HD1 HD2 W1 W2
CD4
10 1 - 10 1 - 10 1 - 10 1 aCD3(pg/ml)
- 10 - - 10 - ■ 10 - - 10 aCD28 (pg/ml)
S 3  _  - ^pa-pERK1/2 
s=r a-ERK1/2
CD8
^Ia-pERK1/2 
a-ERK1/2
Figure 25
HD1 HD2
Time (min) 0 15 60 120 180240 cnt- 0 15 60 120 180240 cnt-
4 5 -  i t  I I  — II
I
V II
!
II
!
W2
0 15 60120 180 240
r r r
I 
\'
i 
I
I 
I!
Ill
111
m m —  T~r ------------------
W1
Time (min) 0 15 60 120 180240 cnt-
45~ | |  1^a-pERK1/2
^  a-ERK1/2
Figure 24. Analysis of ERK1/2 phosphorylation in WAS CD4+ and CD8 + T cell 
lines. Serum-starved CD4+ and CD8 + T cell lines from patients W1 and W2 and from 
two healthy donors (HD) were stimulated with beads coated with 1 pg/ml anti-CD3 
plus 10 pg/ml anti-CD28 mAb for 15 min. Cell lysates were resolved by SDS PAGE 
and phosphorylation of ERK1/2 MAPK was assessed, after immunoblotting, by 
sequentially probing with anti-phospho ERK Ab (a-pERKl/2) and anti-panERK Ab (a- 
ERK1/2). The two bands corresponding to p44 and p42 ERK are indicated by arrows. 
One representative experiment out of two is shown.
Figure 25. Analysis of sustained ERK1/2 phosphorylation in WAS CD4+ T cell 
lines. Serum-starved CD4+ T cell lines from patients W1 and W2 and from two healthy 
donors (HD) were stimulated with beads coated with 1 qg/ml anti-CD3 plus 10 pg/ml 
anti-CD28 mAb for the indicated times. Cell lysates were resolved by SDS PAGE and 
phosphorylation of ERK1/2 MAPK was assessed, as described for figure 24.
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4.3.8 Normal JNK1/2 phosphorylation in CD4+ T cell lines from WAS patients
Since Cdc42 has been shown to activate JNK1/2 MAPKs (Minden et al., 1995), 
it is possible that WASP plays a role in transmitting the signals from activated Cdc42 to 
these kinases. Therefore, the phosphorylation of these MAPKs was also analyzed in 
cytosolic extracts of WAS and control T cells, stimulated with beads coated with anti- 
CD3, in the presence of anti-CD28 mAb, or with TPA plus ionomycin (Figure 26). 
Phosphorylation of both JNK1 and JNK2 was observed, after 30 minutes of stimulation 
through TCR/CD28 in both WAS and control CD4+ T cells. After 120 minutes of 
stimulation, phosphorylated JNK1/2 were not detectable anymore neither in WAS nor 
in control CD4+ T cells. The pattern of phosphorylation was comparable in WAS and 
control cells tested (Figure 26). Stimulation with TPA plus ionomycin induced robust 
phosphorylation of p46 JNK1/2 both in WAS and in control CD4+ T cells. Together, 
these data indicated that, consistently with what observed in T cells from WASP knock­
out mice (Zhang et al., 1999), WASP deficiency does not lead to evident alterations in 
the activation of JNK1/2 MAPKs.
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Figure 26. Analysis of JNK1/2 phosphorylation in WAS CD4+ T cell lines.
Serum-starved CD4+ T cell lines from patients W1 and W2 and from two 
healthy donors (HD) were stimulated with beads coated with 1 pg/ml anti-CD3 
plus 10 pg/ml anti-CD28 mAb, or with TPA plus ionomycin, for the indicated 
times. Cell lysates were resolved by SDS-PAGE and phosphorylation of 
JNK1/2 MAPK was assessed, after immunoblotting, by sequentially probing 
with anti-phospho JNK1/2 Ab and anti-panJNKl/2 Abs. The two bands 
corresponding to p46 and p52 JNK1/2 are indicated by arrows. Positive and 
negative controls of JNK1/2 phosphorylation are indicated as “Cnt”. The same 
membranes were then re-probed by anti-WASP Ab.
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4.3.9 Normal TCR-triggered Ca2+ flux in CD4+ and in CD8+ T cell lines from 
WAS patients
In previous experiments we observed a mild defect in Ca2+ flux of bulk WAS T 
cell lines, stimulated through TCR and CD28 (Dupre et al., 2002). Since it is possible 
that CD4+ and CD8+ have intrinsically different responses in terms of Ca2+ flux, the 
levels of Ca2+ were analyzed in resting CD4+ (Figure 27A) and in CD8+ (Figure 27B) T 
cells stimulated with cross-linked anti-CD3 mAb. Analysis of the mean fluorescence 
intensity (MFI) of the Ca2+-binding dye Fluo3 showed that the levels of Ca2+, analyzed 
either at the peak or 400 seconds after the stimulation, were normal in both CD4+ and in 
CD8+ T cells. These data differ from those we previously obtained, although it should 
be noted that in this second set of experiments stimulation was performed by anti-CD3 
mAb only. Therefore, it may possible that a defect in Ca2+ flux is present in WAS T 
cells only upon stimulation through TCR and CD28. Further experiments will be 
required to address this point. However, it should be noted that the effect of WASP 
deficiency on Ca2+ flux in T cells, has been quite controversial, as it will be discussed in 
the discussion section.
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Figure 27. FACS analysis of TCR-elicited Ca2+ flux in WAS CD4+ and  CD8 + 
T cell lines. Ca2+ flux in CD4+ (A) and CD8+ (B) T cell lines from patients W1 
and W2 and from one (out of two) healthy donor (HD), stimulated with 
crosslinked anti-CD3 mAb, is shown. Levels of Fluo3 fluorescence were recorder 
for 400 s ca., then ionomycin was added. MFI calculated at the peak and after 
400 s of stimulation is shown for CD4+ (A) and CD8+ (B) T cells. Results from 
two independent experiments are shown. Values corresponding to WAS patients 
are shown separately, while values corresponding to healthy donors are 
collectively shown as HD. Cl: crosslinking.
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4.3.10 Reduced NFAT nuclear levels in CD4+ and in CD8+ WAS T cell lines
Since defective NFAT-1 activation and Fos expression have been recently 
shown to be associated to defective IL-2 gene transcription in T cells from WASP 
knock-out mice (Cianferoni et al., 2005), we investigated the nuclear levels of NFAT 
family members (NFAT-1 and NFAT-2) and Fos family members in T cell lines from 
WAS patients. Recruitment of the dephosphorylated forms of NFAT-1 and NFAT-2 to 
the nucleus was observed in both WAS and control CD4+ T cells, as early as 10 min 
after stimulation through TCR/CD28 and persisted for at least 120 min (Figure 28A). 
However, in WAS CD4+ T cells, the levels of nuclear NFAT-1 were lower than in 
control CD4+ T cells at the 10 min time point (Figure 28B). This difference was 
observed in three out of four independent experiments. At later time points, comparable 
levels of nuclear NFAT-1 were detected in WAS and control CD4+ T cells. Nuclear 
recruitment of NFAT-2 was observed after a 10-min stimulation and persisted for at 
least 120 min, and it was comparable in WAS and control CD4+ T cells (Figure 28A 
and 28B). WAS and control CD4+ T cells showed a similar profile of expression of Fos 
family members, which were induced at 29 min and further increased 120 min after 
stimulation (Figure 28A and 28B). In WAS CD8+ T cells, a significant reduction in the 
nuclear levels of both NFAT-1 and NFAT-2 were observed 10 min after TCR/CD28 
triggering (Figure 29A and 29B; NFAT-1 p<0.05; NFAT-2 p<0.01). Although in WAS 
CD8+ T cells, decreased levels of NFAT-1 and NFAT-2 were also found at later time 
points (Figure 29A and 29B), this reduction was not significant. Fos family members 
were expressed at similar levels in WAS and control CD8+ T cells 120 min after 
TCR/CD28 triggering (Figure 29A and 29B). These data indicate that the absence of 
WASP in human CD4+ and CD8+ T cells, stimulated through TCR/CD28, leads to a
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reduction in the early nuclear recruitment of NFAT proteins, while the expression of 
Fos proteins appears normal.
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Figure 28. Analysis of expression levels of NFAT-1, NFAT-2 and Fos in the 
nuclei of WAS and control CD4+ T cell lines stimulated via TCR and CD28.
Levels of NFAT-1, NFAT-2 and of Fos family members in the nuclei of CD4+ T 
cell lines from WAS patients and healthy donor (A) stimulated by anti-CD3 plus 
anti-CD28 mAbs-coated beads for the indicated times are shown. Membranes were 
blotted with anti-NFAT-1, anti-NFAT-2 and anti Fos Abs, then re-probed with 
anti-Spl and anti-G3PDH Abs, to check nuclear and cytosolic separation. One 
(out of two) healthy donor is shown for each experiment. As control, whole cell 
lysate from control resting T cells is shown (A). Densitometric analysis of three to 
four independent experiments is shown (B).
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Figure 29. Analysis of expression levels of NFAT-1, NFAT-2 and Fos in the 
nuclei of WAS and control CD8+ T cells stimulated via TCR and CD28. Levels 
of NFAT-1, NFAT-2 and of Fos family members in the nuclei of CD8+ T cell lines 
from WAS patients and healthy donor (A) stimulated by anti-CD3 plus anti-CD28 
mAbs for the indicated times are shown. Membranes were blotted with anti- 
NFAT-1, anti-NFAT-2 and anti Fos Abs, then re-probed with anti-Spl and anti- 
G3PDH Abs, to check nuclear and cytosolic separation. One (out of two) healthy 
donor is shown for each experiment. Densitometric analysis of three independent 
experiments is shown (B).
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4.3.11 Prolonged IkBa phosphorylation in WAS CD4+ T cell lines upon
TCR/CD28 triggering
We then analyzed the activation of another family of transcription factor, NFkB, 
which is involved in the transcription of IL-2 and other cytokine genes (see section 
1.5.3.7.5). In resting cells NFkB proteins are retained in the cytoplasm through binding 
to IkB proteins. Upon receptor triggering, IkB proteins are rapidly phosphorylated and 
therefore targeted for ubiquitination and proteasome-mediated degradation. IkB 
degradation allows nuclear translocation of NFkB dimers. We then analyzed the 
phosphorylation of IkBa induced by stimulation of WAS and control CD4+ T cells with 
beads coated with anti-CD3 plus anti-CD28 mAb. As shown in figure 30A, after 30 
minutes of stimulation, IkBa is phosphorylated in both control and WAS CD4+ T cells, 
but at slightly higher levels in the latter (Figure 30B). After 120 minutes of stimulation, 
levels of phosphorylated IkBa were higher in WAS with respect to control CD4+ T cells 
(Figure 30A and 30B).
Higher phosphorylation of IkB a could be the resu lt of defective 
IkB a degradation, or more in general, to altered turnover of the protein. Although in 
WASP knock-out murine T cells normal NFkB activity has been reported (Cianferoni et 
al., 2005), our results suggest that WASP deficiency could alter NFkB activity. Further 
experiments will be necessary to address this point.
146
F ig u re  30 
A
W1 W2 HD1 HD2
Jlm® 0 30 120 0 30 120 0 30 120 0 30 120(min)
—  —  —  M l M M
45— —  ~ * 4  - —— —- — - * * ^ —  plkba
- -  * M  <— G3PDH.BBSS I
B
W HD W HD
Time (min) 30 120
Figure 30. Analysis of phosphorylation of IkBa in WAS and control CD4+ T 
cell lines stimulated via TCR and CD28. Resting T cell lines fron patients W1 
and W2 and from two healthy donors (HD) were stimulated with beads coated 
with 1 pg/ml anti-CD3 plus 10 pg/ml anti-CD28 mAb for the indicated times and 
cytosolic extracts were resolved by SDS-PAGE. After blotting, phosphorylation 
of IkBa was detected by specific Ab (A). Membranes were re-probed with anti- 
G3PDH Ab to normalize for the amount of proteins loaded (A). Densitometric 
analysis of two independent experiments is shown (B). Values from WAS 
patients (W) and from healthy donors (HD) are collectively shown.
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4.3.12 Reduced T-bet mRNA induction in WAS CD4+ T cell lines stimulated via
TCR and CD28
We next analyzed the levels of T-bet and GATA-3 mRNA in WAS CD4+ T cell 
lines, as these transcription factors are involved in the transcription of IFN-y and IL-4 
genes, respectively (Szabo et al., 2002; Zheng and Flavell, 1997). Levels of both T-bet 
and GATA-3 mRNA were comparable in resting CD4+ T cells from W1 and W2 
patients and healthy controls (Figure 31A and 3 IB). Upon stimulation with 1 pg/ml 
anti-CD3 plus 10 pg/ml anti-CD28 mAb, T-bet was induced in both control and WAS 
CD4+ T cells, but at a lower levels in the latter (Figure 31 A, p<0.05 for patient W2 
compared to healthy donors). At suboptimal dose of anti-CD3 (0.1 p-g/ml) plus anti- 
CD28 mAb, T-bet mRNA expression was significantly higher in control cells than in 
WAS CD4+ T cells (Figure 31 A, p< 0.05 for both W1 and W2 patients). Stimulation 
with TPA plus ionomycin induced comparable T-bet expression in WAS and control 
CD4+ T cells (data not shown). At high doses of anti-CD3 mAb (1 pg/ml), GATA-3 
mRNA was expressed by WAS and control cells at comparable levels (Figure 3 IB). At 
the lower anti-CD3 mAb dose (0.1 p-g/ml), GATA-3 mRNA was not induced in WAS 
CD4+ T cells whereas only a fraction of control T cells expressed it (Figure 3 IB). These 
data show that CD4+ T cells from WAS patients have a reduced ability to induce T-bet 
mRNA upon TCR/CD28-mediated stimulation.
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Figure 31. Analysis of T-Bet and GATA-3 relative mRNA levels in WAS CD4+ 
T cell lines upon TCR/CD28-mediated stim ulation. Measurement of T-bet (A) 
and of GATA-3 (B) gene expression before and after TCR/CD28-mediated 
stimulation of CD4+ T cells from patients W1 and W2 and two healthy controls. 
Total RNA was prepared from either resting or stimulated cells and gene 
expression was measured by semi-quantitative RT-PCR. Values were normalized 
on expression of the housekeeping gene HPRT and correspond to duplicate wells. 
Results derived from three independent experiments are shown. Values of three 
healthy donors are collectively shown as HD. Statistical significance is represented 
as follows: * p<0.05; ** p<0.01
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All together, these studies on the cellular and molecular mechanisms involved in 
WAS T cells unresponsiveness to TCR/CP28-mediated stimulation, indicate a role of 
WASP in the modulation of GM1 levels during T cell activation. In addition, WASP 
deficiency affects the activation of different transcription factors, which is likely to 
contribute to the impairment in the transcriptional activation of Thl cytokine genes.
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4.4 Cellular mechanisms of WAS-associated autoimmunity: a role for natural
T regulatory (nTreg) cells?
4.4.1 CD47CD25+/FoxP3+ cells in the peripheral blood of WAS patients
Studies performed in our laboratory revealed a defect in the function of 
CD47CD257FoxP3+ nTreg cells isolated from the spleen of WASP knock-out mice 
(Marangoni F., Personal communication). WAS is often associated to autoimmune 
manifestations and therefore we hypothesized that alterations of nTreg cells could be 
present in WAS patients (see section 1.7). First, the presence of nTreg in the blood of 
different WAS patients was investigated, based on the presence of cells expressing of 
CD25 and of the forkhead transcription factor FoxP3. Percentages of CD47CD25bnght 
cells in the blood of WAS patients were comparable to percentages observed in age- 
matched healthy donors (not shown). The percentages of CD47FoxP3+ cells in PBMC 
of WAS patients were higher among PBMC of WAS patients than in PBMC of healthy 
controls (Figure 32A and 32B). The percentages of FoxP37CD25+ cells were also 
slightly higher in the blood of WAS patients than in healthy controls, although this 
difference was not significant (Figure 32B). However, it should be considered that some 
of these patients are lymphopenic (W1 and W14) meaning that the absolute numbers of 
nTreg cells among total PBMCs can be lower than the normal. The analysis is currently 
being extended to other WAS patients. It would be also important to evaluate the 
proportion of nTreg cells in the secondary lymphoid organs of WAS patients.
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Figure 32. Analysis of WAS nTreg phenotype: CD25 and FoxP3 expression.
PBMC from WAS patients and from age-matched healthy donors were stained 
with anti-CD4 FITC and anti-FoxP3 PE Abs. Analysis of Foxp3 expression in 
CD4+ population is shown (A). Analysis of the percentages of FoxP3 + and 
FoxP3 +/CD25 + cells in four WAS patients and 10 healthy donors is shown (B). 
Statistical significance is represented as follows: * p<0.05.
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4.4.2 Defective suppressor activity of nTreg cells from WAS patients
We next investigated the ability of freshly isolated nTreg from WAS patients 
and age-matched healthy donors to suppress proliferation by allogenic CD47CD25' 
effector T cells, isolated from healthy donors. As shown in Figure 33A, nTreg cells 
isolated from healthy donors were able to suppress proliferation of allogenic effector T 
cells (range of suppression: 39-85%) at higher levels than the nTreg cells from the two 
WAS patients analyzed (range of suppression: 0-10%). Stimulation of nTreg alone from 
either WAS patients or healthy donors did not elicit significant proliferation, confirming 
that these cells are anergic in vitro, as previously reported (Levings et al., 2002). The 
mechanisms underlying defective suppression by nTreg cells from WAS patients 
remain to be clarified. However, data obtained in our group with nTreg cells from 
WASP knock-out mice indicate that WASP absence leads to defective activation of 
nTreg cells upon stimulation with anti-CD3 mAb plus anti-CD28 (Marangoni F., 
Personal communication). The ability of human WAS nTreg cells to suppress IFN-y 
secretion by allogenic effector T cells was also reduced in vitro, although to a lesser 
extent compared to the ability to suppress proliferation, tested in the same assays 
(Figure 33B). It is possible that the ability to suppress proliferation or cytokine secretion 
by nTreg cells is controlled by different mechanisms, or even it requires different levels 
of activation of nTreg cells. Future studies in additional WAS patients are required to 
confirm and clarify this point.
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Figure 33. Analysis of the suppressive capacity of WAS nTreg cells d irected  
tow ard allogenic effector cells. CD47CD25+ nTreg cells were isolated from the 
peripheral blood of WAS patients and age-matched healthy donors. The ability of 
nTreg cells to suppress the proliferation of allogenic CD47CD25' effector cells, 
stimulated with either anti-CD3 mAb plus APC (W4, HD1 and HD3) or with anti- 
CD3/28 mAb-coated beads (W14 and HD2) was evaluated after 72 hs of 
stimulation. In parallel, levels of IFN-y in the supernatants of the cultures was 
measured after 72 hs of stimulation. Percentages of suppression are indicated.
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To further investigate whether WAS-associated autoimmune manifestations are 
due to the inability of WAS nTreg cells to suppress the response of autologous effector 
T cells, the suppressive capacity of W4 nTreg cells was evaluated using as effector T 
cells autologous CD47CD25' cells. Figure 34 shows that the ability of W4 nTreg cells 
to suppress both proliferation and IFN-y secretion by autologous effector cells was 
lower than the one of control nTreg cells.
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Figure 34. Analysis of the ability  of WAS nT reg  cells to suppress the 
proliferation of autologous effector cells. CD47CD25+ nTreg cells were isolated 
from the peripheral blood of patients W4 and from one age-matched healthy donor. 
The ability of nTreg cells to suppress the proliferation of autologous CD47CD25' 
effector cells, stimulated with anti-CD3 mAb plus APC was evaluated after three 
day-culture. In parallel the ability to suppress IFN-y secretion was evaluated by 
collecting the supernatants of the cultures after 72 hs of stimulation.
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These data support the possibility that altered regulatory T cell function 
contributes to the increased susceptibility to autoimmune manifestations in WAS 
patients and suggest that defective suppressive ability of WAS nTreg cells maybe due to 
defective activation.
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5 DISCUSSION
The results obtained during the course of this PhD project represent new findings, 
which contribute to the understanding of the role played by WASP in T cell activation, 
and to gain insight into the cellular and molecular basis of T cell dysfunction in patients 
affected by WAS. This study indicates that WASP plays a crucial role in the 
responsiveness of T cells to TCR/CD28 triggering, i) by setting the threshold for T cell 
activation/proliferation and ii) by influencing the transcriptional activation of cytokine 
genes. In addition, these results clearly define the effect of WASP deficiency in CD4+ 
Th cells, CD4+/CD25+ nTr cells and CD8+ CTL cells. Here the results obtained will be 
discussed in view of the existing data and in view of possible novel treatment 
approaches for WAS patients such as gene therapy.
5.1 The role of WASP in T cell activation mediated by the TCR and CD28
5.1.1 Role of WASP in regulating the proliferative response after anti-CD3/CD28
mAb-mediated activation
Previous studies showed that WASP-deficient T cells, including human T cell 
lines and T cells isolated from secondary lymphoid organs of WASP knock-out mice, 
display a defective proliferation to anti-CD3 mAb-mediated stimulation (Molina et al., 
1993; Snapper et al., 1998; Zhang et al., 1999). We established T cell lines from WAS 
and XLT patients, with a broad spectrum of disease severity. For the first time, TCR- 
mediated activation of WAS CD4+ and CD8+ T cells was individually studied, using a 
large scale of anti-CD3 mAb doses, combined or not with anti-CD28 mAb. Our study 
confirmed that WASP-deficient T cells have a specific defect in response to TCR 
triggering induced by immobilized anti-CD3 mAb (Figure 2A). Our results also 
indicated clearly that T cell lines established from a patient with a mild phenotype 
(XLT) and displaying residual WASP expression showed very limited defect of
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proliferation in response to TCR triggering. Importantly, the proliferation defect of 
WASP-deficient T cells is attributable to both CD4+ and CD8+ T cells, indicating that 
these two cell subsets require WASP for optimal activation and proliferation (Figure 
2C, 2D, 3C and 3D). Interestingly, a milder proliferation defect was observed in WAS T 
cell lines upon stimulation with high dose of anti-CD3 mAb in the presence (or 
absence) of anti-CD28 mAb. These findings, together with the evidence that the defect 
in proliferation of WAS T cells is more evident at sub-optimal anti-CD3 mAb doses, 
indicate that WASP lowers the threshold for T cell activation, thus suggesting that 
WASP is enhancing or sustaining the signals delivered through the TCR. One 
explanation would be that WASP, through its regulation of actin cytoskeleton, is 
involved in the re-localization of TCR and associated signalling molecules, which takes 
place during T cell activation. Our data also indicate that the defective proliferative 
response to anti-CD3 mAbs of WAS T cells is not associated to a defective TCR 
downregulation (Figure 2B), or to a defective ability to adhere to immobilized anti-CD3 
mAbs (Figure 21)
Although the addition of anti-CD28 mAb to anti-CD3 mAb stimulation 
enhanced the proliferative response of WAS T cells (Figure 2D), costimulation was not 
able to restore normal proliferation in WAS T cells. In our experiments it is difficult to 
conclude that WAS T cells respond normally to CD28 costimulation, since all the 
experiments were performed with a single (high) dose of anti-CD28 mAb. However, 
results obtained in WASP knock-out mice showed that WASP-deficient naive CD4+ T 
cells required approximately 10 fold higher anti-CD28 mAb concentrations than control 
cells, in order to respond to proliferate in response to TCR triggering (Morales-Tirado et 
al., 2004). CD28 costimulation amplifies TCR signalling and therefore it is able to 
lower the numbers of triggered TCRs, which are necessary for productive T cell 
activation, making CD28-mediated costimulation particularly required in conditions of
suboptimal TCR engagement (Viola and Lanzavecchia, 1996). Whether costimulation 
via CD28 is also able to cooperate in trans with TCR signalling, via the activation of 
independently regulated signalling pathways, is still a matter of debate (Michel and 
Acuto, 2002; Rudd and Raab, 2003). However, Vav-1 is considered a crucial molecule 
involved in an early connection between TCR and CD28 pathways, which is necessary 
for signal amplification. This pathway is linked to the remodelling of actin cytoskeleton 
through the activation of Racl and Cdc42. Therefore, WASP could be implied in this 
pathway through the formation of a Vav-1/SLP76/Nck complex, and therefore being a 
key molecule involved in TCR/CD28 signal integration. TCR triggering was also shown 
to induce phosphorylation of WASP on the tyrosine residue 291 (Badour et al., 2004a) 
and mutation of this residue strongly impaired TCR-mediated NFAT activation. 
Evidences for a possible role of WASP in transmitting CD28-evoked signals comes 
from the recent finding that WASP phosphorylation induced upon TCR triggering is 
strongly enhanced upon CD28 co-engagement (Kim and White, 2006). In addition, 
WASP has been proposed to regulate CD28 endocytosis in murine T cells (Badour et 
al., 2004b). Therefore, it would worth to analyze the pathway of CD28 endocytosis in T 
cells from WAS patients.
Our study helped to clarify the role of IL-2 deficiency in the (partial) inability of 
WAS T cells to proliferate in response to anti-CD3/CD28 mAb. T cell proliferation is 
controlled by both TCR/CD28 and IL-2R-mediated signals. Exit from the G1 phase of 
the cell cycle and entering into the S phase requires IL-2 generated signals (Nourse et 
al., 1994). Indeed, triggering of the IL-2 receptor induces key events of Gl-to-S phase 
transition, including up-regulation of cyclin D, down-regulation of p27Kip, and hyper- 
phorphorylation of Rb, mediated by PI3K (Brennan et al., 1997). In WAS T cells, 
defective proliferation correlates with reduced IL-2 production (Figure 8,9,11,12) both 
in CD4+ and CD8+ T cells from WAS patients. WAS T cells were able to proliferate
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normally to exogenous IL-2, and the addition of IL-2 to sub-optimal doses of anti-CD3 
mAb had a synergistic effect on the proliferation of CD8+ T cells (Figure 7). This 
synergistic effect was less clear in WAS CD4+ T cells. Thus, WASP deficiency seems 
not to affect IL-2R signalling and the inability to secrete sufficient amounts of IL-2 is 
likely to be the main reason for the poor proliferation of WAS T cells. However, it was 
shown that TCR and CD28-generated signals can mediate Gl-to-S phase transition and 
T cell proliferation independently of IL-2 (Appleman et al., 2000; Boonen et al., 1999). 
Therefore, it is possible that, in our system, proliferation in response to anti-CD3/CD28 
mAb is elicited by both IL-2-dependent and independent mechanisms. Therefore, 
WASP could be required not only for IL-2 production but also for IL-2 independent 
mitogenic signals. Therefore, it would be interesting to analyze down-regulation of 
p27Kip in T cells from WAS patients, stimulated either through TCR/CD28 or IL-2R, in 
order to further clarify the molecular mechanisms of WASP-mediated regulation of T 
cell proliferation.
5.1.2 Restoration of physiological levels of WASP expression in WAS T cells by
LV gene transfer leads to normal TCR/CD28-induced proliferation
Transfer of WASP-encoding cDNA into T cell lines from WAS patients was 
performed to verify whether WASP deficiency is directly responsible for the defective 
proliferation of WAS T cells, and to evaluate the efficacy of RV versus LV gene 
transfer in view of a future gene therapy approach for WAS patients.
Expression of human WASP into T cell lines derived from WAS patients 
mediated by either RV and LV gene transfer led to different degrees of correction of the 
proliferative response after TCR/CD28 stimulation (Figure 4C and 5C). Since 
correction of proliferation is probably the consequence of restoration of IL-2 
production, it is possible that in a mixture of WASP* (transduced) and W A SP 
(untransduced) cells, the former help the latter to proliferate, by providing a source of
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IL-2 production. However, it seems that expression of physiological level of WASP is 
required to achieve full correction of anti-CD3 mAb-driven proliferation. In accordance 
with this data, intermediate levels of WASP expression in CD4+ and CD8+ T cells from 
the XLT patient (X6) were able to sustain intermediate levels of proliferation, in 
response to TCR/CD28 triggering (Figure 3C and 3D). We observed that the reduced 
proliferation of WAS CD4+ and CD8+ T cells was due to a reduced proportion of cells, 
which underwent cell division (not shown). This analysis (based on CFSE dilution) 
could be extended to the cells of XLT patients expressing residual point-mutated 
WASP, to see whether the expression of a point-mutated WASP correlates with the 
ability to proliferate. This kind of analysis could be also useful to evaluate more 
precisely the degree of functional correction of WASP-transduced WAS T cells.
Our results strongly argue in favour of LV as the tools of choice to mediate WAS 
gene transfer into T cells for a gene therapy purpose. Indeed, LV allowed efficient 
transduction of T cell lines and freshly isolated PBMC from WAS patients (Figure 6) 
and long-term gene expression. Importantly, correction of proliferation was achieved by 
using either the PGK promoter or the autologous WAS promoter (Figure 5C). The latter 
was able to drive physiological levels of WASP expression with a relatively low 
numbers of integrants per cell (1 to 3: not shown). This is particularly important in the 
context of the safety of LV versus RV regarding the risk of insertional mutagenesis. 
Bases on these, and on other results obtained from experiments using an ex vivo gene 
therapy approach in the WASP knock-out mouse (Dupre et al., 2006), the wasp-WASP 
LV has been chosen for the development of a future gene therapy clinical trial in WAS. 
In accordance with previous data (Cavalieri et al., 2003), LV were also able to transduce 
PBMC from WAS patient in the presence of cytokines but in the absence of TCR 
engagement, thus substantially preserving the naive phenotype (Figure 6). This feature 
of LV would be particularly important if gene therapy using peripheral blood
lymphocytes (PBL) is to be envisaged in some of these patients. However, the high 
frequency of autoimmune manifestations in WAS patients (Dupuis-Girod et al., 2003) 
should be taken into consideration, as it could reflect the presence of abnormal 
circulating auto-reactive T cells, possibly due to inefficient negative selection. 
Therefore, re-introduction of the WAS gene into mature T cells could be deleterious. For 
this (and for other reasons) the ideal target of gene therapy for WAS will be HSC, in 
order to allow the development of a balanced immune system and the establishment of 
tolerance towards the newly expressed protein. However, untransformed T cell lines 
from WAS patients revealed to be a powerful experimental in vitro system for the 
evaluation of the efficacy (and safety) of different vectors, providing key information 
for the selection of the vector to be developed for clinical use and helping to define 
read-outs for the pre-clinical study performed in the laboratory (Dupre et al., 2006).
5.2 Role of WASP in regulating cytokine production in CD4+ and CD8+ T cells
WASP deficiency in T cells has been linked to defective production of different 
cytokines in response to TCR/CD28 triggering. Defective IL-2 secretion has been 
classically considered a hallmark of WASP-deficient T cells. We showed that both 
WAS CD4+ and CD8+ T cells accounted for the defective IL-2 production observed in 
the supernatants of bulk T cell lines after TCR/CD28 triggering (Figure 8, 9,11 and 12). 
Impaired IL-2 production was also observed in WAS CD8+ T cells stimulated through 
TCR only (not shown), in accordance with previous data (Strom et al., 2003a). In CD4+ 
T cells from both control and WAS cells, stimulation through TCR alone elicited only 
minimal IL-2 production (not shown), since this cell subset is highly dependent on 
CD28-mediated costimulation. In our study, analysis of the pattern of cytokine 
production by WAS T cells also revealed a strong impairment in the secretion of Thl 
cytokines (IFN -yand TN F-a) both in CD4+ and CD8+ T cells, after TCR/CD28
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stimulation. For IFN-y we demonstrated that the low levels in the supernatants 
correspond to reduced protein synthesis (Figure 9 and 12). In accordance with our data, 
analysis of immune response to Influenza virus in the WASP knock-out mouse model 
showed that despite normal viral clearance during primary Influenza inoculation 
occurred, the secondary immune response was defective (Andreansky et al., 2005). In 
particular, T cells isolated from the spleen of WASP knock-out mice after secondary 
infection with Influenza virus showed defective production of both IFN-y and TNF-a.
Previous studies in CD4+ T cells from WASP knock-out mice showed that 
reduced levels of IFN-y in the supernatants of TCR/CD28-stimulated WAS cells was 
due to defective secretion rather than to defective synthesis (Morales-Tirado et al., 
2004). This was attributed to lack of polarization of IFN-y and Golgi apparatus, which 
suggested that altered intracellular localization of this cytokine was responsible for its 
defective secretion. These data substantially differ from ours, as in our experiments 
IFN-y reduction in human WAS T cells is present both at the intra-cellular and extra­
cellular level, thus arguing against a defect of secretion. Moreover, treatment of WAS T 
cells with phorbol ester (TPA) and Ca2+ ionophore (ionomycin) was able to trigger high 
levels of IFN-y production (Figure 9 and 12) and secretion (not shown) in WAS T cells, 
indicating that IFN-y production could be restored, likely bypassing defective signalling 
via the TCR. However, we cannot rule out the possibility that, in WAS T cells 
stimulated with TPA plus ionomycin, vesicles containing IFN-y are secreted without the 
correct polarization of the secretory apparatus. Recent data indicate that secretion of IL- 
2 and IFN-y follows a different pathway from the one followed by IL-4 and TNF-a. 
Indeed, the vesicles containing the first two cytokines are polarized at the secretory 
synapse, while vesicles containing the second two cytokines are scattered throughout 
the cell (Huse et al., 2006). It would be important to investigate whether WASP is 
involved in one of these two mechanisms of secretion. Indeed, given the role of WASP
in IS formation, we can speculate that WASP could be also involved in polarized 
secretion of IL-2 and IFN-y. However, the defect could be more complex, since WASP 
deficiency also impairs the synthesis production of IL-2 and IFN-y.
The acquisition of the ability to produce effector cytokines, including IFN-y and 
IL-4 is linked to cell division (Bird et al., 1998). Indeed, the capacity to produce IFN-y 
or IL-4 is positively regulated by demethylation of cytokine genes, which increase the 
accessibility of chromatin to available transcription factors (Agarwal and Rao, 1998). 
These chromatin modifications are likely to be acquired during cell cycle progression 
(Richter et al., 1999). We reasoned that our culture conditions, which provide signals 
through TCR, CD28 and IL-2, should favour cell divisions in WAS and control T cells 
to a similar extent. Indeed, in our culture system WAS T cells proliferated normally in 
response to TCR/IL-2. Therefore, impaired production of T hl cytokines by WAS T 
cells is likely not to be a consequence of impaired in vitro proliferation.
Our finding that in WAS CD4+ T cells the production of Th2 cytokines was 
normal to minimally impaired, while production of T hl cytokines was strongly 
defective, could result from an in vitro selection of Th2 over Thl-like cells in WAS 
CD4+ T cell cultures. However, WAS CD4+ T cells were not intrinsically unable to 
produce Thl cytokines, as shown by high levels of IL-2 and IFN-y produced upon 
stimulation with TPA plus ionomycin (Figure 9). Moreover, analysis of T-bet and 
GATA-3 mRNA levels in resting WAS and control CD4+ T cell lines argues against a 
Th2 skewing in WAS cell cultures (Figure 32). Therefore, our results indicate that 
defective T hl cytokine production in WAS CD4+ T cells results from altered 
TCR/CD28 signalling. These results were confirmed by the reduced frequency of cells 
producing IL-2 and IFN-y, upon TCR/CD28 triggering, in naive WAS CD4+ T cells 
cultured in Thl-polarizing conditions (Figure 10).
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The unbalanced Th2 versus Thl cytokine production could have at least two 
possible explanations: the first is that WASP is specifically involved in transmitting the 
signals leading to the synthesis of Thl but not Th2 cytokines, the second is that 
induction of Thl cytokine gene transcription has a higher threshold than the activation 
of Th2 cytokine gene transcription. This latest hypothesis has been supported by studies 
showing that Thl differentiation and IFN-y production requires “stronger” or more 
sustained signalling than the ones required for Th2 and IL-4 differentiation (Constant et 
al., 1995). This hypothesis is also favoured by the observation that Th2 cytokine 
secretion was reduced in WAS CD4+ T cells with respect to control cells, in case of 
stimulation with suboptimal anti-CD3 mAb dose (not shown).
Our in vitro results are relevant for the understanding of the cellular mechanisms 
associated WAS immunodeficiency. Reduced IL-2 and IFN-y production by activated 
CD4+ T cells, and overall impairment in Thl differentiation is likely to result, in vivo, 
into poor help to CD8+ T cells during the establishment of immune response against 
viral pathogens. The precise requirements of CD4+ T cells for the generation and 
survival of memory CD8+ T cells has been deeply investigated (Rocha and Tanchot, 
2004). While the activation and acquisition of effector functions by CD8+ T cells during 
primary immune response do not require CD4+ help at the moment of priming, the 
capacity to undergo clonal expansion upon Ag re-exposure is programmed via 
interaction with CD4+ T cells and APC during primary stimulation (Janssen et al.,
2003). It has been proposed that help by CD4+ cells confers competitive “fitness” to 
memory CD8+ T cells, thus contributing to the generation of long-term surviving 
memory CD8+ T cells (Johansen et al., 2004). We can speculate that, in WAS patients, 
the inability to efficiently clear viral infections results from both an intrinsic CD8+ T 
cell defect and from inadequate help by Thl cells. WAS patients often display HSV 
infections. In healthy individuals, innate and adaptive immunity efficiently control
primary HSV infection. The virus has the ability to persist in the host in a latent state 
and its reactivation is usually controlled by memory cellular response. Indeed, killing 
activity and IFN-y production by virus-specific CD4+ and CD8+ CTLs were shown to be 
crucial to control the reactivation phase (Bouley et al., 1995; Rouse and Gierynska,
2001). Therefore, impairment of the Thl-CD8+ T cells axis could explain in part the 
susceptibility to HSV infections in WAS patients, in addition to a defect in NK activity.
Interestingly, we found that CD8+ T cell lines established from patient W1 were 
able to lyse both allogenic EBV-transformed B cells and allogenic PHA-blasts at levels 
comparable to those of normal donors (Figure 14). Although we cannot exclude an 
impairment of lytic activity triggered by Ag presented by self MHC, these results 
suggest that in WAS patients the inability to clear viral infections could be due to poor 
expansion of Ag-specific CD8+ T cells, rather than to defective lytic activity per se.
Finally, our data imply a severe impairment in cellular-mediated immunity in 
WAS patients, which, in addition to a reported defect in NK activity (Gismondi et al., 
2004) might be responsible for the high susceptibility not only to viral infections but 
also to haematological malignancies. The reason for the increased susceptibility of 
WAS patients to haematological tumours has not been clarified. Immunodeficiency, 
with lack of immunological surveillance by T cells, plays an important role, as 
demonstrated by the high percentages of EBV+ lymphomas (Imai et al., 2004; Sullivan et 
al., 1994), however, there could be other causes. Indeed, high incidence of lymphomas in 
a group of WAS patients carrying a mutation, which is associated with a mild clinical 
phenotype was reported (Shcherbina et al., 2003). Considering the relatively high 
frequency of myelodisplasia in WAS patients, it has been proposed that genomic 
instability contribute to the development of tumours (Burns et al., 2004a). This 
possibility would be supported by the finding that the yeast-homologue of WASP is 
involved in the mechanism of cytokinesis (Pelham and Chang, 2002).
5.3 Recruitment of WASP into detergent resistant membranes (DRM) upon T cell
activation: a possible association with lipid rafts
The importance of WASP in T cell activation is well established based on the 
functional defects of WASP deficient human and murine T cells. We and others showed 
that WASP deficiency impairs the polarization of T cells toward beads coated with anti- 
CD3/CD28 mAb and the organization of the IS, particularly in conditions of sub- 
optimal stimulation (Badour et al., 2003; Cannon and Burkhardt, 2004; Dupre et al., 
2002). Following studies showed that WASP is recruited to the site of TCR engagement 
where it is likely to induce localized actin polymerisation (Barda-Saad et al., 2005). We 
demonstrated that, in normal T cells, early upon TCR/CD28-mediated stimulation, a 
fraction of WASP re-localizes from soluble fraction to DRM fractions (Figure 15), 
which have been proposed to correspond to lipid rafts in intact cells (London and 
Brown, 2000). In accordance with this model, we recovered LAT, a protein which is 
constitutively associated to rafts, in DRM fractions, independently on T cell activation. 
These results were subsequently confirmed in an independent study, showing WASP 
recruitment to DRM (defined as lipid rafts) upon TCR triggering (Sasahara et al., 2002). 
Partition of WASP to DRM is probably not mediated by Cdc42, as we could never 
detect Cdc42 in DRM fractions in the same stimulation conditions (not shown). In 
accordance, binding of Cdc42 was shown to be required for WASP activation at the IS, 
but not for its localization (Cannon et al., 2001; Zeng et al., 2003).
Following our initial work, the mechanisms regulating WASP association to 
lipid rafts were further investigated. WASP was found in a complex containing ZAP-70, 
Lck and Dlgh-1, a member of the MAGUK family of proteins (Round et al., 2005). In 
the same study, Dlgh-1 was shown to be recruited to GM1-containing lipid rafts upon T 
cell activation, likely via interaction with Lck. Interestingly, downregulation of Dlgh-1
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causes a reduction in the secretion of IL-2 and IFN-y by T cells, while its 
overexpression induces an increase of NFAT activity. The accordance between these 
findings and our results in WASP-deficient T cells suggest that Dlgh-1 could influence 
either WASP localization and/or activation.
An additional study showed that T cell stimulation via TCR and CD2 induced 
the formation of a complex containing WASP, PSTPIP1, the adaptor protein CD2AP 
and the costimulatory molecule CD2. In the stimulation conditions used by the authors, 
WASP was recovered only in non-DRM fractions, suggesting that the mechanisms of 
WASP partition to DRM may depend on CD28-mediated co-stimulation.
It should be noted that although the inducible partition of WASP to DRM 
constitutes an indication of the increase of the affinity of the protein for lipid raft 
microdomains, whether DRM can be really considered the counterpart of rafts in living 
cells is still a matter of debate. In addition, the extent of partition of a given protein to 
DRM is strongly influenced by the extraction conditions (Munro, 2003). A formal proof 
of the association of WASP with specific membrane microdomains (possibly rafts) 
would ideally come from high-resolution electron microscopy, a system which has been 
used to investigate dynamic association of signalling molecules with membrane 
microdomains (Wilson et al., 2004)
5.4 Role of WASP in regulating glycosphingolipids levels: implications for T 
cell activation
Our data indicate that WASP modulates the levels of GM1 on the surface of T 
cells (Figure 16 and 17). GM1 up-regulation was functionally linked to T cell activation 
and to maturation from a naive to a memory phenotype (Tuosto et al., 2001; Viola et al.,
1999). After stimulation through TCR/CD28, reduced levels of GM1 were found on the 
plasma membrane of WAS T cells, compared to control cells. This reduction was
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present both in CD4+ and CD8+ T cells from patients W1 and W2, although in these 
patients the defect was more pronounced in CD8+ than in CD4+ T cells (similarly to 
what observed in proliferation: Figure 17). Analysis of the total cellular GM1 versus the 
surface one, after TCR/CD28-mediated stimulation, suggested that defective GM1 
upregulation in WAS T cells is due both to reduced synthesis (or increased degradation) 
and reduced translocation of GM1 from intracellular compartments to the plasma 
membrane. The level of GM1 on plasma membrane of T cells has been correlated with 
the activation and differentiation status (Tuosto et al., 2001; Viola et al., 1999). 
Therefore, it was proposed that higher levels of surface GM1 implies higher levels of 
rafts-associated proteins and a more ready-to-go signalling machinery, which would 
assure more responsiveness to stimulation. In accordance with this possibility, GM1 
was shown to act as a functional co-receptor for the fibroblast growth receptor 2 
(FGF2), enhancing the proliferation of CHO cells in response to FGF (Rusnati et al., 
2002). Moreover, gangliosides (glycosphingolipids containing sialic acids, as GM1) 
were found to influence cytokine secretion by T cells (Kanda and Watanabe, 2001). It 
should be noted, however, that recent studies challenged the importance of the 
association of signalling molecules to GM1-enriched domains or, more in general to 
lipid rafts, during T cell activation. One of these study, performed with high-resolution 
imaging techniques, showed that, in activated T cells, clustered signalling molecules do 
not necessarily co-localize with clustered lipid rafts, simply because stimulation with 
anti-CD3/CD28 mAbs does not induce a significant cluster of rafts components 
(Douglass and Vale, 2005; Glebov and Nichols, 2004). It is then possible that different 
mechanisms account,for molecules segregation during IS formation, including both 
protein-lipid and protein-protein interactions. In addition, it is possible that different 
kind of rafts microdomains exist in native membranes, which could have different lipid 
composition. For this reason, and also to extend the study on GM1 expression, we are
currently investigating the lipid composition of WAS versus control T cells by thin 
layer chromatography (TLC). In the future we would like to extend this kind of analysis 
to DRM isolated to WAS and control T cells, either in resting or activated state.
In normal T cell lines, inhibition of glycosphingolipids synthesis by the 
ceramide analogue PDMP (threo-l-phenyl-2-decanoylamino-3-morpholino-l propanol) 
did not affect either proliferation or IL-2 secretion in response to TCR/CD28 triggering 
(Figure 19 and 20). However, a reduction in IL-2 secretion was observed in T cell lines 
stimulated with immobilized anti-CD3 mAb and treated with PDMP (Figure 19). 
However, levels of IL-2 elicited by stimulation with anti-CD3 mAb only were in any 
case very low (<150 pg/ml). Another group obtained similar results in Jurkat T cells, 
where PDMP treatment was shown to impair signalling mediated by GPI-anchored 
proteins, but not by the TCR (Nagafuku et al., 2003).
As an overall conclusion, our data imply that reduced GM1 upregulation in 
WAS T cells is probably the consequence, and not the cause, of their unresponsiveness. 
However, it is possible that the basal levels of glycosphingolipids influence the 
responsiveness of T cells to Ag stimulation. In this view, it would be of interest to 
measure the levels of GM1 and GM3 levels at the plasma membrane of anergic T cells, 
such as in vitro anergized T cells (Schwartz, 2003) or naturally anergic T regulatory 
cells (Roncarolo et al., 2001a) compared to responsive effector T cells.
5.5 Role of WASP in TCR/CD28-mediated signalling
5.5.1 Defective Thl cytokine gene transcription in WAS CD4+ and CD8+ T cells
In this study, we showed that the defects in T cell activation by human WAS 
CD4+ and CD8+ T cells resulted in impaired proliferation in response to anti-CD3/CD28 
mAb, associated to defective Thl cytokine production. Analysis of cytokine gene
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transcription, after TCR/CD28 triggering, demonstrated that the defective IL-2 and IFN- 
y production is due to reduced expression of the corresponding mRNA species (Figure 
22 and 23). However, small amounts of IL-2 and IFN-y mRNA could be produced by 
WAS CD4+ and CD8+ T cells, showing that WASP deficiency did not completely block 
the signalling pathways leading to the transcriptional activation of these cytokine genes. 
Whether a partial block of transcription is the mechanism responsible for defective Thl 
cytokine production in WAS T cells, upon TCR/CD28-mediated stimulation, remains to 
be determined. It is possible that other functions, such as cell survival or proliferation, 
influence the secretion of these cytokines. The observation that stimulation with TPA 
plus ionomycin induced comparable expression of IL-2 and IFN-y mRNA in WAS and 
control T cells (Figure 22 and 23) indicates that WAS T cells are not intrinsically 
unable to activate the signalling pathways, but that they have a specific defect in 
TCR/CD28-mediated signalling. Interestingly, in WAS CD4+ T cells, the levels of IL-4 
mRNA were even higher than in control CD4+ T cells (Figure 22). Since this finding 
was not paralleled by an increase in IL-4 secretion by WAS CD4+ T cells, we cannot 
exclude that other post-transcriptional events related to IL-4 synthesis or secretion are 
affected by WASP deficiency. In different experiments, the relative amount of IL-4 
versus IFN-y mRNA was very different in WAS versus control CD4+ T cells. Indeed, in 
the former the levels of IL-4 and IFN-y mRNA species were comparable, while in the 
latter higher IFN-y than IL-4 mRNA was expressed (Figure 22). These results indicate 
that the balance between these two cytokines is altered by the absence of WASP.
5.5.2 Defective T-bet induction in WAS CD4+ T cells: implications for IFN-y
production and Thl commitment
Regulation of transcription of IFN-y or IL-4 in committed Th cells is the result 
of both epigenetic modifications, which include histone acetylation and DNA 
methylation at the cytokine gene loci and of acute transcription (Agarwal and Rao,
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1998; Avni et al., 2002; Murphy and Reiner, 2002). GATA-3 and T-bet are two crucial 
factors involved in IL-4 and IFN-y gene transcription through regulation of the 
accessibility of cytokine genes, which accompany Th2 or Thl cell differentiation (Ansel 
et al., 2003). Our analysis of T-bet and GATA-3 mRNA levels revealed that 
TCR/CD28-mediated stimulation induced T-bet at lower levels in WAS than in control 
CD4+ T cells, this reduction being more significant at low anti-CD3 mAb dose (Figure 
31). Therefore, it is likely that the reduced T-bet expression contributes to the defective 
IFN-y gene transcription in WAS CD4+ T cells, as T-bet is one of the key factors 
involved in IFN-y production by CD4+ T cells (Szabo et al., 2000; Szabo et al., 2002) 
and in Thl differentiation. T-bet was shown to positively regulate its own expression by 
a mechanism involving IFN-y-induced STAT1 activity (Afkarian et al., 2002). 
Therefore, defective production of T-bet and IFN-y in WAS CD4+ T cells could also 
result from the lack of a positive feedback. Interestingly, the T-bet defect is less 
pronounced upon stimulation with higher doses of anti-CD3 mAb (especially in W1 
CD4+ T cells) and is not present upon TPA plus ionomycin stimulation (Figure 31 and 
not shown) suggesting that the higher threshold required for activation of WASP- 
deficient CD4+ T cells (Cannon and Burkhardt, 2004; Dupre et al., 2002) could 
contribute to the reduced ability to express T-bet mRNA. On the other hand, WAS 
CD4+ T cells were able to express normal levels of the transcription factor GATA-3 
mRNA (Figure 31), which positively regulate IL-4 gene transcription and Th2 
commitment (Ouyang et al., 2000). Although after TCR/CD28 stimulation, we found 
higher levels of IL-4 mRNA in WAS CD4+ T cells, than in control cells (Figure 22), 
GATA-3 mRNA expression was not enhanced in WAS T cells. These results can be 
explained by the fact that GATA-3 is not the only factor involved in IL-4 gene 
transcription (Murphy and Reiner, 2002). In addition, relative levels of T-bet versus 
GATA-3 are likely to influence the commitment and cytokine production by a T cell, as
T-bet was shown to reduce GATA-3 activity by direct binding (Hwang et al., 2005). 
Although T hl cells from WASP knock-out mice displayed reduced IFN-y secretion 
(Morales-Tirado et al., 2004), no data were available until present regarding a possible 
involvement of WASP in the regulation of T-bet and GATA-3 expression. Commitment 
to Thl or Th2 phenotype requires signalling through TCR and, in a second moment, 
through the receptor of polarizing cytokines (Ansel et al., 2003). Human committed Thl 
or Th2 cells were shown to re-acquire the ability to produce IL-4 or IFN-y, respectively, 
upon culturing in the opposite polarizing conditions (Messi et al., 2003), a property 
defined as flexibility. It was proposed that irreversible Thl or Th2 commitment could 
require the down-regulation of GATA-3 or T-bet, respectively. Based on our data, the 
balance in IL4 versus IFN-y levels, secreted by WAS CD4+ T cells, upon TCR/CD28 
triggering, was strongly in favour of the first cytokine. Therefore, although culture of 
naive WAS CD4+ T cells in Thl polarizing conditions, in the presence of anti-IL-4 
neutralizing Ab, could confer to WAS cells the acquisition of a Thl-like phenotype 
(Figure 10), in vivo this could not happen due to unbalanced IL-4 versus IFN-y 
production and a consequent inability to properly down-regulate GATA-3 expression.
In future studies it will be crucial to measure T-bet and GATA-3 expression 
during in vitro Thl and Th2 polarization of naive WAS CD4+ T cells. In addition, the 
possible involvement of defective Thl responses should be completed by studies in 
vivo, in WASP knock-out mice. These mice could be challenged with pathogens known 
to induce protective T hl immune response, such as M ycobacterium bovis or 
Leishmania major in the C57BL/6 strain (Murray, 1999; Reiner and Locksley, 1995) 
and the function of Thl cells could be tested by their ability to clear infections.
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5.5.3 Influence of WASP deficiency on T cell signalling
The above results on cytokine genes transcription strongly suggest that WASP is 
required to transduce signals from the membrane TCR/CD28 to the cell nucleus. How 
WASP plays this role has been a matter of debate in the last years. Indeed, although it is 
now generally accepted that WASP plays an important role in driving actin 
polymerization and sustaining the formation of IS, it is not clear how the IS modulates 
downstream events of TCR signalling, such as the activation of transcription factors. 
We analyzed some of the main signalling events triggered by TCR/CD28 engagements 
in CD4+ and CD8+ T cells from WAS patients, using the same stimulation method 
which previously allowed us to highlight the defects in T cell polarization (Dupre et al.,
2002). Our observation that phosphorylation of the MAPK ERK1/2 is generally not 
affected by WASP deficiency in either CD4+ or in CD8+ T cells (Figure 24 and 25) is in 
accordance with previous data obtained in freshly isolated T cells from WASP knock­
out mice (Zhang et al., 1999). In addition, we observed normally sustained ERK1/2 
phosphorylation. This event was linked to IL-2 and IFN-y production (Badou et al., 
2001; Koike et al., 2003). ERK1/2 MAPK also regulates cell proliferation through 
direct stimulation of DNA synthesis (Graves et al., 2000). Moreover, in T cells, ERK1/2 
is involved in the induction of AP-1 activity by promoting Fos expression (Hunter and 
Karin, 1992). These activities require translocation of phosphorylated ERK1/2 to the 
nucleus. Recently, in T cells from WASP knock-out mice, reduced nuclear levels of 
ERK1/2 have been reported, despite normal phoshorylation, and it has been proposed to 
be the cause of defective induction of Fos mRNA (Cianferoni et al., 2005). Whether in 
our system ERK1/2 translocation to the nucleus is affected by WASP deficiency 
remains to be determined. However, we found no evidence of abnormal levels of 
nuclear Fos family members in both WAS CD4+ and CD8+ T cells, stimulated through 
TCR/CD28 (Figure 28 and 29), which argues against defective ERK1/2 function. This
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discrepancy could be due to the different systems considered: T cell lines versus freshly 
isolated T cells. Regarding this possibility, the consistency of defective IL-2 gene 
transcription in the two systems suggests that T cell lines established from WAS 
patients retain the main molecular features of freshly isolated T cells. It is however 
possible that the signalling machinery of our T cells, which have been primed in vitro, 
is different, to some extent, to the one of freshly isolated murine T cells, which are 
likely to comprise just a small proportion of memory cells. The relevance of our data is 
supported by the current proposal that WASP deficiency could impair mainly the 
generation and function of memory T cells (Andreansky et al., 2005).
Similarly to ERK1/2, we found no evidence of reduced phosphorylation of the 
JNK1/2 MAPKs in WAS CD4+ T cells, after TCR/CD28 triggering (Figure 26). JNK 
activation in T cells requires TCR/CD28 triggering (Su et al., 1994) and it is 
downstream of the small GTPases Racl and Cdc42 (Coso et al., 1995; Minden et al., 
1995). Although we cannot exclude that other features of JNK activation (including 
nuclear translocation) are altered in WAS CD4+ T cells, our data do not support a main 
role of WASP in the regulation of this pathway. In accordance, JNK1/2 are normally 
phosphorylated in T cells from WASP knock-out mice and the downstream induction of 
c-Jun mRNA is normal (Cianferoni et al., 2005; Zhang et al., 1999). These results are 
in accordance with normal TCR/CD28-mediated activation of SAPK/JNK and ERKs in 
mature T cells from Vav-1 knock-out mice (Fischer et al., 1998). We initially found a 
modest impairment in Ca2+ flux in bulk WAS T cells, upon TCR triggering (Dupre et 
al., 2002). However, later experiments performed in purified WAS CD4+ and CD8+ T 
cells failed to show significant alteration in Ca2+ flux (Figure 28). It is possible that 
these differences are due to the different experimental approaches. Therefore, we 
provided evidences that in the absence of WASP TCR/CD28 proximal signalling is 
generally conserved. This finding could challenge the functional relevance of the
reported defects of T cell polarization and IS formation in WASP-deficient T cells 
(Badour et al., 2003; Cannon and Burkhardt, 2004; Dupre et al., 2002), or even, the role 
of the IS as the main structure where T cell signalling actually occurs.
Despite the fact that proximal signalling is basically conserved, in CD4+ T cells 
from WAS patients, a reduction in the nuclear levels of NFAT-1, but not NFAT-2, was 
observed early after TCR/CD28 triggering (Figure 28). Delayed NFAT-1 activation 
could partially contribute to the defects in IL-2 gene transcription. Similar data have 
been recently obtained in T cells from WASP knock-out mice, which display defective 
dephosphorylation and nuclear translocation of NFAT-1, associated to a block in IL-2 
gene transcription (Cianferoni et al., 2005). The activation of NFAT by WASP could 
rely on its binding to WIP. Indeed, WIP was shown to strongly enhance NFAT/AP-1- 
driven transcription when overexpressed in T cells, together with Vav-1 (Savoy et al.,
2000) and moreover, the ability of WASP to potentiate NFAT activity was mapped to 
its WH1 domain, which comprises the WIP binding site (Silvin et al., 2001). Since it 
has recently been demonstrated thatT-bet positively regulates the binding of NFAT-1 to 
the IFN-y promoter by regulating the promoter accessibility (Avni et al., 2002), it is 
possible that the selective defect in Thl cytokine production by WAS CD4+ T cells 
results, at least partially, from the combination of NFAT-1 and T-bet defects. It would 
be important to study the accessibility of IL-2 and IFN-y promoters in WAS T cells or 
the in vivo binding of transcription factors, such as NFAT by CHIP (chromatin 
immuno-precipitation).
In WAS CD8+ T cells, reduced nuclear levels of both NFAT-1 and NFAT-2 
were observed early after TCR/CD28 triggering and could partially account for the 
defects in cytokine gene transcription. In agreement with our findings, a defect in early 
NFAT-2 nuclear translocation has been recently reported in NK cells from WAS 
patients (Huang et al., 2005). Differences observed in CD4+ versus CD8+ T cells from
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WAS patients, in terms of NFATs activation, could be the consequence of intrinsic 
differences in the threshold required to activate NFAT proteins in these two cell subsets. 
We have not investigated the expression of T-bet in WAS CD8+ T cells. T-bet plays a 
different role in CD4+ T cells, where it is required for IFN-y production, and in CD8+ T 
cell, where it is dispensable for IFN-y production (Szabo et al., 2002), but required for 
perforin-mediated killing. Indeed, in CD8+ T cells, T-bet seems to cooperate or act in 
parallel with eomesodermin, a T-bet homologue, expressed in activated CD8+ T cells 
(Intlekofer et al., 2005). It would be interesting to investigate the expression of these 
two transcription factors in resting versus activated CD8+ T cells from WAS patients.
How WASP deficiency could affect NFAT activation remains to be determined. 
NFAT nuclear translocation requires dephosphorylation of several serine residues by 
calcineurin, which is activated by Ca2+/calmodulin (Hogan et al., 2003), however we 
found no differences in the Ca2+ flux in WAS versus control T cells. It is possible that 
an inability to sustain Ca2+ flux for longer times may be responsible for defective NFAT 
activation in WAS T cells. The analysis of TCR-mediated Ca2+ flux in human and 
murine WASP-deficient T cells gave contrasting results (Henriquez et al., 1994; Molina 
et al., 1993; Zhang et al., 1999). One possible explanation for these discrepancies is that 
WASP deficiency causes only very mild alteration in TCR-mediated Ca2+ flux, which 
can be identified or not, with a strong dependency on the experimental conditions. 
However, NFAT activation was shown to be regulated also by post-translational 
modification, including phosphorylation and sumoylation (Chow et al., 2000; Terui et 
al., 2004). Therefore, defective NFAT1 and NFAT-2 activation in WAS T cells could 
be due either to reduced, or less sustained, Ca2+ flux or to alteration of other signalling 
pathways.
Analysis of IkBa phosphorylation in WAS CD4+ T cells, after CD3/CD28 
triggering, showed that at late time points the levels of phosphorylation were higher
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than in control cells (Figure 30). IkBa is normally degraded after phosphorylation by 
the protesome pathway (Karin and Ben-Neriah, 2000). At the later time point evaluated 
(2 h) higher levels of IkBa phosphorylation could reflect either reduced degradation or 
increased re-synthesis of IkBa In T cells from WASP knock-out mice, activity of NFkB 
was found to be normal (Cianferoni et al., 2005). Costimulation of T cells through 
CD28 is necessary to induce NFkB activation, which is involved in the transcription of 
IL-2 (Ghosh et al., 1993). NFkB activity was shown to be regulated by Vav-1, possibly 
by direct interaction with members of the NFkB complex (Piccolella et al., 2003). In 
addition, the activation of NFkB has been shown to occur upon recruitment to the IS, at 
the level of rafts (Gaide et al., 2002; Wang et al., 2004). Therefore it would be 
interesting to further evaluate NFkB activity and localization of the various NFkB 
subunit (including p65 and c-Rel) upon stimulation with anti-CD3/CD28 mAb-coated 
beads.
This study demonstrates that T cells from WAS patients displayed alteration in 
the activation of various transcription factors, as it was shown in previous studies in 
different cellular models (Badour et al., 2004a; Cannon and Burkhardt, 2004; 
Cianferoni et al., 2005; Huang et al., 2005). These results suggest that rather than 
controlling a single signalling pathway downstream the TCR/CD28, WASP may 
regulate the threshold for activation of different pathways converging towards the 
transcriptional induction of cytokine genes. In addition, we can speculate that the 
influence of WASP on the transcriptional regulation of T cells could be partially due to 
a possible translocation of WASP itself from the cytosol to the nucleus. Such a 
mechanism, indeed, has been demonstrated for the WASP homologue N-WASP, whose 
nuclear versus cytosolic localization has been shown to influence the expression of the 
heat shock protein HSP90 and, by a feedback mechanisms, the activity of Src kinase
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(Suetsugu and Takenawa, 2003). This possibility could be tested by analyzing the sub- 
cellular localization of WASP in resting versus activated T cells.
In addition, WASP-deficient cells represent a useful model to study the 
connection of T cell polarization and IS formation to downstream TCR-related events, 
such as the activation of transcription factors. We showed that WASP deficiency 
impairs both lipid rafts dynamics and activation/expression of transcription factors, 
upon TCR/CD28 triggering. In the future, a single-cell analysis, performed by living 
microscopy, could be envisaged in the WAS model, or in other models of defective IS 
formation, in order to define the precise functional and temporal links between IS 
organization, and activation of transcription factors.
5.6 The role of WASP in nTreg function
Results obtained from the study of nTreg cells from WAS patients (Figure 33 and 
34), as well as of nTreg cells from WASP knock-out mice (Marangoni F. Personal 
communication), suggest that defective nTreg function could contribute to the high 
susceptibility to autoimmune manifestations reported in WAS patients (Dupuis-Girod et 
al., 2003). The observation that the suppressive function of human WAS nTreg was 
partially abrogated, suggests that either the frequency of “bona fide” nTreg cells among 
the CD47CD25bnght population is lower in WAS patients than in healthy donors, or that 
nTreg cells are not properly activated. Regarding the first hypothesis, the frequency of 
FoxP3+ cells amomg CD4+ cells in the peripheral blood of WAS patients was found to 
be elevated (Figure 32B). FoxP3 was shown to be expressed in human CD47CD25+ 
nTreg cells and also in recently activated CD47CD25' effector T cells (Allan et al., 
2005; Walker et al., 2003). We have no information on the proportion of nTreg cells in 
secondary lymphoid organs of WAS patients, but a parallel study performed in our 
laboratory showed normal percentages of nTreg cells in the spleen of WASP knock-out
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mice (Marangoni F. et al, Personal communication). Our data suggest that the defective 
suppressive ability of WAS nTreg cells is due to impaired function. However, a more 
wide analysis of CD25 versus FoxP3 expression levels on CD4+ T cells will clarify 
whether a difference could also exist in the percentages of cells expressing CD25 only, 
FoxP3 only, or both CD25 and FoxP3, in WAS patients versus age-matched healthy 
donors.
Several reports indicated IL-2 as a crucial, non-redundant factor, able to drive 
maturation and function of nTreg cells, both in vitro and in vivo (Malek and Bayer,
2004). Indeed, an intact IL-2/IL2R signalling was shown to be required for nTreg 
development (Bayer et al., 2005; Malek et al., 2000). However, recent findings indicate 
that IL-2-mediated signals are not strictly required for the maturation of murine nTreg 
cells, identified by the expression of FoxP3. IL-2 has been rather proposed to be 
required for the survival of nTreg cells in the periphery and for the maintenance of 
FoxP3 expression (Fontenot et al., 2005b). In WAS patients, IL-2 defects seems not to 
affect the generation of nTreg cells. Therefore, either IL-2 is dispensable for nTreg 
generation in humans, or, more likely, IL-2 could be produced in sufficient amounts in 
WAS patients to drive nTreg development. In addition, it is conceivable that, in addition 
to T cells, other cells in the thymus could provide IL-2 to the developing nTreg. For 
example, DC have been shown to drive positive selection of nTreg in thymic Hassall’s 
corpuscles (Watanabe et al., 2005).
Although nTreg cells are anergic in vitro (but not in vivo) (von Boehmer, 2003) 
their ability to suppress requires signalling through the TCR and the presence of IL-2 
(Thornton et al., 2004a). Although nTreg actively suppress IL-2 mRNA transcription by 
effector T cells, it was proposed that low levels of IL-2, produced in a first phase by 
effector T cells, are sufficient to sustain nTreg suppressive activity, without reversing 
their anergy (Thornton et al., 2004b). Since WASP lowers the threshold for TCR-
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mediated T cell activation, it is possible that WAS nTreg cells require stronger 
stimulation than normal nTreg cells to suppress at comparable levels. This possibility is 
supported by the observation than the defective suppressive activity of nTreg cells from 
WASP knock-out mice was more pronounced when suppression was carried out with 
low dose of anti-CD3 mAb (Marangoni F., Personal communication). In addition, 
proliferative response of murine WAS nTreg cells to anti-CD3/CD28 mAb was strongly 
defective, supporting the hypothesis of impaired activation. We have preliminary data 
suggesting that nTreg cells from WAS patients respond less efficiently, in terms of 
proliferation, than control nTreg to TCR/CD28/IL-2-mediated signals (not shown). This 
finding differs from the results obtained in WAS effector T cells, which proliferate 
normally in response to high dose of IL-2 plus anti-CD3/CD28 stimulation. This 
difference could be explained by the observation that murine nTreg cells seem to have a 
higher threshold for IL-2-driven proliferation than effector T cells (Thornton et al., 
2004b). We can speculate that in a context of high threshold for activation, IL-2- 
induced signalling and proliferation in WAS nTreg could be affected in a way similar to 
TCR-induced signalling and proliferation in effector T cells. This hypothesis could be 
investigated by evaluating IL-2 dose-response, with concomitant TCR triggering, of 
murine WASP knock-out nTreg cells.
Finally, another relevant issue in the context of WAS could be the repertoire of 
nTreg cells. A recent study proposed that in wild type mice a subset of non regulatory T 
cells express self reactive TCRs which are shared also by a fraction of nTreg cells 
(Hsieh et al., 2006). Therefore, the shaping of the TCR repertoire seems to be crucial in 
the homeostasis of nTreg versus auto-reactive T cells. In WAS patients, skewing of 
TCR repertoire was shown starting from the 15 years of age (Wada et al., 2005). This 
could have important implications in the development of autoimmunity on one side, and 
of cancer, on the other. Analysis of the TCR repertoire of nTreg and non regulatory T
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cells in WASP knock-out mice could provide useful additional information on the role 
played by nTreg cells in WAS-associated autoimmunity. However, the most relevant 
findings would arise only from the study of nTreg cells repertoire in WAS patients, as 
this repertoire would be shaped by the natural history of infections and eventually 
autoimmunity experienced by the patient.
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6 CONCLUDING REMARKS
The results presented in this thesis, show that WASP regulates the threshold for 
T cell activation. We demonstrated that WASP is recruited to DRM upon T cell 
activation and that its deficiency impairs GM1 upregulation upon TCR/CD28 
triggering. Although WASP deficiency does not significantly affect proximal 
TCR/CD28 signalling, it alters the transcriptional activation of T hl cytokine genes in 
CD4+ and CD8+ T cells. The reduced activation of NFAT, especially in CD8+ T cells, 
and the defective induction of T-bet transcription factors, in CD4+ T cells, could 
contribute to the defects of cytokine gene trascription observed in T cells from WAS 
patients. The defects in cellular immunity here identified help to clarify the mechanisms 
underlying WAS-associated immunodeficiency, characterized by high susceptibility 
towards infections and tumours. Finally, we propose that a defect in the suppressive 
function of nTreg cells contributes to the development of autoimmune manifestations in 
WAS patients.
Altogether, these data help to clarify the role of WASP in T cell activation and 
regulation and in the mechanisms implicated in WAS pathogenesis. In addition, they 
provided the basis for a future gene therapy approach in this genetic disease.
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